Targeting hypoxia in cancer therapy

Nature Reviews Cancer

11, 393-410

DOI: 10.1038/nrc3064

Citation Report

#	Article	IF	Citations
2	Shedding light by cancer redoxâ€"human NAD(P)H:quinone oxidoreductase 1 activation of a cloaked fluorescent dye. Chemical Communications, 2011, 47, 11264.	2.2	43
3	Gene expression and hypoxia in breast cancer. Genome Medicine, 2011, 3, 55.	3.6	73
4	Oxygen Sensing, Homeostasis, and Disease. New England Journal of Medicine, 2011, 365, 1845-1846.	13.9	35
5	Phosphorylation of Carbonic Anhydrase IX Controls Its Ability to Mediate Extracellular Acidification in Hypoxic Tumors. Cancer Research, 2011, 71, 7558-7567.	0.4	117
6	Molecular and translational radiation biology/oncology: Whatâ€™s up?. Radiotherapy and Oncology, 2011, 99, 257-261.	0.3	11
7	Frontiers in molecular radiation biology/oncology. Radiotherapy and Oncology, 2011, 101, 1-6.	0.3	11
8	The impact of hypoxia on oncolytic virotherapy. Virus Adaptation and Treatment, 0, , 71.	1.5	6
9	Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS ONE, 2011, 6, e23108.	1.1	108
10	The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy. Bioorganic and Medicinal Chemistry, 2011, 19, 5989-5998.	1.4	7
11	Towards automated production and drug sensitivity testing using scaffoldâ€free spherical tumor microtissues. Biotechnology Journal, 2011, 6, 1488-1496.	1.8	115
12	The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins. Bioorganic and Medicinal Chemistry, 2011, 19, 4851-4860.	1.4	10
13	Oxygen Sensing, Homeostasis, and Disease. New England Journal of Medicine, 2011, 365, 968-968.	13.9	2
14	Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma, 2011, 2011, 1-11.	0.7	18
15	When Cells Suffocate: Autophagy in Cancer and Immune Cells under Low Oxygen. International Journal of Cell Biology, 2011, 2011, 1-13.	1.0	30
16	Immunocytes as a Biocarrier to Delivery Therapeutic and Imaging Contrast Agents to Tumors. Journal of Nanomaterials, 2012, 2012, 1-8.	1.5	3
17	Inhibition of Hypoxia Inducible Factor Alpha and Astrocyte-Elevated Gene-1 Mediates Cryptotanshinone Exerted Antitumor Activity in Hypoxic PC-3 Cells. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-13.	0.5	24
18	Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers, 2012, 4, 821-845.	1.7	44
19	The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia. Clinical Cancer Research, 2012, 18, 1684-1695.	3.2	67

#	Article	IF	Citations
21	Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement. Expert Opinion on Drug Discovery, 2012, 7, 1093-1106.	2.5	4
22	Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15101-15108.	3.3	677
23	Î³-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. British Journal of Cancer, 2012, 106, 1953-1959.	2.9	47
24	Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia. Molecular Pharmacology, 2012, 81, 31-40.	1.0	61
25	Expression of a Truncated Active Form of VDAC1 in Lung Cancer Associates with Hypoxic Cell Survival and Correlates with Progression to Chemotherapy Resistance. Cancer Research, 2012, 72, 2140-2150.	0.4	64
26	Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells. Cancer Research, 2012, 72, 4629-4641.	0.4	168
27	Innovation in Cancer Imaging. European Surgical Research, 2012, 48, 121-130.	0.6	7
28	Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302. Molecular Cancer Therapeutics, 2012, 11, 740-751.	1.9	166
29	New Challenges for Cancer Systems Biomedicine. SIMAI Springer Series, 2012, , .	0.4	8
30	Neuropilin-1 Identifies a Subset of Bone Marrow Gr1â^' Monocytes That Can Induce Tumor Vessel Normalization and Inhibit Tumor Growth. Cancer Research, 2012, 72, 6371-6381.	0.4	51
31	Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. DMM Disease Models and Mechanisms, 2012, 5, 763-771.	1.2	51
32	Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives as Hypoxic Selective Anti-tumor Agents. Molecules, 2012, 17, 9683-9696.	1.7	31
33	Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1Î±-dependent manner. International Journal of Oncology, 2012, 41, 2005-2012.	1.4	51
34	Development of a Hypoxia-Selective Near-Infrared Fluorescent Probe for Non-invasive Tumor Imaging. Chemical and Pharmaceutical Bulletin, 2012, 60, 402-407.	0.6	18
35	Reversible Offâ€“On Fluorescence Probe for Hypoxia and Imaging of Hypoxiaâ€“Normoxia Cycles in Live Cells. Journal of the American Chemical Society, 2012, 134, 19588-19591.	6.6	110
36	Passing the baton: the HIF switch. Trends in Biochemical Sciences, 2012, 37, 364-372.	3.7	451
37	Dual Targeting of Hypoxic and Acidic Tumor Environments with a Cobalt(III) Chaperone Complex. Journal of Medicinal Chemistry, 2012, 55, 11013-11021.	2.9	85
38	2-Nitroimidazole-Tricarbocyanine Conjugate as a Near-Infrared Fluorescent Probe for in Vivo Imaging of Tumor Hypoxia. Bioconjugate Chemistry, 2012, 23, 324-329.	1.8	150

#	Article	IF	Citations
39	An Insertion/Deletion Polymorphism within RERT-lncRNA Modulates Hepatocellular Carcinoma Risk. Cancer Research, 2012, 72, 6163-6172.	0.4	86
40	Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends in Molecular Medicine, 2012, 18, 534-543.	3.5	184
41	Reduced expression of FASN through SREBPâ€1 downâ€regulation is responsible for hypoxic cell death in HepG2 cells. Journal of Cellular Biochemistry, 2012, 113, 3730-3739.	1.2	22
42	Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HCT116 colon cancer. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 938-949.	2.2	72
43	Anti-VEGF therapy in pituitary carcinoma. Pituitary, 2012, 15, 445-449.	1.6	115
44			

#	Article	IF	Citations
57	Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 412-419.	0.7	15
58	DNA Strand Cleavage by the Phenazine Di-N-oxide Natural Product Myxin under Both Aerobic and Anaerobic Conditions. Chemical Research in Toxicology, 2012, 25, 197-206.	1.7	66
59	Polyacetal-stilbene conjugates â€" The first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours. Journal of Controlled Release, 2012, 164, 314-322.	4.8	26
60	Transferring oxygen isotopes to 1,2,4-benzotriazine 1-oxides forming the corresponding 1,4-dioxides by using the HOFÂ·CH3CN complex. Tetrahedron, 2012, 68, 8942-8944.	1.0	5
61	Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncology, 2012, 48, 1263-1271.	0.8	30
62	Nitro seco Analogues of the Duocarmycins Containing Sulfonate Leaving Groups as Hypoxia-Activated Prodrugs for Cancer Therapy. Journal of Medicinal Chemistry, 2012, 55, 2780-2802.	2.9	27
63	Hypoxic Cell Waves Around Necrotic Cores in Glioblastoma: A Biomathematical Model and Its Therapeutic Implications. Bulletin of Mathematical Biology, 2012, 74, 2875-2896.	0.9	99
64	Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Medical Oncology, 2012, 29, 2849-2857.	1.2	28
65	Versatile approach to Î±-alkoxy carbamate synthesis and stimulus-responsive alcohol release. Organic and Biomolecular Chemistry, 2012, 10, 7980.	1.5	31
66	Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy. Advances in Cancer Research, 2012, 114, 237-267.	1.9	151
67	Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiation Oncology, 2012, 7, 75.	1.2	25
68	The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus under a Hypoxic Microenvironment. PLoS ONE, 2012, 7, e39292.	1.1	16
69	Quantitative Ex-Vivo Micro-Computed Tomographic Imaging of Blood Vessels and Necrotic Regions within Tumors. PLoS ONE, 2012, 7, e41685.	1.1	24
70	SIRT1 Regulates Endothelial Notch Signaling in Lung Cancer. PLoS ONE, 2012, 7, e45331.	1.1	49
71	Tissue Transglutaminase Constitutively Activates HIF-1Î± Promoter and Nuclear Factor-ÎºB via a Non-Canonical Pathway. PLoS ONE, 2012, 7, e49321.	1.1	84
72	Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape. Frontiers in Immunology, 2012, 3, 21.	2.2	148
73	Targeting Tumor Microenvironments for Cancer Prevention and Therapy. , 2012, , .		4
74	What is a tumour?. , 0, , 103-152.		0

#	Article	IF	Citations
75	The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy. , 0, , .		4
76	Ubiquitin-specific Protease 19 (USP19) Regulates Hypoxia-inducible Factor 1Î± (HIF-1Î±) during Hypoxia. Journal of Biological Chemistry, 2012, 287, 1962-1969.	1.6	71
77	Stromal Estrogen Receptor-Î± Promotes Tumor Growth by Normalizing an Increased Angiogenesis. Cancer Research, 2012, 72, 3010-3019.	0.4	88
78	Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer, 2012, 12, 487-493.	12.8	573
79	Molecular Pathways: Emerging Pathways Mediating Growth, Invasion, and Metastasis of Tumors Progressing in an Irradiated Microenvironment. Clinical Cancer Research, 2012, 18, 5196-5202.	3.2	68
80	A Zebrafish Model to Study and Therapeutically Manipulate Hypoxia Signaling in Tumorigenesis. Cancer Research, 2012, 72, 4017-4027.	0.4	71
81	Development of a Reductionâ€Responsive Amino Acid that Induces Peptide Bond Cleavage in Hypoxic Cells. ChemBioChem, 2012, 13, 968-971.	1.3	18
82	Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nature Reviews Clinical Oncology, 2012, 9, 378-390.	12.5	150
83	Alterations of monocarboxylate transporter densities during hypoxia in brain and breast tumour cells. Cellular Oncology (Dordrecht), 2012, 35, 217-227.	2.1	27
84	Expression and role in glycolysis of human ADP-dependent glucokinase. Molecular and Cellular Biochemistry, 2012, 364, 131-145.	1.4	29
85	TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemotherapy and Pharmacology, 2012, 69, 1487-1498.	1.1	98
86	The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 272-296.	3.3	116
87	Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs. Biochemical Pharmacology, 2012, 83, 574-585.	2.0	42
88	Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials, 2012, 33, 4195-4203.	5.7	182
89	Gene expression profiling to dissect the complexity of cancer biology: Pitfalls and promise. Seminars in Cancer Biology, 2012, 22, 250-260.	4.3	28
90	Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy. , 2012, 133, 334-350.		86
91	Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype. Experimental and Molecular Pathology, 2012, 92, 296-303.	0.9	40
92	Oxidative stress in inflammationâ€based gastrointestinal tract diseases: Challenges and opportunities. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1004-1010.	1.4	176

#	Article	IF	Citations
93	Geranylgeranyltransferase I regulates HIF-1Î± promoting glioblastoma cell migration and invasion. Journal of Neuro-Oncology, 2013, 112, 365-374.	1.4	12
94	Systemic Delivery of SapC-DOPS Has Antiangiogenic and Antitumor Effects Against Glioblastoma. Molecular Therapy, 2013, 21, 1517-1525.	3.7	45
95	Enzymatic Conversion of 6-Nitroquinoline to the Fluorophore 6-Aminoquinoline Selectively under Hypoxic Conditions. Chemical Research in Toxicology, 2013, 26, 555-563.	1.7	25
96	Nanomedicine in chemoradiation. Therapeutic Delivery, 2013, 4, 239-250.	1.2	25
98	Modeling the connection between primary and metastatic tumors. Journal of Mathematical Biology, 2013, 67, 657-692.	0.8	8
99	Caspase-7 ablation modulates UPR, reprograms TRAF2-JNK apoptosis and protects T17M rhodopsin mice from severe retinal degeneration. Cell Death and Disease, 2013, 4, e528-e528.	2.7	48
100	Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death and Disease, 2013, 4, e537-e537.	2.7	222
101	HIF1 regulates WSBâ€1 expression to promote hypoxiaâ€induced chemoresistance in hepatocellular carcinoma cells. FEBS Letters, 2013, 587, 2530-2535.	1.3	41
102	Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. BMC Bioinformatics, 2013, 14, S12.	1.2	20
103	Autophagy and Cancer. , 2013, , .		5
104	Nanopreparations to overcome multidrug resistance in cancer. Advanced Drug Delivery Reviews, 2013, 65, 1748-1762.	6.6	294
105	Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone. Journal of Cancer Research and Clinical Oncology, 2013, 139, 669-679.	1.2	22
106	Cobalt derivatives as promising therapeutic agents. Current Opinion in Chemical Biology, 2013, 17, 189-196.	2.8	143
107	Transcriptional control of cancer metastasis. Trends in Cell Biology, 2013, 23, 603-611.	3.6	94
108	PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. British Journal of Cancer, 2013, 109, 1795-1804.	2.9	32
109	Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nature Medicine, 2013, 19, 1178-1183.	15.2	212
110	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. Breast Diseases, 2013, 24, 79-81.	0.0	2
111	Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiotherapy and Oncology, 2013, 109, 65-70.	0.3	37

#	Article	IF	Citations
112	Optimization of Tumor Radiotherapy With Modulators of Cell Metabolism: Toward Clinical Applications. Seminars in Radiation Oncology, 2013, 23, 262-272.	1.0	24
113	The Roles of Reactive Oxygen Species and Autophagy in Mediating the Tolerance of Tumor Cells to Cycling Hypoxia. Seminars in Radiation Oncology, 2013, 23, 252-261.	1.0	41
114	Metabolic targets for cancer therapy. Nature Reviews Drug Discovery, 2013, 12, 829-846.	21.5	592
115	Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers. Journal of Clinical Oncology, 2013, 31, 2205-2218.	0.8	925
116	Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials. Cancer Research, 2013, 73, 4965-4977.	0.4	231
117	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis, 2013, 34, 725-738.	1.3	86
118	Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence. Journal of Biological Chemistry, 2013, 288, 37138-37153.	1.6	22
120	Prostate Cancer: Shifting from Morphology to Biology. , 2013, , .		1
121	Wnt/Î²-catenin signaling enhances hypoxia-induced epithelialâ€“mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1Î± signaling. Carcinogenesis, 2013, 34, 962-973.	1.3	208
122	Microfluidic Platforms for Evaluating Angiogenesis and Vasculogenesis. , 2013, , 385-403.		0
123	Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma. Molecular Cancer Therapeutics, 2013, 12, 831-843.	1.9	144
124	Microenvironment and tumor cell plasticity: An easy way out. Cancer Letters, 2013, 341, 80-96.	3.2	214
125	Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. Journal of Controlled Release, 2013, 171, 1-10.	4.8	25
126	The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Biochemistry and Cell Biology, 2013, 91, 369-377.	0.9	68
127	Biology â€“ cancer metabolic phenotype. , 2013, , 15-138.		2
128	Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Research, 2013, 15, 202.	2.2	78
130	A highly sensitive long-wavelength fluorescence probe for nitroreductase and hypoxia: selective detection and quantification. Chemical Communications, 2013, 49, 10820.	2.2	122
131	HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis, 2013, 34, 1699-1707.	1.3	153

#	Article	IF	Citations
132	Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: Potential role of hypoxia. Cancer Letters, 2013, 341, 63-72.	3.2	203
133	Hypoxia, Therapeutic Resistance, and Sphingosine 1-Phosphate. Advances in Cancer Research, 2013, 117, 117-141.	1.9	38
134	Diastereomerically pure platinum(II) complexes as antitumoral agents.. Journal of Inorganic Biochemistry, 2013, 118, 1-12.	1.5	30
135	The Tumor Microenvironment: Characterization, Redox Considerations, and Novel Approaches for Reactive Oxygen Species-Targeted Gene Therapy. Antioxidants and Redox Signaling, 2013, 19, 854-895.	2.5	97
136	Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2013, 132, 993-1003.	2.3	87
137	Mapping In Vivo Tumor Oxygenation within Viable Tumor by 19F-MRI and Multispectral Analysis. Neoplasia, 2013, 15, 1241-IN1.	2.3	20
138	MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Letters, 2013, 331, 230-238.	3.2	73
139	Radiation-induced nitric oxide mitigates tumor hypoxia and radioresistance in a murine SCCVII tumor model. Biochemical and Biophysical Research Communications, 2013, 437, 420-425.	1.0	29
140	Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncology, 2013, 49, 287-292.	0.8	211
141	The CSB repair factor is overexpressed in cancer cells, increases apoptotic resistance, and promotes tumor growth. DNA Repair, 2013, 12, 293-299.	1.3	25
142	Baseline Tumor Oxygen Saturation Correlates withÂa Pathologic Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Breast Diseases, 2013, 24, 78-79.	0.0	0
143	Planar triazinium cations from vanadyl-mediated ring cyclizations: the thiazole species for efficient nuclear staining and photocytotoxicity. Dalton Transactions, 2013, 42, 4436.	1.6	6
144	Emerging targeted agents in metastatic breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 191-210.	12.5	158
145	Autophagy and the Tumor Microenvironment. , 2013, , 167-189.		0
146	Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Medicinal Chemistry, 2013, 5, 553-572.	1.1	116
147	Repression of the Long Noncoding RNA-LET by Histone Deacetylase 3 Contributes to Hypoxia-Mediated Metastasis. Molecular Cell, 2013, 49, 1083-1096.	4.5	458
148	Therapeutic gene modified cell based cancer vaccines. Gene, 2013, 525, 200-207.	1.0	46
149	Cross-Bridged Cyclen or Cyclam Co(III) Complexes Containing Cytotoxic Ligands as Hypoxia-Activated Prodrugs. Inorganic Chemistry, 2013, 52, 7688-7698.	1.9	35

#	Article	IF	Citations
150	Inactivation of lysyl oxidase by Î²-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells. Oncology Reports, 2013, 29, 541-548.	1.2	48
151	Melatonin reverses tunicamycinâ€induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing <scp>CHOP</scp> and decreasing Survivin. Journal of Pineal Research, 2013, 55, 184-194.	3.4	66
152	CH-01 is a Hypoxia-Activated Prodrug That Sensitizes Cells to Hypoxia/Reoxygenation Through Inhibition of Chk1 and Aurora A. ACS Chemical Biology, 2013, 8, 1451-1459.	1.6	53
153	Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer and Metastasis Reviews, 2013, 32, 623-642.	2.7	948
154	Hypoxia-inducible factor-1Î² (HIF-1Î²) is upregulated in a HIF-1Î±-dependent manner in 518A2 human melanoma cells under hypoxic conditions. Biochemical and Biophysical Research Communications, 2013, 434, 166-172.	1.0	24
155	Development of Azoâ€Based Fluorescent Probes to Detect Different Levels of Hypoxia. Angewandte Chemie - International Edition, 2013, 52, 13028-13032.	7.2	241
156	Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates. Journal of Medicinal Chemistry, 2013, 56, 8512-8520.	2.9	76
157	A microfluidic long-term bacteria culture device with controllable humidity and dissolved oxygen. , 2013, , .		0
158	Programming Membrane Fusion and Subsequent Apoptosis into Mammalian Cells. ACS Synthetic Biology, 2013, 2, 173-179.	1.9	12
159	Expression and Significance of Hypoxiaâ€Inducible Factorâ€“1Î± and Survivin in Laryngeal Carcinoma Tissue and Cells. Otolaryngology - Head and Neck Surgery, 2013, 148, 75-81.	1.1	20
160	Metabolic gradients as key regulators in zonation of tumor energy metabolism: A tissueâ€scale modelâ€based study. Biotechnology Journal, 2013, 8, 1058-1069.	1.8	13
161	Tumour oxygenation: implications for breast cancer prognosis. Journal of Internal Medicine, 2013, 274, 105-112.	2.7	73
162	Nitroreductase Detection and Hypoxic Tumor Cell Imaging by a Designed Sensitive and Selective Fluorescent Probe, 7-[(5-Nitrofuran-2-yl)methoxy]-3H-phenoxazin-3-one. Analytical Chemistry, 2013, 85, 3926-3932.	3.2	194
163	Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7312-7317.	3.3	768
164	Three-dimensional cell culture: the missing link in drug discovery. Drug Discovery Today, 2013, 18, 240-249.	3.2	983
165	DLK1: A Novel Target for Immunotherapeutic Remodeling of the Tumor Blood Vasculature. Molecular Therapy, 2013, 21, 1958-1968.	3.7	28
166	Targeting hypoxia in the leukemia microenvironment. International Journal of Hematologic Oncology, 2013, 2, 279-288.	0.7	45
167	Multimodality pH imaging in a mouse dorsal skin fold window chamber model. Proceedings of SPIE, 2013, 8574, .	0.8	3

#	Article	IF	Citations
168	FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells. Biochemical Journal, 2013, 452, 79-86.	1.7	24
169	siRNA-based nanomedicine. Nanomedicine, 2013, 8, 859-862.	1.7	35
170	The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. Frontiers in Oncology, 2013, 3, 263.	1.3	46
171	Upregulation of Drug Transporter Expression by Osteopontin in Prostate Cancer Cells. Molecular Pharmacology, 2013, 83, 968-977.	1.0	45
172	Biosensor-Expressing Spheroid Cultures for Imaging of Drug-Induced Effects in Three Dimensions. Journal of Biomolecular Screening, 2013, 18, 736-743.	2.6	21
173	PET Imaging of Tumor Hypoxia Using ¹⁸F-Fluoroazomycin Arabinoside in Stage IIIâ€“IV Nonâ€“Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2013, 54, 1175-1180.	2.8	73
174	Hypoxia Modulates A431 Cellular Pathways Association to Tumor Radioresistance and Enhanced Migration Revealed by Comprehensive Proteomic and Functional Studies. Molecular and Cellular Proteomics, 2013, 12, 485-498.	2.5	70
175	Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors. Molecular Cancer Therapeutics, 2013, 12, 542-552.	1.9	29
176	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. Journal of the National Cancer Institute, 2013, 105, 1188-1201.	3.0	101
177	Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models. Journal of Nuclear Medicine, 2013, 54, 1362-1368.	2.8	21
178	TRAF6 Upregulates Expression of HIF-1Î± and Promotes Tumor Angiogenesis. Cancer Research, 2013, 73, 4950-4959.	0.4	85
179	HIF1 Contributes to Hypoxia-Induced Pancreatic Cancer Cells Invasion via Promoting QSOX1 Expression. Cellular Physiology and Biochemistry, 2013, 32, 561-568.	1.1	38
180	The Tumor Microenvironment and Strategies to Improve Drug Distribution. Frontiers in Oncology, 2013, 3, 154.	1.3	106
181	NCIâ€“RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers. Journal of the National Cancer Institute, 2013, 105, 11-24.	3.0	60
182	Hypoxia-Inducible Factors: Mediators of Cancer Progression; Prognostic and Therapeutic Targets in Soft Tissue Sarcomas. Cancers, 2013, 5, 320-333.	1.7	51
183	Downregulation of PHLPP Expression Contributes to Hypoxia-Induced Resistance to Chemotherapy in Colon Cancer Cells. Molecular and Cellular Biology, 2013, 33, 4594-4605.	1.1	40
184	mi<scp>R</scp>â€214 and hypoxia downâ€regulate <scp>N</scp>eclâ€2/<scp>CADM</scp>1 and enhance <scp>E</scp>rb<scp>B</scp>2/<scp>E</scp>rb<scp>B</scp>3 signaling. Genes To Cells, 2013, 18, 195-202.	0.5	18
185	¹⁸F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Nonâ€“Small Cell Lung Cancer Xenograft Model. Journal of Nuclear Medicine, 2013, 54, 1339-1346.	2.8	31

#	Article	IF	Citations
186	The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. British Journal of Cancer, 2013, 109, 1859-1866.	2.9	30
187	Real-time dynamics of methyl-CpG-binding domain protein 3 and its role in DNA demethylation by fluorescence correlation spectroscopy. Epigenetics, 2013, 8, 1089-1100.	1.3	23
188	Mapping of oxygen by imaging lipids relaxation enhancement: A potential sensitive endogenous MRI contrast to map variations in tissue oxygenation. Magnetic Resonance in Medicine, 2013, 70, 732-744.	1.9	41
189	Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase. Tumor Microenvironment and Therapy, 2013, 1, .	1.2	14
191	Impact of Wee1 inhibition on the hypoxia-induced DNA damage response. Tumor Microenvironment and Therapy, 2013, 1, .	1.2	2
192	Screening of a Novel Peptide Targeting the Proteoglycan-Like Region of Human Carbonic Anhydrase IX. Molecular Imaging, 2013, 12, 7290.2013.00066.	0.7	17
194	Tumor hypoxia as a driving force in genetic instability. Genome Integrity, 2013, 4, 5.	1.0	181
195	Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 8880.	1.4	83
196	Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. Journal of Extracellular Vesicles, 2013, 2, .	5.5	140
197	Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy. Current Cancer Drug Targets, 2013, 13, 670-685.	0.8	63
198	Expression and significance of hypoxia-inducible factor-1Î± and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncology Letters, 2013, 6, 232-238.	0.8	31
199	Sickle Erythrocytes Target Cytotoxics to Hypoxic Tumor Microvessels and Potentiate a Tumoricidal Response. PLoS ONE, 2013, 8, e52543.	1.1	18
200	Transcriptional Shift Identifies a Set of Genes Driving Breast Cancer Chemoresistance. PLoS ONE, 2013, 8, e53983.	1.1	28
201	Alpha-Particle Emitting 213Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation. PLoS ONE, 2013, 8, e64730.	1.1	64
202	Prognostic Value of HIFs Expression in Head and Neck Cancer: A Systematic Review. PLoS ONE, 2013, 8, e75094.	1.1	52
203	Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling. Frontiers in Oncology, 2013, 3, 314.	1.3	36
204	Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells. Journal of Pharmaceutics, 2013, 2013, 1-10.	4.6	3
205	HIF-1alpha in lung carcinoma: Histopathological evidence of hypoxia targets in patient biopsies. Journal of Solid Tumors, 2013, 3, .	0.1	1

#	Article	IF	Citations
206	DNA Hypomethylation-Mediated Overexpression of Carbonic Anhydrase 9 Induces an Aggressive Phenotype in Ovarian Cancer Cells. Yonsei Medical Journal, 2014, 55, 1656.	0.9	16
207	The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckland, N Z), 2014, 2, 91.	1.9	58
208	A Synthetic Manassantin A Derivative Inhibits Hypoxia-Inducible Factor 1 and Tumor Growth. PLoS ONE, 2014, 9, e99584.	1.1	19
209	Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells. PLoS ONE, 2014, 9, e100814.	1.1	19
210	Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302. PLoS ONE, 2014, 9, e107995.	1.1	35
211	Identification and Analysis of Genome-Wide SNPs Provide Insight into Signatures of Selection and Domestication in Channel Catfish (Ictalurus punctatus). PLoS ONE, 2014, 9, e109666.	1.1	55
212	Quinone Methides as DNA Alkylating Agents: An Overview on Efficient Activation Protocols for Enhanced Target Selectivity. Current Organic Chemistry, 2014, 18, 19-43.	0.9	47
213	Recent Progress on Liver Kinase B1 (LKB1): Expression, Regulation, Downstream Signaling and Cancer Suppressive Function. International Journal of Molecular Sciences, 2014, 15, 16698-16718.	1.8	61
214	Biological Evaluation of the Activity of Some Benzimidazole-4,7-dione Derivatives. Molecules, 2014, 19, 15361-15373.	1.7	5
215	Exploiting Endogenous Cellular Process to Generate Quinone Methides In Vivo. Current Organic Chemistry, 2014, 18, 70-85.	0.9	21
216	The Hypoxia-Inducible Factor-1ÃŽÂ± Signaling Pathway and its Relation to Cancer and Immunology. American Journal of Immunology, 2014, 10, 215-224.	0.1	6
217	Personalized In Vitro Cancer Modeling â€" Fantasy or Reality?. Translational Oncology, 2014, 7, 657-664.	1.7	34
218	The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biology and Therapy, 2014, 15, 1552-1560.	1.5	21
219	Hypoxia promotes tumor cell motility via RhoA and ROCK1 signaling pathways. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 887-888.	3.3	15
220	Competing Endogenous RNA and Interactome Bioinformatic Analyses on Human Telomerase. Rejuvenation Research, 2014, 17, 161-167.	0.9	23
221	Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer, 2014, 110, 107-114.	2.9	49
222	Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 2501-2514.	1.9	40
223	Imaging Tumor Hypoxia to Advance Radiation Oncology. Antioxidants and Redox Signaling, 2014, 21, 313-337.	2.5	77

#	Article	IF	Citations
224	Dihydroartemisinin is a Hypoxia-Active Anti-Cancer Drug in Colorectal Carcinoma Cells. Frontiers in Oncology, 2014, 4, 116.	1.3	22
225	Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Frontiers in Physiology, 2014, 4, 400.	1.3	157
227	Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. British Journal of Pharmacology, 2014, 171, 224-236.	2.7	31
228	Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue. Free Radical Biology and Medicine, 2014, 77, 340-352.	1.3	38
229	CD44 Expressed on Cancer-Associated Fibroblasts Is a Functional Molecule Supporting the Stemness and Drug Resistance of Malignant Cancer Cells in the Tumor Microenvironment. Stem Cells, 2014, 32, 145-156.	1.4	135
230	Activity of the hypoxiaâ€activated proâ€drug THâ€302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. International Journal of Cancer, 2014, 134, 2726-2734.	2.3	47
231	Identification of Hypoxic Cells Using an Organotellurium Tag Compatible with Mass Cytometry. Angewandte Chemie - International Edition, 2014, 53, 11473-11477.	7.2	37
232	Janus-Faced Tumor Microenvironment and Redox. Antioxidants and Redox Signaling, 2014, 21, 723-729.	2.5	72
233	Tumorâ€Targeting of EGFR Inhibitors by Hypoxiaâ€Mediated Activation. Angewandte Chemie - International Edition, 2014, 53, 12930-12935.	7.2	55
234	Upâ€regulation of survivin by <scp>AKT</scp> and hypoxiaâ€inducible factorÂÎ± contributes to cisplatin resistance in gastric cancer. FEBS Journal, 2014, 281, 115-128.	2.2	75
236	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. Cancer Research, 2014, 74, 6094-6106.	0.4	45
237	Dual-Specificity Phosphatases as Molecular Targets for Inhibition in Human Disease. Antioxidants and Redox Signaling, 2014, 20, 2251-2273.	2.5	75
238	Advances in Intravital Microscopy. , 2014, , .		4
239	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Advanced Drug Delivery Reviews, 2014, 79-80, 222-237.	6.6	146
240	Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Molecular Carcinogenesis, 2014, 53, 722-735.	1.3	51
241	Preparation and Properties of Clickable Amino Analogues of the Duocarmycins: Factors That Affect the Efficiency of Their Fluorescent Labelling of DNA. ChemMedChem, 2014, 9, 2193-2206.	1.6	6
242	Prodrug Strategies for Targeting Tumour Hypoxia. Cancer Drug Discovery and Development, 2014, , 283-328.	0.2	2
243	Carbonic Anhydrase IX: Regulation and Role in Cancer. Sub-Cellular Biochemistry, 2014, 75, 199-219.	1.0	108

#	Article	IF	Citations
244	Evaluation of repeated [18F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomas. EJNMMI Research, 2014, 4, 65.	1.1	4
245	Taxanes as radiosensitizers. Anti-Cancer Drugs, 2014, 25, 502-511.	0.7	25
246	Glucose Metabolism and the Antioxidative Defense System in Cancer Cells: Options for the Application of ROS-based Anticancer Drugs. Cancer Drug Discovery and Development, 2014, , 109-130.	0.2	0
247	Hypoxia Promotes Nuclear Translocation and Transcriptional Function in the Oncogenic Tyrosine Kinase RON. Cancer Research, 2014, 74, 4549-4562.	0.4	27
248	Regulation of Cancer Cell Metabolism by Hypoxia. Cancer Drug Discovery and Development, 2014, , 75-108.	0.2	0
249	Crosstalk of Oncogenic Signaling Pathways during EpithelialÃ¢â‚¬â€œMesenchymal Transition. Frontiers in Oncology, 2014, 4, 358.	1.3	137
250	Hypoxia Provokes Base Excision Repair Changes and a Repair-Deficient, Mutator Phenotype in Colorectal Cancer Cells. Molecular Cancer Research, 2014, 12, 1407-1415.	1.5	47
251	Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses. Science Translational Medicine, 2014, 6, 249ra111.	5.8	285
252	Upregulation of HIF-2Î± induced by sorafenib contributes to the resistance by activating the TGF-Î±/EGFR pathway in hepatocellular carcinoma cells. Cellular Signalling, 2014, 26, 1030-1039.	1.7	111
253	The protective effects of Trolox-loaded chitosan nanoparticles against hypoxia-mediated cell apoptosis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1411-1420.	1.7	17
254	Bioengineered human tumor within a bone niche. Biomaterials, 2014, 35, 5785-5794.	5.7	67
255	The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs. Biochemical Pharmacology, 2014, 89, 224-235.	2.0	21
256	T-type calcium channels blockers as new tools in cancer therapies. Pflugers Archiv European Journal of Physiology, 2014, 466, 801-810.	1.3	82
258	Adrenomedullin is a therapeutic target in colorectal cancer. International Journal of Cancer, 2014, 134, 2041-2050.	2.3	22
259	Pre-treatment Haemoglobin and Peripheral Blood Lymphocyte Count as Independent Predictors of Outcome in Carcinoma of Cervix. Clinical Oncology, 2014, 26, 179-184.	0.6	24
260	Macro-/micro-environment-sensitive chemosensing and biological imaging. Chemical Society Reviews, 2014, 43, 4563-4601.	18.7	720
261	Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials, 2014, 35, 1735-1743.	5.7	296
262	The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Molecular Cancer, 2014, 13, 12.	7.9	39

#	Article	IF	Citations
263	Emerging evidence of the physiological role of hypoxia in mammary development and lactation. Journal of Animal Science and Biotechnology, 2014, 5, 9.	2.1	33
264	Imaging as a pharmacodynamic and response biomarker in cancer. Clinical and Translational Imaging, 2014, 2, 13-31.	1.1	5
265	A study on the properties and reactivity of naphthoquinoneâ€“cobalt(III) prototypes for bioreductive prodrugs. Journal of Inorganic Biochemistry, 2014, 132, 37-44.	1.5	26
266	Hypoxia and Cancer. Cancer Drug Discovery and Development, 2014, , .	0.2	7
267	Hypoxiaâ€Targeted siRNA Delivery. Angewandte Chemie - International Edition, 2014, 53, 3362-3366.	7.2	200
268	Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. International Journal of Cancer, 2014, 134, 2798-2807.	2.3	45
269	Hypoxia induces peroxisome proliferator-activated receptor Î³ expression via HIF-1-dependent mechanisms in HepG2 cell line. Archives of Biochemistry and Biophysics, 2014, 543, 40-47.	1.4	27
270	Emerging Roles of Non-Coding RNAs in the Hypoxic Response. Cancer Drug Discovery and Development, 2014, , 43-64.	0.2	3
271	A low dicer expression is associated with resistance to 5â€<scp>FU</scp>â€based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2014, 43, 350-356.	1.4	23
272	Hypoxia as a biomarker for radioresistant cancer stem cells. International Journal of Radiation Biology, 2014, 90, 636-652.	1.0	115
273	Hypoxia-regulated gene network in drug resistance and cancer progression. Experimental Biology and Medicine, 2014, 239, 779-792.	1.1	45
275	Cancer biomarker discovery: Current status and future perspectives. International Journal of Radiation Biology, 2014, 90, 659-677.	1.0	98
276	Enhanced Anticancer Efficacy by ATPâ€Mediated Liposomal Drug Delivery. Angewandte Chemie - International Edition, 2014, 53, 5815-5820.	7.2	175
277	Inhibition of tumor cell growth and angiogenesis by 7-Aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors. European Journal of Medicinal Chemistry, 2014, 79, 369-381.	2.6	27
278	Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1Î±. European Journal of Pharmacology, 2014, 723, 46-54.	1.7	25
279	The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity. Journal of Biological Chemistry, 2014, 289, 3339-3351.	1.6	45
280	The Clinical Use of PET/CT in the Evaluation of Melanoma. Methods in Molecular Biology, 2014, 1102, 553-580.	0.4	9
281	c-Kitâ€“Positive Cardiac Stem Cells Nested in Hypoxic Niches Are Activated by Stem Cell Factor Reversing the Aging Myopathy. Circulation Research, 2014, 114, 41-55.	2.0	87

#	Article	IF	Citations
282	Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. British Journal of Cancer, 2014, 110, 172-182.	2.9	135
283	Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications. Sub-Cellular Biochemistry, 2014, , .	1.0	49
284	Identifying novel targets in renal cell carcinoma: Design and synthesis of affinity chromatography reagents. Bioorganic and Medicinal Chemistry, 2014, 22, 711-720.	1.4	6
285	MUC4-induced nuclear translocation of Î²-catenin: A novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. Cancer Letters, 2014, 346, 104-113.	3.2	54
286	Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1Î±. Biochemical Pharmacology, 2014, 89, 20-30.	2.0	31
287	miR-210: Fine-Tuning the Hypoxic Response. Advances in Experimental Medicine and Biology, 2014, 772, 205-227.	0.8	101
288	Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response. Acta Biochimica Et Biophysica Sinica, 2014, 46, 220-232.	0.9	72
289	Tumor Microenvironment and Cellular Stress. Advances in Experimental Medicine and Biology, 2014, 772, v-viii.	0.8	29
290	Carbonic Anhydrase IX (CAIX) as a Mediator of Hypoxia-Induced Stress Response in Cancer Cells. Sub-Cellular Biochemistry, 2014, 75, 255-269.	1.0	63
291	Gene expression alterations in chronic hypoxic MCF7 breast cancer cell line. Genomics, 2014, 104, 477-481.	1.3	20
292	Complete Stereochemistry and Preliminary Structureâ€“Activity Relationship of Rakicidin A, a Hypoxia-Selective Cytotoxin from Micromonospora sp.. Journal of Natural Products, 2014, 77, 2561-2565.	1.5	35
293	Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 2014, 26, 605-622.	7.7	1,184
294	15â€LOXâ€1 suppression of hypoxiaâ€induced metastatic phenotype and HIFâ€1 Î± expression in human colon cancer cells. Cancer Medicine, 2014, 3, 472-484.	1.3	20
295	Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Bioorganic and Medicinal Chemistry, 2014, 22, 6796-6805.	1.4	19
296	The unexpected effect of PEGylated gold nanoparticles on the primary function of erythrocytes. Nanoscale, 2014, 6, 9017-9024.	2.8	51
297	Targeting hypoxia in the treatment of small cell lung cancer. Lung Cancer, 2014, 86, 126-132.	0.9	26
298	Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000. Organic and Biomolecular Chemistry, 2014, 12, 3386-3392.	1.5	22
299	Friend Leukemia Virus Integration 1 Expression Has Prognostic Significance in Nasopharyngeal Carcinoma. Translational Oncology, 2014, 7, 493-502.	1.7	12

#	Article	IF	Citations
300	Ru(II) Dyads Derived from 2-(1-Pyrenyl)-1H-imidazo[4,5-f][1,10]phenanthroline: Versatile Photosensitizers for Photodynamic Applications. Journal of Physical Chemistry A, 2014, 118, 10507-10521.	1.1	90
301	Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming. Cell Research, 2014, 24, 1121-1136.	5.7	38
302	2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Letters, 2014, 355, 96-105.	3.2	73
303	Tetracycline analogues with a selective inhibitory effect on HIF-1Î±. MedChemComm, 2014, 5, 923.	3.5	3
304	Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opinion on Drug Delivery, 2014, 11, 1601-1618.	2.4	33
305	ATP-triggered anticancer drug delivery. Nature Communications, 2014, 5, 3364.	5.8	571
306	Ultrasensitive Nanosensors Based on Upconversion Nanoparticles for Selective Hypoxia Imaging in Vivo upon Near-Infrared Excitation. Journal of the American Chemical Society, 2014, 136, 9701-9709.	6.6	304
307	Quantitative measurement of redox potential in hypoxic cells using SERS nanosensors. Nanoscale, 2014, 6, 12104-12110.	2.8	67
308	Isotopic Labeling Experiments That Elucidate the Mechanism of DNA Strand Cleavage by the Hypoxia-Selective Antitumor Agent 1,2,4-Benzotriazine 1,4-Di-N-oxide. Chemical Research in Toxicology, 2014, 27, 111-118.	1.7	13
309	Comparison of the Hypoxia PET Tracer ¹⁸F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. Journal of Nuclear Medicine, 2014, 55, 1192-1197.	2.8	18
313	Redox Regulation of Cancer Metastasis: Molecular Signaling and Therapeutic Opportunities. Drug Development Research, 2014, 75, 331-341.	1.4	40
314	Toward Hypoxia-Selective DNA-Alkylating Agents Built by Grafting Nitrogen Mustards onto the Bioreductively Activated, Hypoxia-Selective DNA-Oxidizing Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine). Journal of Organic Chemistry, 2014, 79, 7520-7531.	1.7	24
315	Vessel calibreâ€"a potential MRI biomarker of tumour response in clinical trials. Nature Reviews Clinical Oncology, 2014, 11, 566-584.	12.5	55
318	Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles. ACS Nano, 2014, 8, 8374-8382.	7.3	161
319	Synthesis, crystal structure description, electrochemical, and DNA-binding studies of â€œpaddlewheelâ€• copper(II) carboxylate. Journal of Coordination Chemistry, 2014, 67, 1731-1745.	0.8	29
320	Prodrug Applications for Targeted Cancer Therapy. AAPS Journal, 2014, 16, 899-913.	2.2	87
321	The Role of Mechanical Forces in Tumor Growth and Therapy. Annual Review of Biomedical Engineering, 2014, 16, 321-346.	5.7	742
322	Site-directed delivery of nitric oxide to cancers. Nitric Oxide - Biology and Chemistry, 2014, 43, 8-16.	1.2	39

#	Article	IF	Citations
323	An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. British Journal of Radiology, 2014, 87, 20130753.	1.0	40
324	Defining normoxia, physoxia and hypoxia in tumoursâ€"implications for treatment response. British Journal of Radiology, 2014, 87, 20130676.	1.0	694
325	Engineering strategies to mimic the glioblastoma microenvironment. Advanced Drug Delivery Reviews, 2014, 79-80, 172-183.	6.6	118
326	Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochemical Pharmacology, 2014, 92, 12-21.	2.0	44
327	Calpains and cancer: Friends or enemies?. Archives of Biochemistry and Biophysics, 2014, 564, 26-36.	1.4	55
328	Modulation of Blood Flow, Hypoxia, and Vascular Function in Orthotopic Prostate Tumors During Exercise. Journal of the National Cancer Institute, 2014, 106, dju036.	3.0	102
329	Metabolic-Stress-Induced Rearrangement of the 14-3-3Î¶ Interactome Promotes Autophagy via a ULK1- and AMPK-Regulated 14-3-3Î¶ Interaction with Phosphorylated Atg9. Molecular and Cellular Biology, 2014, 34, 4379-4388.	1.1	93
330	Influence of Phosphate and Phosphoesters on the Decomposition Pathway of		

#	Article	IF	Citations
342	Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. Expert Opinion on Biological Therapy, 2014, 14, 1145-1159.	1.4	43
343	Obesity and cancerâ€"mechanisms underlying tumour progression and recurrence. Nature Reviews Endocrinology, 2014, 10, 455-465.	4.3	575
344	New PARP targets for cancer therapy. Nature Reviews Cancer, 2014, 14, 502-509.	12.8	143
345	4â€²,6-Dihydroxy-4-methoxyisoaurone Inhibits the HIF-1Î± Pathway Through Inhibition of Akt/mTOR/p70S6K/4E-BP1 Phosphorylation. Journal of Pharmacological Sciences, 2014, 125, 193-201.	1.1	29
346	Transgelin overexpression in lung adenocarcinoma is associated with tumor progression. International Journal of Molecular Medicine, 2014, 34, 585-591.	1.8	30
347	Synthesis, Anticancer Activity and UPLC Analysis of the Stability of Some New Benzimidazole-4,7-dione Derivatives. Molecules, 2014, 19, 400-413.	1.7	21
348	Hypoxia and fatty liver. World Journal of Gastroenterology, 2014, 20, 15087.	1.4	79
349	Crystal structure ofN-(quinolin-6-yl)hydroxylamine. Acta Crystallographica Section E: Structure Reports Online, 2014, 70, 322-324.	0.2	1
350	Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. Oncology Reports, 2014, 32, 723-729.	1.2	17
351	The glioblastoma vasculature as a target for cancer therapy. Biochemical Society Transactions, 2014, 42, 1647-1652.	1.6	41
352	KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung cancer cells via HIF-1Î±. International Journal of Oncology, 2014, 45, 1507-1514.	1.4	50
353	Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S13693.	0.6	35
354	In vivo ¹<scp>H</scp><scp>MR</scp> spectroscopic imaging of aggressive prostate cancer: Can we detect lactate?. Magnetic Resonance in Medicine, 2014, 71, 26-34.	1.9	21
355	Hypoxia After Liver Surgery Imposes an Aggressive Cancer Stem Cell Phenotype on Residual Tumor Cells. Annals of Surgery, 2014, 259, 750-759.	2.1	47
356	Tumorspezifische, Hypoxieâ€basierte Aktivierung von EGFRâ€Inhibitoren. Angewandte Chemie, 2014, 126, 13144-13149.	1.6	8
357	Photodegradation of the Benzotriazine 1,4-Di-N-Oxide Hypoxia-Activated Prodrug SN30000 in Aqueous Solution. Journal of Pharmaceutical Sciences, 2014, 103, 3464-3472.	1.6	7
358	Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1Î± functional interplay. International Journal of Oncology, 2014, 44, 2121-2131.	1.4	64
359	Transglutaminase II and Metastasis: How Hot Is the Link?. , 2015, , 215-228.		0

#	Article	IF	Citations
360	Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonatorâ€based oximetry. International Journal of Cancer, 2015, 136, 1688-1696.	2.3	19
361	Suppression of miRâ€199a maturation by HuR isÂcrucial for hypoxiaâ€induced glycolytic switch inÂhepatocellular carcinoma. EMBO Journal, 2015, 34, 2671-2685.	3.5	84
363	Role of TGFÎ² in regulation of the tumor microenvironment and drug delivery (Review). International Journal of Oncology, 2015, 46, 933-943.	1.4	160
364	Azo-Based Iridium(III) Complexes as Multicolor Phosphorescent Probes to Detect Hypoxia in 3D Multicellular Tumor Spheroids. Scientific Reports, 2015, 5, 14837.	1.6	52
365	The accumulation mechanism of the hypoxia imaging probe â€œFMISOâ€•by imaging mass spectrometry: possible involvement of low-molecular metabolites. Scientific Reports, 2015, 5, 16802.	1.6	56
368	Kill-painting of hypoxic tumours in charged particle therapy. Scientific Reports, 2015, 5, 17016.	1.6	124
369	X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo. Molecular Medicine Reports, 2015, 12, 3115-3120.	1.1	4
370	Increased expression of surface CD44 in hypoxia-DCs skews helper T cells toward a Th2 polarization. Scientific Reports, 2015, 5, 13674.	1.6	19
371	Texture Analysis of Nonâ€“Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma. Journal of Computer Assisted Tomography, 2015, 39, 607-612.	0.5	45
372	Oxygenâ€Sensing Methods in Biomedicine from the Macroscale to the Microscale. Angewandte Chemie - International Edition, 2015, 54, 8340-8362.	7.2	145
373	A mechanistic investigation of the oxygen fixation hypothesis and oxygen enhancement ratio. Biomedical Physics and Engineering Express, 2015, 1, 045209.	0.6	107
374	Occupational Exposure to Veterinary Workers from the Positron Emission Tomography Imaging Agent 64Cu-ATSM. Health Physics, 2015, 109, S219-S223.	0.3	2
377	Cell Death Conversion under Hypoxic Condition in Tumor Development and Therapy. International Journal of Molecular Sciences, 2015, 16, 25536-25551.	1.8	35
378	Hypoxia: from basic mechanisms to therapeutics – a meeting report on the Keystone and HypoxiaNet Symposium. Hypoxia (Auckland, N Z), 2015, 3, 67.	1.9	2
379	Ultrasound-guided RNA interference targeting HIF-1 alpha improves the effects of transarterial chemoembolization in rat liver tumors. OncoTargets and Therapy, 2015, 8, 3539.	1.0	8
380	ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. ELife, 2015, 4, e10870.	2.8	71
381	Ginseng Metabolites on Cancer Chemoprevention: An Angiogenesis Link?. Diseases (Basel, Switzerland), 2015, 3, 193-204.	1.0	29
382	RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2Î± Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo. International Journal of Molecular Sciences, 2015, 16, 16263-16274.	1.8	11

#	Article	IF	Citations
383	Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. International Journal of Molecular Sciences, 2015, 16, 26936-26952.	1.8	38
384	Structure-Activity Relationship and in Vivo Anti-Tumor Evaluations of Dictyoceratin-A and -C, Hypoxia-Selective Growth Inhibitors from Marine Sponge. Marine Drugs, 2015, 13, 7419-7432.	2.2	20
385	Cancer Metabolism and Drug Resistance. Metabolites, 2015, 5, 571-600.	1.3	130
386	Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. Frontiers in Oncology, 2015, 5, 170.	1.3	27
387	Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy. Frontiers in Oncology, 2015, 5, 214.	1.3	96
388	Radiation-Induced Alterations of Osteogenic and Chondrogenic Differentiation of Human Mesenchymal Stem Cells. PLoS ONE, 2015, 10, e0119334.	1.1	14
389	ACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via Î±-ketoglutarate. PLoS Genetics, 2015, 11, e1005599.	1.5	36
390	Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy. PLoS ONE, 2015, 10, e0136725.	1.1	8
391	Hypoxia-Targeted Drug Q6 Induces G2-M Arrest and Apoptosis via Poisoning Topoisomerase II under Hypoxia. PLoS ONE, 2015, 10, e0144506.	1.1	9
392	Oxygen Availability for Porphyrin Biosynthesis Enzymes Determines the Production of Protoporphyrin IX (PpIX) during Hypoxia. PLoS ONE, 2015, 10, e0146026.	1.1	15
393	The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckland, N Z), 2015, 3, 83.	1.9	1,372
394	The Transcription Factor ZNF395 Is Required for the Maximal Hypoxic Induction of Proinflammatory Cytokines in U87-MG Cells. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	13
396	Repurposing Drugs in Oncology (ReDO)â€"nitroglycerin as an anti-cancer agent. Ecancermedicalscience, 2015, 9, 568.	0.6	34
397	Improved In Vitro Human Tumor Models for Cancer Gene Therapy. Human Gene Therapy, 2015, 26, 249-256.	1.4	6
398	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. Radiotherapy and Oncology, 2015, 116, 94-99.	0.3	44
399	HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFÎ²-signaling in hypoxic microenvironment.. Scientific Reports, 2015, 5, 9650.	1.6	79
400	Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapyâ€"Are We There Yet?. Cancer Journal (Sudbury, Mass), 2015, 21, 337-342.	1.0	8
401	MRI assessment of changes in tumor oxygenation post hypoxia-targeted therapy. , 2015, , .		2

#	Article	IF	Citations
402	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 2015, 100, 927-934.	1.7	93
403	Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them. Cancer Journal (Sudbury, Mass), 2015, 21, 254-262.	1.0	53
404	Transglutaminases. , 2015, , .		10
405	Optical imaging of hemoglobin oxygen saturation using a small number of spectral images for endoscopic application. Journal of Biomedical Optics, 2015, 20, 126011.	1.4	19
406	Measurement of the acute metabolic response to hypoxia in rat tumours in vivo using magnetic resonance spectroscopy and hyperpolarised pyruvate. Radiotherapy and Oncology, 2015, 116, 392-399.	0.3	8
407	Ubiquitin ligase Siah1 promotes the migration and invasion of human glioma cells by regulating HIF-1Î± signaling under hypoxia. Oncology Reports, 2015, 33, 1185-1190.	1.2	23
408	M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1Î± in human breast cancer cells. Oncology Reports, 2015, 34, 334-340.	1.2	6
409	CXCR4 inhibition in tumor microenvironment facilitates antiâ€programmed death receptorâ€1 immunotherapy in sorafenibâ€treated hepatocellular carcinoma in mice. Hepatology, 2015, 61, 1591-1602.	3.6	355
410	Optimizing Hypoxia Detection and Treatment Strategies. Seminars in Nuclear Medicine, 2015, 45, 163-176.	2.5	40
411	Radiopharmaceuticals as probes to characterize tumour tissue. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 537-561.	3.3	14
413	Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1Î± pathway to predict survival in resectable pancreatic cancer. British Journal of Cancer, 2015, 112, 514-522.	2.9	39
414	Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death and Disease, 2015, 6, e1636-e1636.	2.7	202
415	Resistance to Targeted ABC Transporters in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , .	0.1	3
416	Antitumor Sulfonylhydrazines: Design, Structureâ€“Activity Relationships, Resistance Mechanisms, and Strategies for Improving Therapeutic Utility. Journal of Medicinal Chemistry, 2015, 58, 3639-3671.	2.9	12
417	Tumor Microenvironment Activated Photothermal Strategy for Precisely Controlled Ablation of Solid Tumors upon NIR Irradiation. Advanced Functional Materials, 2015, 25, 1574-1580.	7.8	129
418	The circadian clock and hypoxia in tumor cell de-differentiation and metastasis. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1633-1641.	1.1	19
419	Long nonâ€coding RNAâ€LET is a positive prognostic factor and exhibits tumorâ€suppressive activity in gallbladder cancer. Molecular Carcinogenesis, 2015, 54, 1397-1406.	1.3	62
420	An internal ribosome entry site in the 5â€² untranslated region of epidermal growth factor receptor allows hypoxic expression. Oncogenesis, 2015, 4, e134-e134.	2.1	12

#	Article	IF	Citations
421	Noncanonical Amino Acids to Improve the pH Response of pHLIP Insertion at Tumor Acidity. Angewandte Chemie - International Edition, 2015, 54, 3658-3663.	7.2	72
422	Imaging tumour hypoxia with positron emission tomography. British Journal of Cancer, 2015, 112, 238-250.	2.9	272
423	Advanced targeted nanomedicine. Journal of Biotechnology, 2015, 202, 88-97.	1.9	54
424	FGF2 as a potential prognostic biomarker for proneural glioma patients. Acta OncolÃ³gica, 2015, 54, 385-394.	0.8	22
425	Bimetallic lanthanide complexes that display a ratiometric response to oxygen concentrations. Chemical Science, 2015, 6, 2054-2059.	3.7	71
426	Combined therapies of antithrombotics and antioxidants delayin silicobrain tumour progression. Mathematical Medicine and Biology, 2015, 32, 239-262.	0.8	22
427	F-18 Fluoromisonidazole for Imaging Tumor Hypoxia: Imaging the Microenvironment for Personalized Cancer Therapy. Seminars in Nuclear Medicine, 2015, 45, 151-162.	2.5	106
428	A paper-based invasion assay: Assessing chemotaxis of cancer cells in gradients of oxygen. Biomaterials, 2015, 52, 262-271.	5.7	132
429	The Clinical Significance of Hypoxia in Human Cancers. Seminars in Nuclear Medicine, 2015, 45, 110-121.	2.5	166
430	Textbook of Cell Signalling in Cancer. , 2015, , .		6
431	ROS and Autophagy: Interactions and Molecular Regulatory Mechanisms. Cellular and Molecular Neurobiology, 2015, 35, 615-621.	1.7	603
432	[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. Molecular Imaging and Biology, 2015, 17, 615-619.	1.3	40
433	Signalling by Oxygen and Nitric Oxide. , 2015, , 191-201.		0
434	Minocycline ameliorates hypoxia-induced bloodâ€“brain barrier damage by inhibition of HIF-1Î± through SIRT-3/PHD-2 degradation pathway. Neuroscience, 2015, 304, 250-259.	1.1	54
435	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	21.5	1,058
436	Synthesis of pH sensitive gold nanoparticles for potential application in radiosensitization. Materials Science and Engineering C, 2015, 55, 34-41.	3.8	10
437	Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases. AAPS Journal, 2015, 17, 813-827.	2.2	37
438	Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clinical Cancer Research, 2015, 21, 2898-2904.	3.2	176

#	Article	IF	Citations
439	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clinical Cancer Research, 2015, 21, 2984-2992.	3.2	95
440	Some characteristics of activity of potential chemotherapeutics â€“ benzimidazole derivatives. Advances in Medical Sciences, 2015, 60, 125-132.	0.9	13
441	Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate Evofosfamide (TH-302). Organic Chemistry Frontiers, 2015, 2, 1026-1029.	2.3	19
442	CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials, 2015, 67, 194-203.	5.7	108
443	Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Investigational New Drugs, 2015, 33, 835-847.	1.2	44
444	Long noncoding RNA HOTAIR, a hypoxia-inducible factor-1Î± activated driver of malignancy, enhances hypoxic cancer cell proliferation, migration, and invasion in non-small cell lung cancer. Tumor Biology, 2015, 36, 9179-9188.	0.8	101
445	Modulation of the tumor vasculature and oxygenation to improve therapy. , 2015, 153, 107-124.		104
446	The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treatment Reviews, 2015, 41, 623-633.	3.4	44
447	Advances in cobalt complexes as anticancer agents. Dalton Transactions, 2015, 44, 13796-13808.	1.6	219
448	Hypoxia signalling manipulation for bone regeneration. Expert Reviews in Molecular Medicine, 2015, 17, e6.	1.6	59
449	Mechanisms of Drug Release in Nanotherapeutic Delivery Systems. Chemical Reviews, 2015, 115, 3388-3432.	23.0	412
450	Targeting Tumor Hypoxia With Hypoxia-Activated Prodrugs. Journal of Clinical Oncology, 2015, 33, 1505-1508.	0.8	41
451	Ultrasensitive Near-Infrared Fluorescence-Enhanced Probe for in Vivo Nitroreductase Imaging. Journal of the American Chemical Society, 2015, 137, 6407-6416.	6.6	408
452	Automated synthesis and PET evaluation of both enantiomers of [18F]FMISO. Nuclear Medicine and Biology, 2015, 42, 413-419.	0.3	7
453	Nitroimidazole-Containing H2dedpa and H2CHXdedpa Derivatives as Potential PET Imaging Agents of Hypoxia with 68Ga. Inorganic Chemistry, 2015, 54, 4953-4965.	1.9	26
454	PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discovery Today, 2015, 20, 306-317.	3.2	43
455	Complex micelles with the bioactive function of reversible oxygen transfer. Nano Research, 2015, 8, 491-501.	5.8	11
456	Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy. RSC Advances, 2015, 5, 20848-20857.	1.7	40

#	Article	IF	Citations
457	Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302. Cancer & Metabolism, 2015, 3, 2.	2.4	69
458	Imaging Cell and Tissue O2 by TCSPC-PLIM. Springer Series in Chemical Physics, 2015, , 225-247.	0.2	7
459	Tumor chemosensitization by physical exercise? Insights from an animal model. Future Oncology, 2015, 11, 885-887.	1.1	2
460	Hypoxia and Predicting Radiation Response. Seminars in Radiation Oncology, 2015, 25, 260-272.	1.0	73
461	Genomic Analyses Reveal Potential Independent Adaptation to High Altitude in Tibetan Chickens. Molecular Biology and Evolution, 2015, 32, 1880-1889.	3.5	193
462	Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulationâ€"An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302. Clinical Cancer Research, 2015, 21, 2107-2114.	3.2	59
463	Molecular mechanisms of mTOR regulation by stress. Molecular and Cellular Oncology, 2015, 2, e970489.	0.3	62
464	Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma. Cancer Research, 2015, 75, 2071-2082.	0.4	160
465	Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair, 2015, 32, 180-189.	1.3	122
466	Enhancement of vascular endothelial growth factor release in long-term drug-treated breast cancer via transient receptor potential channel 5-Ca2+-hypoxia-inducible factor 1Î± pathway. Pharmacological Research, 2015, 93, 36-42.	3.1	36
467	Exploiting replicative stress to treat cancer. Nature Reviews Drug Discovery, 2015, 14, 405-423.	21.5	243
468	Benzimidazole derivatives as anticancer drugs: A theoretical investigation. Journal of Theoretical and Computational Chemistry, 2015, 14, 1550018.	1.8	5
469	Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand. Clinical Cancer Research, 2015, 21, 1995-2000.	3.2	43
470	Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell, 2015, 161, 790-802.	13.5	626
471	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Research and Treatment, 2015, 150, 559-567.	1.1	56
472	Rhodamine-6G can photosensitize folic acid decomposition through electron transfer. Chemical Physics Letters, 2015, 627, 26-29.	1.2	5
473	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1475-1481.	0.8	152
474	The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death and Disease, 2015, 6, e1600-e1600.	2.7	97

#	Article	IF	Citations
475	AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. Cell Stem Cell, 2015, 17, 585-596.	5.2	200
476	Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 1593-1605.	1.5	28
477	Efficient Two-Photon Fluorescent Probe for Nitroreductase Detection and Hypoxia Imaging in Tumor Cells and Tissues. Analytical Chemistry, 2015, 87, 11832-11839.	3.2	135
478	Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer, 2015, 15, 422.	1.1	16
479	Bioreductive deprotection of 4-nitrobenzyl group on thymine base in oligonucleotides for the activation of duplex formation. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5632-5635.	1.0	17
480	Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1840-1849.	3.3	55
481	A cyanine-derived â€œturn-onâ€•fluorescent probe for imaging nitroreductase in hypoxic tumor cells. Analytical Methods, 2015, 7, 10125-10128.	1.3	26
482	Designer hydrogels for precision control of oxygen tension and mechanical properties. Journal of Materials Chemistry B, 2015, 3, 7939-7949.	2.9	23
483	A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic ranges. Analytical Biochemistry, 2015, 491, 1-3.	1.1	3
484	Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. Journal of Controlled Release, 2015, 219, 295-312.	4.8	11
485	In vitro engineering of human 3D chondrosarcoma: a preclinical model relevant for investigations of radiation quality impact. BMC Cancer, 2015, 15, 579.	1.1	34
486	Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. British Journal of Cancer, 2015, 113, 864-871.	2.9	63
487	Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53. Molecular Cancer Research, 2015, 13, 1533-1543.	1.5	6
488	Functional significance of macrophages in pancreatic cancer biology. Tumor Biology, 2015, 36, 9119-9126.	0.8	15
489	Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer Research, 2015, 75, 4839-4851.	0.4	62
490	Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-1Î±. Chemico-Biological Interactions, 2015, 240, 48-58.	1.7	11
491	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Research, 2015, 75, 4211-4223.	0.4	65
492	Metal Stable Isotopes in the Human Body: A Tribute of Geochemistry to Medicine. Elements, 2015, 11, 265-269.	0.5	47

#	Article	IF	Citations
493	Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chemical Reviews, 2015, 115, 10530-10574.	23.0	864
494	Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biology and Therapy, 2015, 16, 610-622.	1.5	27
495	Are BiTEs the â€œmissing linkâ€•in cancer therapy?. OncoImmunology, 2015, 4, e1008339.	2.1	59
496	New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 2015, 116, 352-357.	0.3	49
497	Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma â€“ an auto-commentary on clinical potential and future development. OncoImmunology, 2015, 4, e1029703.	2.1	9
498	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Reviews and Reports, 2015, 11, 919-943.	5.6	72
499	Stimuli-responsive nanoparticles for targeting the tumor microenvironment. Journal of Controlled Release, 2015, 219, 205-214.	4.8	271
500	Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield. Organic and Biomolecular Chemistry, 2015, 13, 11220-11227.	1.5	30
501	The twisted survivin connection to angiogenesis. Molecular Cancer, 2015, 14, 198.	7.9	64
502	Marine Sponge Derived Antiangiogenic Compounds. , 2015, , 29-58.		2
503	Copper isotope effect in serum of cancer patients. A pilot study. Metallomics, 2015, 7, 299-308.	1.0	99
504	Galbanic acid inhibits HIF-1Î± expression via EGFR/HIF-1Î± pathway in cancer cells. FÃ¬toterapÃ¬Ã¢, 2015, 101, 1-11	1.1	48
505	Differential contribution of key metabolic substrates and cellular oxygen in HIF signalling. Experimental Cell Research, 2015, 330, 13-28.	1.2	24
506	Hypoxia Activation of Mitophagy and Its Role in Disease Pathogenesis. Antioxidants and Redox Signaling, 2015, 22, 1032-1046.	2.5	80
507	EMT in cervical cancer: Its role in tumour progression and response to therapy. Cancer Letters, 2015, 356, 321-331.	3.2	202
508	Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma. Cancer Research, 2015, 75, 316-329.	0.4	34
509	Nanotechnology to Combat Multidrug Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 245-272.	0.1	5
510	Ru(II) dyads derived from Î±-oligothiophenes: A new class of potent and versatile photosensitizers for PDT. Coordination Chemistry Reviews, 2015, 282-283, 127-138.	9.5	226

#	Article	IF	Citations
511	Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 2015, 29, 981-984.	3.3	28
512	Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. European Journal of Medicinal Chemistry, 2015, 89, 826-834.	2.6	23
513	Microbial amphiphiles: a class of promising new-generation anticancer agents. Drug Discovery Today, 2015, 20, 136-146.	3.2	47
514	Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Seminars in Cancer Biology, 2015, 31, 52-64.	4.3	257
515	Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene, 2015, 34, 3640-3650.	2.6	168
516	Engineering of stimuli-sensitive nanopreparations to overcome physiological barriers and cancer multidrug resistance. , 2016, , 1-28.		6
517	Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer. Hypoxia (Auckland, N Z), 2016, Volume 4, 163-174.	1.9	2
518	The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug. Oncotarget, 2016, 7, 48467-48480.	0.8	10
519	c-Myc is regulated by HIF-2Î± in chronic hypoxia and influences sensitivity to 5-FU in colon cancer. Oncotarget, 2016, 7, 78910-78917.	0.8	25
520	Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. Oncotarget, 2016, 7, 37081-37091.	0.8	105
521	Correlation-Based Network Generation, Visualization, and Analysis as a Powerful Tool in Biological Studies: A Case Study in Cancer Cell Metabolism. BioMed Research International, 2016, 2016, 1-9.	0.9	68
522	Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-16.	1.9	225
523	Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. Oncotarget, 2016, 7, 36666-36680.	0.8	25
524	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. Frontiers in Cell and Developmental Biology, 2016, 4, 27.	1.8	107
525	Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines, 2016, 4, 46.	2.1	87
526	Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now?. International Journal of Nanomedicine, 2016, Volume 11, 3191-3203.	3.3	54
527	Diverse Mechanisms of Sp1-Dependent Transcriptional Regulation Potentially Involved in the Adaptive Response of Cancer Cells to Oxygen-Deficient Conditions. Cancers, 2016, 8, 2.	1.7	32
528	Targeting DNA Replication Stress for Cancer Therapy. Genes, 2016, 7, 51.	1.0	76

#	Article	IF	Citations
529	Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes. Journal of Clinical Medicine, 2016, 5, 24.	1.0	48
530	Biosurfactants Produced by Marine Microorganisms with Therapeutic Applications. Marine Drugs, 2016, 14, 38.	2.2	129
531	Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia. Molecules, 2016, 21, 1693.	1.7	9
532	Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A. PLoS ONE, 2016, 11, e0150219.	1.1	22
533	Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent â€œPimonidazoleâ€•in Hypoxia. PLoS ONE, 2016, 11, e0161639.	1.1	23
534	Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells. Molecular Medicine Reports, 2016, 14, 1817-1822.	1.1	21
535	Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. Journal of Cancer, 2016, 7, 314-323.	1.2	247
536	Overview of DNA repair pathways, current targets, and clinical trials bench to clinic. , 2016, , 1-54.		6
537	Recent Advances of Light-Mediated Theranostics. Theranostics, 2016, 6, 2439-2457.	4.6	171
538	Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes proteinO-glycosylation extension. Oncotarget, 2016, 7, 63138-63157.	0.8	58
539	Metformin suppresses hypoxia-induced stabilization of HIF-1Î± through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget, 2016, 7, 873-884.	0.8	89
540	Phase I study of evofosfamide, an investigational hypoxiaâ€activated prodrug, in patients with advanced leukemia. American Journal of Hematology, 2016, 91, 800-805.	2.0	31
541	Reductionâ€Responsive Guanine Incorporated into Gâ€Quadruplexâ€Forming DNA. ChemBioChem, 2016, 17, 1304-1307.	1.3	17
542	Iridium(III) Anthraquinone Complexes as Twoâ€Photon Phosphorescence Probes for Mitochondria Imaging and Tracking under Hypoxia. Chemistry - A European Journal, 2016, 22, 8955-8965.	1.7	67
543	Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 189-205.	2.0	136
544	Mortalin-mediated and ERK-controlled targeting of HIF-1Î± to mitochondria confers resistance to apoptosis under hypoxia. Journal of Cell Science, 2017, 130, 466-479.	1.2	64
545	Effects of RNAi-mediated TUSC3 silencing on radiation-induced autophagy and radiation sensitivity of human lung adenocarcinoma cell line A549 under hypoxic condition. Tumor Biology, 2016, 37, 16357-16365.	0.8	10
546	MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Scientific Reports, 2016, 6, 22793.	1.6	28

#	Article	IF	Citations
547	Radiosensitizing Effect of TRPV1 Channel Inhibitors in Cancer Cells. Biological and Pharmaceutical Bulletin, 2016, 39, 1224-1230.	0.6	13
548	Usefulness of positron emission tomographic studies for gliomas. Neurologia Medico-Chirurgica, 2016, 56, 396-408.	1.0	15
549	Artificial neural network classifier predicts neuroblastoma patientsâ€™ outcome. BMC Bioinformatics, 2016, 17, 347.	1.2	32
550	Communication: â€œPositionâ€•does matter: The photofragmentation of the nitroimidazole isomers. Journal of Chemical Physics, 2016, 145, 191102.	1.2	25
551	Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer. EJNMMI Physics, 2016, 3, 30.	1.3	13
552	Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response. Npj Genomic Medicine, 2016, 1, 16020.	1.7	22
553	Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1Î±/HDAC1/Slug axis. Nature Communications, 2016, 7, 13867.	5.8	69
554	Aptamer-PEG-modified Fe3O4@Mn as a novel T1- and T2- dual-model MRI contrast agent targeting hypoxia-induced cancer stem cells. Scientific Reports, 2016, 6, 39245.	1.6	34
555	Hypoxia increases genome-wide bivalent epigenetic marking by specific gain of H3K27me3. Epigenetics and Chromatin, 2016, 9, 46.	1.8	63
556	Proteomic profiling reveals that collismycin A is an iron chelator. Scientific Reports, 2016, 6, 38385.	1.6	29
557	Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and Implications for Cancer Therapy. Neoplasia, 2016, 18, 732-741.	2.3	87
558	UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncology Letters, 2016, 12, 4485-4492.	0.8	41
559	Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia. Radiation Oncology, 2016, 11, 75.	1.2	27
560	The impact of hypoxia and its modification of the outcome of radiotherapy. Journal of Radiation Research, 2016, 57, i90-i98.	0.8	229
561	Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radical Biology and Medicine, 2016, 100, 175-181.	1.3	137
562	Real-Time Bioluminescence Imaging of Nitroreductase in Mouse Model. Analytical Chemistry, 2016, 88, 5610-5614.	3.2	73
563	The Current and Evolving Role of PET in Personalized Management of Lung Cancer. PET Clinics, 2016, 11, 243-259.	1.5	7
564	Cold-inducible proteins CIRP and RBM3, a unique couple with activities far beyond the cold. Cellular and Molecular Life Sciences, 2016, 73, 3839-3859.	2.4	182

#	Article	IF	Citations
565	A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nature Nanotechnology, 2016, 11, 724-730.	15.6	411
566	Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors. Molecular Pharmaceutics, 2016, 13, 2283-2289.	2.3	36
567	In Vivo Chemiluminescent Imaging Agents for Nitroreductase and Tissue Oxygenation. Analytical Chemistry, 2016, 88, 4995-5002.	3.2	109
568	Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. British Journal of Cancer, 2016, 114, 1071-1077.	2.9	155
569	Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-Î². Cell Death and Disease, 2016, 7, e2191-e2191.	2.7	23
570	Simultaneous fluorescence imaging of selenol and hydrogen peroxide under normoxia and hypoxia in HepG2 cells and in vivo. Chemical Communications, 2016, 52, 6693-6696.	2.2	31
571	Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 197-202.	2.5	21
572	Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, 164, 152-169.		507
573	A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response. British Journal of Cancer, 2016, 114, 1206-1211.	2.9	11
574	Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nature Reviews Clinical Oncology, 2016, 13, 611-626.	12.5	103
575	Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives. Chemical Communications, 2016, 52, 8492-8500.	2.2	125
576	Hypoxic tumor microenvironment: Opportunities to develop targeted therapies. Biotechnology Advances, 2016, 34, 803-812.	6.0	152
577	Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging. Cancer Research, 2016, 76, 769-772.	0.4	48
578	RNA. , 2016, , 290-313.		0
579	Synthesis and Characterization of Cell-Permeable Oligonucleotides Bearing Reduction-Activated Protecting Groups on the Internucleotide Linkages. Bioconjugate Chemistry, 2016, 27, 2149-2156.	1.8	17
580	Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors. Advanced Healthcare Materials, 2016, 5, 2788-2798.	3.9	51
581	Hibernation for space travel: Impact on radioprotection. Life Sciences in Space Research, 2016, 11, 1-9.	1.2	57
582	An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome. Acta Biomaterialia, 2016, 44, 341-354.	4.1	34

#	Article	IF	Citations
583	Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization. MedChemComm, 2016, 7, 2418-2427.	3.5	35
584	Tumor microenvironment-mediated chemoresistance in breast cancer. Breast, 2016, 30, 92-100.	0.9	112
585	The A 2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism. Cancer Letters, 2016, 383, 135-143.	3.2	23
586	Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chemical Society Reviews, 2016, 45, 6597-6626.	18.7	1,483
587	Targeting a Targeted Drug: An Approach Toward Hypoxiaâ€Activatable Tyrosine Kinase Inhibitor Prodrugs. ChemMedChem, 2016, 11, 2410-2421.	1.6	18
588	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11937-11942.	3.3	37
590	Kamebakaurin inhibits the expression of hypoxia-inducible factor-1Î± and its target genes to confer antitumor activity. Oncology Reports, 2016, 35, 2045-2052.	1.2	6
591	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a027094.	2.9	119
592	Hypoxia-induced epithelial-mesenchymal transition is regulated by phosphorylation of GSK3-Î² via PI3 K/Akt signaling in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, 719-730.	0.2	15
593	Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1Î± via mTOR/4E-BP1 signaling pathways. International Immunopharmacology, 2016, 39, 1-9.	1.7	24
594	Hypoxia induces copper stable isotope fractionation in hepatocellular carcinoma, in a HIF-independent manner. Metallomics, 2016, 8, 1177-1184.	1.0	32
595	Inhibition of HIF-1Î± enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1159-1167.	2.0	74
596	Multifunctional Phosphorescent Conjugated Polymer Dots for Hypoxia Imaging and Photodynamic Therapy of Cancer Cells. Advanced Science, 2016, 3, 1500155.	5.6	111
597	Investigation of cobalt(<scp>iii</scp>)-triazole systems as prototypes for hypoxia-activated drug delivery. Dalton Transactions, 2016, 45, 13671-13674.	1.6	32
598	Fibroblast activation in cancer: when seed fertilizes soil. Cell and Tissue Research, 2016, 365, 607-619.	1.5	217
599	Microenvironmentâ€Responsive Threeâ€Pronged Approach Breaking Traditional Chemotherapy to Target Cancer Stem Cells for Synergistic Inoperable Large Tumor Therapy. Small, 2016, 12, 5516-5523.	5.2	16
600	Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nature Nanotechnology, 2016, 11, 941-947.	15.6	810
601	Comparing the Effectiveness of Methods to Measure Oxygen in Tissues for Prognosis and Treatment of Cancer. Advances in Experimental Medicine and Biology, 2016, 923, 113-120.	0.8	11

#	Article	IF	Citations
602	Exosomal <scp>miR</scp>â€24â€3p impedes Tâ€cell function by targeting <scp>FGF11</scp> and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. Journal of Pathology, 2016, 240, 329-340.	2.1	184
603	Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Scientific Reports, 2016, 6, 23269.	1.6	90
604	Heralding a new paradigm in 3D tumor modeling. Biomaterials, 2016, 108, 197-213.	5.7	127
605	Alcohol, Aldehyde, and Ketone Liberation and Intracellular Cargo Release through Peroxide-Mediated Î±-Boryl Ether Fragmentation. Journal of the American Chemical Society, 2016, 138, 13353-13360.	6.6	36
606	Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. Angewandte Chemie, 2016, 128, 13353-13357.	1.6	9
607	Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. Angewandte Chemie - International Edition, 2016, 55, 13159-13163.	7.2	32
608	Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histoneÂdemethylation. Nature Cell Biology, 2016, 18, 1090-1101.	4.6	291
609	A Mitochondriaâ€Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia. Angewandte Chemie, 2016, 128, 10101-10105.	1.6	77
610	A Mitochondriaâ€Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia. Angewandte Chemie - International Edition, 2016, 55, 9947-9951.	7.2	422
611	Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor. Biomaterials, 2016, 104, 119-128.	5.7	84
612	Regulation of TAZ in cancer. Protein and Cell, 2016, 7, 548-561.	4.8	41
613	Genes and miRNA expression signatures in peripheral blood mononuclear cells in healthy subjects and patients with metabolic syndrome after acute intake of extra virgin olive oil. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1671-1680.	1.2	84
614	Hypoxia in Gliomas: Opening Therapeutical Opportunities Using a Mathematical-Based Approach. Advances in Experimental Medicine and Biology, 2016, 936, 11-29.	0.8	4
615	Discover the network mechanisms underlying the connections between aging and age-related diseases. Scientific Reports, 2016, 6, 32566.	1.6	40
616	Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line. Oncology Reports, 2016, 36, 1731-1738.	1.2	10
617	Liposome encapsulated perfluorohexane enhances radiotherapy in mice without additional oxygen supply. Journal of Translational Medicine, 2016, 14, 268.	1.8	24
618	Hypoxia: A Double-Edged Sword in Cancer Therapy. Cancer Investigation, 2016, 34, 536-545.	0.6	129
620	Cancer-derived extracellular vesicles: the â€˜soil conditionerâ€™ in breast cancer metastasis?. Cancer and Metastasis Reviews, 2016, 35, 669-676.	2.7	48

#	Article	IF	Citations
621	Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Science Translational Medicine, 2016, 8, 360ra135.	5.8	184
622	The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature Communications, 2016, 7, 12308.	5.8	173
623	Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-Î°B/HIF-1Î± signal axis. Scientific Reports, 2016, 6, 35788.	1.6	43
624	Opposing regulation of the late phase TNF response by mTORC1-IL-10 signaling and hypoxia in human macrophages. Scientific Reports, 2016, 6, 31959.	1.6	26
625	Direct and Repeated Clinical Measurements of pO2 for Enhancing Cancer Therapy and Other Applications. Advances in Experimental Medicine and Biology, 2016, 923, 95-104.	0.8	22
626	Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation. Dalton Transactions, 2016, 45, 19157-19171.	1.6	42
627	Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways. BMC Cancer, 2016, 16, 746.	1.1	35
628	Metal-based glycoconjugates and their potential in targeted anticancer chemotherapy. Metallodrugs, 2016, 1, .	1.7	14
630	Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells. Cancer Biology and Therapy, 2016, 17, 1266-1273.	1.5	7
631	PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1749-1752.	3.3	19
632	Autophagy and apoptosis: studies on the effects of bisthiosemicarbazone copper(<scp>ii</scp>) complexes on p53 and p53-null tumour cell lines. Metallomics, 2016, 8, 1255-1265.	1.0	19
633	Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck. British Journal of Cancer, 2016, 115, 1351-1358.	2.9	16
634	Development of a mathematical model to estimate intra-tumor oxygen concentrations through multi-parametric imaging. BioMedical Engineering OnLine, 2016, 15, 114.	1.3	3
635	Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. Journal of Visualized Experiments, 2016, , .	0.2	6
636	FeSe₂â€Decorated Bi₂Se₃ Nanosheets Fabricated via Cation Exchange for Chelatorâ€Free ⁶⁴Cuâ€Labeling and Multimodal Imageâ€Guided Photothermalâ€Radiation Therapy. Advanced Functional Materials, 2016, 26, 2185-2197.	7.8	225
637	Modulation of Hypoxia in Solid Tumor Microenvironment with MnO₂ Nanoparticles to Enhance Photodynamic Therapy. Advanced Functional Materials, 2016, 26, 5490-5498.	7.8	497
638	Molecular Targets and Strategies in Cancer Prevention. , 2016, , .		0
639	Molecular Radio-Oncology. Recent Results in Cancer Research, 2016, , .	1.8	1

#	Article	IF	Citations
640	Targeting Tumor Angiogenesis for Cancer Prevention. , 2016, , 117-149.		1
641	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2016, , .	0.8	3
642	Cancer Stem Cells. Recent Results in Cancer Research, 2016, 198, 25-44.	1.8	7
643	Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers. Advances in Experimental Medicine and Biology, 2016, 899, 269-290.	0.8	3
644	A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control. Chemical Communications, 2016, 52, 9434-9437.	2.2	54
645	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. Clinical Cancer Research, 2016, 22, 5079-5086.	3.2	99
646	Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Letters, 2016, 379, 117-123.	3.2	25
647	Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. Critical Reviews in Oncology/Hematology, 2016, 103, 86-98.	2.0	18
648	Validation of a device for the active manipulation of the tumor microenvironment during intravital imaging. Intravital, 2016, 5, e1182271.	2.0	16
649	Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. Journal of Translational Medicine, 2016, 14, 85.	1.8	79
650	Toward precision medicine of breast cancer. Theoretical Biology and Medical Modelling, 2016, 13, 7.	2.1	48
651	An exploratory study of volumetric analysis for assessing tumor response with 18F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC). EJNMMI Research, 2016, 6, 33.	1.1	11
652	Atomic Force Microscopy Probing of Cancer Cells and Tumor Microenvironment Components. BioNanoScience, 2016, 6, 33-46.	1.5	26
653	Synthesis and evaluation of 18 F-labeled 4-nitrobenzyl derivatives for imaging tumor hypoxia with positron emission tomography: Comparison of 2-[18 F]fluoroethyl carbonate and 2-[18 F]fluoroethyl carbamate. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 584-588.	1.0	3
654	Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells. Cell Stress and Chaperones, 2016, 21, 339-348.	1.2	22
655	Eukaryotic translation initiation factor 5A (eIF5A) is essential for HIF-1Î± activation in hypoxia. Biochemical and Biophysical Research Communications, 2016, 470, 417-424.	1.0	14
656	Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on ¹⁸F-Fluoroazomyin Arabinoside Uptake. Journal of Nuclear Medicine, 2016, 57, 361-366.	2.8	42
657	RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Breakâ€“Inducing Anticancer Drugs. Molecular Cancer Therapeutics, 2016, 15, 276-286.	1.9	13

#	Article	IF	Citations
658	Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact. Expert Opinion on Biological Therapy, 2016, 16, 463-476.	1.4	24
659	High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiotherapy and Oncology, 2016, 118, 393-398.	0.3	24
660	Novel â€œbi-modalâ€•H 2 dedpa derivatives for radio- and fluorescence imaging. Journal of Inorganic Biochemistry, 2016, 162, 253-262.	1.5	8
661	Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. Cancer Research, 2016, 76, 787-795.	0.4	133
662	Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resistance Updates, 2016, 24, 34-54.	6.5	124
663	Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 405-413.	0.6	1
664	4-Nitroimidazole-3-hydroxyflavone conjugate as a fluorescent probe for hypoxic cells. Dyes and Pigments, 2016, 131, 145-153.	2.0	22
665	Influence of Body Mass Index and Body Surface Area on the Behavior of Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 657-666.	2.4	27
666	Hypoxia-responsive drugâ€“drug conjugated nanoparticles for breast cancer synergistic therapy. RSC Advances, 2016, 6, 30268-30276.	1.7	30
667	Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs. Nature Protocols, 2016, 11, 781-794.	5.5	59
668	Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Cancer Science, 2016, 107, 36-44.	1.7	48
669	Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells. ACS Synthetic Biology, 2016, 5, 395-404.	1.9	77
670	Bioreductive fluorescent imaging agents: applications to tumour hypoxia. Chemical Communications, 2016, 52, 8935-8956.	2.2	82
671	Clostridium novyi-NT in cancer therapy. Genes and Diseases, 2016, 3, 144-152.	1.5	73
672	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
673	PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with ⁶⁸Ga-Labeled Benzenesulfonamides. Molecular Pharmaceutics, 2016, 13, 1137-1146.	2.3	49
674	Influence of hypoxia-dependent factors on the progression of neuroblastoma. Pediatric Surgery International, 2016, 32, 187-192.	0.6	13
675	Synthesis of a 4-nitroimidazole indocyanine dye-conjugate and imaging of tumor hypoxia in BALB/c tumor-bearing female mice. Dyes and Pigments, 2016, 126, 251-260.	2.0	8

#	Article	IF	Citations
676	Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment. Oncology Research and Treatment, 2016, 39, 9-16.	0.8	6
677	Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemotherapy and Pharmacology, 2016, 77, 441-457.	1.1	175
678	Cancer TARGETases: DSB repair as a pharmacological target. , 2016, 161, 111-131.		21
679	Exploiting Copper Redox for ¹⁹F Magnetic Resonance-Based Detection of Cellular Hypoxia. Journal of the American Chemical Society, 2016, 138, 2937-2940.	6.6	76
681	Cancer therapy in the necroptosis era. Cell Death and Differentiation, 2016, 23, 748-756.	5.0	256
682	Hypoxia inducible factor: a potential prognostic biomarker in oral squamous cell carcinoma. Tumor Biology, 2016, 37, 10815-10820.	0.8	16
683	Biological evaluation of the toxicity and the cell cycle interruption by some benzimidazole derivatives. Tumor Biology, 2016, 37, 11135-11145.	0.8	8
684	Predicting efficacies of anticancer drugs using single cell HaloChip assay. Analyst, The, 2016, 141, 2454-2462.	1.7	1
685	Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells. BMC Cancer, 2016, 16, 51.	1.1	13
686	Macrophages play an essential role in the long effects of low-dose photodynamic therapy on vessel permeability. International Journal of Biochemistry and Cell Biology, 2016, 71, 55-61.	1.2	7
687	Autophagy, a double-edged sword in anti-angiogenesis therapy. Medical Oncology, 2016, 33, 10.	1.2	56
688	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology, 2016, 27, 409-416.	0.6	597
689	CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2. Oncogene, 2016, 35, 4289-4301.	2.6	24
690	Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Experimental Cell Research, 2016, 340, 62-70.	1.2	44
691	An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors. Molecular Cancer Therapeutics, 2016, 15, 608-617.	1.9	16
692	A new ER-specific photosensitizer unravels 1O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT. Oncogene, 2016, 35, 3976-3985.	2.6	31
693	Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Letters, 2016, 380, 330-339.	3.2	56
694	Synergistic role of three dimensional niche and hypoxia on conservation of cancer stem cell phenotype. International Journal of Biological Macromolecules, 2016, 90, 20-26.	3.6	14

#	Article	IF	Citations
695	Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Research, 2016, 76, 1066-1077.	0.4	104
696	The role of hypoxia in pancreatic cancer: a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 301-316.	1.4	114
697	Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors. Translational Research, 2016, 169, 19-30.e1.	2.2	25
698	Mapping of global R1 and R2* values versus lipids R1 values as potential markers of hypoxia in human glial tumors: A feasibility study. Magnetic Resonance Imaging, 2016, 34, 105-113.	1.0	10
699	Poly(ethylene glycol)-b-poly(lysine) copolymer bearing nitroaromatics for hypoxia-sensitive drug delivery. Acta Biomaterialia, 2016, 29, 261-270.	4.1	82
700	Methoxy poly (ethylene glycol)-block-poly (glutamic acid)-graft-6-(2-nitroimidazole) hexyl amine nanoparticles for potential hypoxia-responsive delivery of doxorubicin. Journal of Biomaterials Science, Polymer Edition, 2016, 27, 40-54.	1.9	34
701	Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia. Dalton Transactions, 2016, 45, 144-155.	1.6	23
702	Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 240-248.	3.3	64
703	Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. Clinical Cancer Research, 2016, 22, 923-934.	3.2	43
704	2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma. Tumor Biology, 2016, 37, 381-391.	0.8	19
705	Disruption of cytochrome c oxidase function induces the Warburg effect and metabolic reprogramming. Oncogene, 2016, 35, 1585-1595.	2.6	75
706	Hypoxia Stress Response Pathways: Modeling and Targeted Therapy. IEEE Journal of Biomedical and Health Informatics, 2017, 21, 875-885.	3.9	10
707	Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene, 2017, 36, 439-445.	2.6	277
708	The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene, 2017, 36, 122-132.	2.6	120
709	Cancer metabolism: a therapeutic perspective. Nature Reviews Clinical Oncology, 2017, 14, 11-31.	12.5	1,028
710	Expression of XBP1s in fibroblasts is critical for TiAl₆V₄ particleâ€induced RANKL expression and osteolysis. Journal of Orthopaedic Research, 2017, 35, 752-759.	1.2	2
711	Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection. Biochimica Et Biophysica Acta - Bioenergetics, 2017, 1858, 602-614.	0.5	276
712	Core-shell and co-doped nanoscale metal-organic particles (NMOPs) obtained via post-synthesis cation exchange for multimodal imaging and synergistic thermo-radiotherapy. NPG Asia Materials, 2017, 9, e344-e344.	3.8	56

#	Article	IF	Citations
713	Conjugatable and Bioreduction Cleavable Linker for the 5â€²-Functionalization of Oligonucleotides. Journal of Organic Chemistry, 2017, 82, 1796-1802.	1.7	13
714	Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nature Cell Biology, 2017, 19, 120-132.	4.6	258
715	Glycine decarboxylase and HIF-1Î± expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 323-330.	1.4	22
716	The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes and Diseases, 2017, 4, 19-24.	1.5	122
717	Synthesis, characterization and biological activity of gallium(III) complexes with non-symmetrical NO-donor Schiff bases. Polyhedron, 2017, 123, 480-489.	1.0	5
718	Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy. Clinical Cancer Research, 2017, 23, 2382-2390.	3.2	101
719	Medical Applications of Isotope Metallomics. Reviews in Mineralogy and Geochemistry, 2017, 82, 851-885.	2.2	41
720	DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A. Chemical Research in Toxicology, 2017, 30, 830-839.	1.7	13
721	Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. Molecular Cancer, 2017, 16, 28.	7.9	106
722	Development of an Azoreductase-based Reporter System with Synthetic Fluorogenic Substrates. ACS Chemical Biology, 2017, 12, 558-563.	1.6	33
723	Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Oncogene, 2017, 36, 3359-3374.	2.6	219
724	Obesity and melanoma: could fat be fueling malignancy?. Pigment Cell and Melanoma Research, 2017, 30, 294-306.	1.5	50
725	Cell physiology regulation by hypoxia inducible factor-1: Targeting oxygen-related nanomachineries of hypoxic cells. International Journal of Biological Macromolecules, 2017, 99, 46-62.	3.6	30
726	Orthogonal near-infrared upconversion co-regulated site-specific O 2 delivery and photodynamic therapy for hypoxia tumor by using red blood cell microcarriers. Biomaterials, 2017, 125, 90-100.	5.7	138
727	Multiparametric Imaging of Tumor Hypoxia and Perfusion with¹⁸F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. Journal of Nuclear Medicine, 2017, 58, 1072-1080.	2.8	31
728	Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy. Journal of Controlled Release, 2017, 253, 82-96.	4.8	67
729	Novel hypoxia-targeting Pt(<scp>iv</scp>) prodrugs. Chemical Communications, 2017, 53, 3749-3752.	2.2	42
730	DNA damage players are linked to HIF-1Î±/hypoxia signaling. Cell Cycle, 2017, 16, 725-726.	1.3	7

#	Article	IF	Citations
731	Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 69-92.	3.3	65
732	Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer. Critical Reviews in Oncology/Hematology, 2017, 113, 22-27.	2.0	84
733	A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection and Imaging of Cancer Tumor Cells. ACS Chemical Biology, 2017, 12, 1121-1132.	1.6	54
734	Cancer stem cells: The root of tumor recurrence and metastases. Seminars in Cancer Biology, 2017, 44, 10-24.	4.3	295
735	A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles. Drug Delivery, 2017, 24, 83-91.	2.5	74
736	Toward optical guidance during endoscopic ultrasound-guided fine needle aspirations of pancreatic masses using single fiber reflectance spectroscopy: a feasibility study. Journal of Biomedical Optics, 2017, 22, 024001.	1.4	20
737	Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis , through regulating different signaling pathways. Chinese Journal of Natural Medicines, 2017, 15, 15-40.	0.7	71
738	Design, synthesis and evaluation of¹⁸F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 722-730.	2.5	42
739	Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer. Clinical Cancer Research, 2017, 23, 4004-4009.	3.2	61
741	Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia. Chemical Reviews, 2017, 117, 6160-6224.	23.0	682
742	Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis. Biomaterials, 2017, 133, 176-207.	5.7	79
743	Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors. Scientific Reports, 2017, 7, 46562.	1.6	6
744	meso-ester BODIPYs for the imaging of hypoxia in tumor cells. Sensors and Actuators B: Chemical, 2017, 249, 229-234.	4.0	20
745	Mesoporous nanocarriers with a stimulus-responsive cyclodextrin gatekeeper for targeting tumor hypoxia. Nanoscale, 2017, 9, 6901-6909.	2.8	48
746	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.	7.7	582
747	Multifunctional Probe Based on Cationic Conjugated Polymers for Nitroreductase-Related Analysis: Sensing, Hypoxia Diagnosis, and Imaging. Analytical Chemistry, 2017, 89, 5503-5510.	3.2	39
748	Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells. Oncogene, 2017, 36, 5263-5273.	2.6	10
749	Bis(thiosemicarbazone) Complexes of Cobalt(III). Synthesis, Characterization, and Anticancer Potential. Inorganic Chemistry, 2017, 56, 6609-6623.	1.9	82

#	Article	IF	Citations
750	Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma. Oncology Letters, 2017, 13, 1101-1108.	0.8	2
751	Facile Preparation and Radiotherapy Application of an Amphiphilic Block Copolymer Radiosensitizer. ACS Macro Letters, 2017, 6, 556-560.	2.3	9
752	Targeting curcumin to specific tumour cell environments: the influence of ancillary ligands. Metallomics, 2017, 9, 699-705.	1.0	13
753	Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma. Nanomedicine, 2017, 12, 1135-1151.	1.7	13
754	Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. Methods, 2017, 128, 78-94.	1.9	37
756	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. Current Problems in Cancer, 2017, 41, 265-272.	1.0	16
757	Metabolomic signature of brain cancer. Molecular Carcinogenesis, 2017, 56, 2355-2371.	1.3	86
758	Nanoformulations for combination or cascade anticancer therapy. Advanced Drug Delivery Reviews, 2017, 115, 3-22.	6.6	145
759	Long noncoding RNAs: emerging regulators of tumor angiogenesis. Future Oncology, 2017, 13, 1551-1562.	1.1	44
760	Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chemical Society Reviews, 2017, 46, 3830-3852.	18.7	719
761	Near-infrared-emitting heteroleptic cationic iridium complexes derived from 2,3-diphenylbenzo[g]quinoxaline as in vitro theranostic photodynamic therapy agents. Dalton Transactions, 2017, 46, 8091-8103.	1.6	56
762	The role of intracellular trafficking of CdSe/ZnS QDs on their consequent toxicity profile. Journal of Nanobiotechnology, 2017, 15, 45.	4.2	31
763	Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors. Advanced Drug Delivery Reviews, 2017, 119, 159-174.	6.6	25
764	Polyoxometalate-Based Radiosensitization Platform for Treating Hypoxic Tumors by Attenuating Radioresistance and Enhancing Radiation Response. ACS Nano, 2017, 11, 7164-7176.	7.3	168
765	Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy. Journal of Medicinal Chemistry, 2017, 60, 5834-5856.	2.9	23
766	Time-lapse microscopy of lung endothelial cells under hypoxia. Proceedings of SPIE, 2017, , .	0.8	1
767	Hypoxia-Responsive ¹⁹F MRI Probes with Improved Redox Properties and Biocompatibility. Inorganic Chemistry, 2017, 56, 6429-6437.	1.9	58
768	Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 2017, 90, 20170157.	1.0	99

#	Article	IF	Citations
769	Nickel-induced HIF-1Î± promotes growth arrest and senescence in normal human cells but lacks toxic effects in transformed cells. Toxicology and Applied Pharmacology, 2017, 331, 94-100.	1.3	15
770	Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIFâ€1Î± synthesis, and decreases breast cancer metastasis. Molecular Carcinogenesis, 2017, 56, 2317-2331.	1.3	66
771	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the â€œLow Drug Uptake Volumeâ€. Radiotherapy and Oncology, 2017, 124, 513-520.	0.3	22
772	A fast-responsive two-photon fluorescent turn-on probe for nitroreductase and its bioimaging application in living tissues. Sensors and Actuators B: Chemical, 2017, 252, 927-933.	4.0	22
773	Blue light induced reactive oxygen species from flavin mononucleotide and flavin adenine dinucleotide on lethality of HeLa cells. Journal of Photochemistry and Photobiology B: Biology, 2017, 173, 325-332.	1.7	50
774	Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. Trends in Cancer, 2017, 3, 529-541.	3.8	84
775	New insights into the role of <scp>EMT</scp> in tumor immune escape. Molecular Oncology, 2017, 11, 824-846.	2.1	332
776	Targeting tumor associated macrophages (TAMs) via nanocarriers. Journal of Controlled Release, 2017, 254, 92-106.	4.8	98
777	Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death. Cell Death and Disease, 2017, 8, e2709-e2709.	2.7	30
778	Cancer stem cells with increased metastatic potential as a therapeutic target for esophageal cancer. Seminars in Cancer Biology, 2017, 44, 60-66.	4.3	58
779	Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38. European Journal of Medicinal Chemistry, 2017, 132, 135-141.	2.6	27
780	Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1Î± via the mTOR/p70S6K/4E-BP1 and MAPK pathways. Journal of Ethnopharmacology, 2017, 203, 27-38.	2.0	88
781	Selective turn-on near-infrared fluorescence probe for hypoxic tumor cell imaging. RSC Advances, 2017, 7, 18217-18223.	1.7	11
782	A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging. ACS Applied Materials & Interfaces, 2017, 9, 13976-13987.	4.0	44
783	Metformin and improved treatment outcomes in radiation therapy â€“ A review. Cancer Treatment Reviews, 2017, 55, 150-162.	3.4	35
784	Development of a Hypoxic Radiosensitizerâ€Prodrug Liposome Delivery DNA Repair Inhibitor Dbait Combination with Radiotherapy for Glioma Therapy. Advanced Healthcare Materials, 2017, 6, 1601377.	3.9	22
785	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. Angiogenesis, 2017, 20, 185-204.	3.7	482
786	Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives. Bioorganic and Medicinal Chemistry, 2017, 25, 2285-2293.	1.4	25

#	Article	IF	Citations
787	20 Medical Applications of Isotope Metallomics. , 2017, , .		1
788	CYP450 Enzymes Effect Oxygen-Dependent Reduction of Azide-Based Fluorogenic Dyes. ACS Central Science, 2017, 3, 20-30.	5.3	53
789	Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy. ACS Nano, 2017, 11, 927-937.	7.3	358
790	Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 636-641.	1.0	13
791	A brief review of exosomes and their roles in cancer. Meta Gene, 2017, 11, 70-74.	0.3	18
792	A NIR turn-on fluorescent probe applied in cytochrome P450 reductase detection and hypoxia imaging in tumor cells. Dyes and Pigments, 2017, 139, 587-592.	2.0	23
793	Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response. Annual Review of Cancer Biology, 2017, 1, 313-334.	2.3	101
794	MicroRNA-21 promotes migration and invasion of glioma cells via activation of Sox2 and Î²-catenin signaling. Molecular Medicine Reports, 2017, 15, 187-193.	1.1	56
795	Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. European Radiology, 2017, 27, 3156-3166.	2.3	27
796	DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chemical Research in Toxicology, 2017, 30, 388-409.	1.7	45
797	Impact of tumoral carbonic anhydrase IX and Kiâ€‘67 expression on survival in oral squamous cell carcinoma patients. Oncology Letters, 2017, 14, 5434-5442.	0.8	9
798	Clinical PET imaging of tumour hypoxia in lung cancer. Clinical and Translational Imaging, 2017, 5, 427-445.	1.1	0
799	Quantitative imaging of pO₂ in orthotopic murine gliomas: hypoxia correlates with resistance to radiation. Free Radical Research, 2017, 51, 861-871.	1.5	16
800	CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in hypoxia- versus normoxia-microenviroment. Journal of Neuro-Oncology, 2017, 135, 37-46.	1.4	25
801	Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5300-5304.	1.0	10
802	Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19 Fâ€“MRI and Multispectral Analysis. Neoplasia, 2017, 19, 950-959.	2.3	15
803	Recent development of luminescent rhenium(<scp>i</scp>) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents. Dalton Transactions, 2017, 46, 16357-16380.	1.6	142
804	Nanotechnology for Multimodal Synergistic Cancer Therapy. Chemical Reviews, 2017, 117, 13566-13638.	23.0	1,392

#	Article	IF	Citations
805	Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy. Accounts of Chemical Research, 2017, 50, 2727-2736.	7.6	454
806	Targeting Inflammation to Improve Tumor Drug Delivery. Trends in Cancer, 2017, 3, 621-630.	3.8	28
807	Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. Acta OncolÃ³gica, 2017, 56, 1591-1596.	0.8	15
808	Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using inÂvivo flow cytometry. Biochemical and Biophysical Research Communications, 2017, 492, 507-512.	1.0	18
809	Oxygen nanobubbles revert hypoxia by methylation programming. Scientific Reports, 2017, 7, 9268.	1.6	45
810	HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. International Journal of Oncology, 2017, 51, 715-723.	1.4	33
811	The medicinal chemistry of ferrocene and its derivatives. Nature Reviews Chemistry, 2017, 1, .	13.8	372
812	Hypoxia-Sensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis. Immunity, 2017, 47, 66-79.e5.	6.6	71
813	Histone demethylase PHF8 regulates hypoxia signaling through HIF1Î± and H3K4me3. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2017, 1860, 1002-1012.	0.9	17
814	HIF-1Î± inhibition by diethylstilbestrol and its polyacetal conjugate in hypoxic prostate tumour cells: insights from NMR metabolomics. Journal of Drug Targeting, 2017, 25, 845-855.	2.1	5
815	Hypoxia inhibits growth, proliferation, and increases response to chemotherapy in retinoblastoma cells. Experimental Eye Research, 2017, 162, 48-61.	1.2	11
816	FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state. Annals of Nuclear Medicine, 2017, 31, 596-604.	1.2	20
817	A Probe for the Detection of Hypoxic Cancer Cells. ACS Sensors, 2017, 2, 1139-1145.	4.0	56
818	Tumor microenvironment determines response to a heat-activated thermosensitive liposome formulation of cisplatin in cervical carcinoma. Journal of Controlled Release, 2017, 262, 182-191.	4.8	13
819	Hypoxia-Responsive Cobalt Complexes in Tumor Spheroids: Laser Ablation Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies. Inorganic Chemistry, 2017, 56, 9860-9868.	1.9	34
820	In vitro and in vivo evaluation of a 64Cu-labeled propylene amine oxime complex as a potential hypoxia imaging agent bearing two 3-nitrotriazole groups. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 111-118.	0.7	4
821	Hyperbranched Phosphorescent Conjugated Polymer Dots with Iridium(III) Complex as the Core for Hypoxia Imaging and Photodynamic Therapy. ACS Applied Materials & Interfaces, 2017, 9, 28319-28330.	4.0	84
822	Cancer Cell Membraneâ€Biomimetic Oxygen Nanocarrier for Breaking Hypoxiaâ€Induced Chemoresistance. Advanced Functional Materials, 2017, 27, 1703197.	7.8	203

#	Article	IF	Citations
823	Prodrug-embedded angiogenic vessel-targeting nanoparticle: A positive feedback amplifier in hypoxia-induced chemo-photo therapy. Biomaterials, 2017, 144, 188-198.	5.7	57
824	Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?. Radiotherapy and Oncology, 2017, 124, 344-356.	0.3	122
825	Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 992-1001.	2.5	7
826	Oxygen-Self-Produced Nanoplatform for Relieving Hypoxia and Breaking Resistance to Sonodynamic Treatment of Pancreatic Cancer. ACS Nano, 2017, 11, 12849-12862.	7.3	356
827	Ferroquine, the next generation antimalarial drug, has antitumor activity. Scientific Reports, 2017, 7, 15896.	1.6	72
828	Transport of drugs from blood vessels to tumour tissue. Nature Reviews Cancer, 2017, 17, 738-750.	12.8	499
829	Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer. Free Radical Biology and Medicine, 2017, 113, 564-570.	1.3	10
830	Design considerations for open-well microfluidic platforms for hypoxic cell studies. Biomicrofluidics, 2017, 11, 054116.	1.2	13
831	The influence of the ancillary ligand on the potential of cobalt(<scp>iii</scp>) complexes to act as chaperones for hydroxamic acid-based drugs. Dalton Transactions, 2017, 46, 15897-15907.	1.6	14
832	Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity. Acta OncolÃ³gica, 2017, 56, 1583-1590.	0.8	5
833	Hypoxia imaging and radiotherapy: bridging the resolution gap. British Journal of Radiology, 2017, 90, 20160939.	1.0	49
834	Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance. Nature Communications, 2017, 8, 15884.	5.8	54
835	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1089-1103.	5.1	214
836	Sickle cells produce functional immune modulators and cytotoxics. American Journal of Hematology, 2017, 92, 981-988.	2.0	4
837	Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1183-1196.	0.4	109
838	Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT). Biomaterials Science, 2017, 5, 1500-1511.	2.6	254
839	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anti-Cancer Drugs, 2017, 28, 127-132.	0.7	4
840	Overexpression and correlation of HIF-2Î±, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression. Experimental and Therapeutic Medicine, 2017, 13, 3529-3534.	0.8	11

#	Article	IF	Citations
841	Microfluidic technologies for anticancer drug studies. Drug Discovery Today, 2017, 22, 1654-1670.	3.2	63
842	H2O2-responsive theranostic nanomedicine. Chinese Chemical Letters, 2017, 28, 1841-1850.	4.8	44
843	Novel Co III complexes containing fluorescent coumarin-N-acylhydrazone hybrid ligands: Synthesis, crystal structures, solution studies and DFT calculations. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 187, 130-142.	2.0	15
844	Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole. ACS Medicinal Chemistry Letters, 2017, 8, 762-765.	1.3	18
845	Mechanisms of Plasma Medicine: Coupling Plasma Physics, Biochemistry, and Biology. IEEE Transactions on Radiation and Plasma Medical Sciences, 2017, 1, 281-292.	2.7	73
846	Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1Î± stabilization. Journal of Experimental and Clinical Cancer Research, 2017, 36, 32.	3.5	23
847	Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories. MedChemComm, 2017, 8, 21-52.	3.5	19
848	Iron, Cancer, and Hypoxia-Inducible Factor Signaling. , 2017, , 203-213.		0
849	A ratiometric nanoprobe consisting of up-conversion nanoparticles functionalized with cobalt oxyhydroxide for detecting and imaging ascorbic acid. Journal of Materials Chemistry B, 2017, 5, 167-172.	2.9	23
850	Molecular targeting of hypoxia in radiotherapy. Advanced Drug Delivery Reviews, 2017, 109, 45-62.	6.6	146
851	Bioresponsive materials. Nature Reviews Materials, 2017, 2, .	23.3	1,117
852	Drug resistance and cancer stem cells: the shared but distinct roles of hypoxiaâ€inducible factors <scp>HIF</scp>1Î± and <scp>HIF</scp>2Î±. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 153-161.	0.9	91
853	Threeâ€dimensional cell culture model utilization in cancer stem cell research. Biological Reviews, 2017, 92, 1505-1520.	4.7	95
854	Clonal cooperativity in heterogenous cancers. Seminars in Cell and Developmental Biology, 2017, 64, 79-89.	2.3	53
855	Molecular Cancer Imaging with Polymeric Nanoassemblies: From Tumor Detection to Theranostics. Macromolecular Bioscience, 2017, 17, 1600305.	2.1	35
856	A novel â€˜â€˜donor-two-acceptorâ€™â€™ type fluorophore-based probe for fast detection and intracellular imaging of nitroreductase. Dyes and Pigments, 2017, 136, 627-632.	2.0	30
857	Cancer heterogeneity and imaging. Seminars in Cell and Developmental Biology, 2017, 64, 48-57.	2.3	39
858	Optical redox ratio and endogenous porphyrins in the detection of urinary bladder cancer: A patient biopsy analysis. Journal of Biophotonics, 2017, 10, 1062-1073.	1.1	21

#	Article	IF	Citations
859	InÂVivo Imaging Reveals Significant Tumor Vascular Dysfunction and Increased Tumor Hypoxia-Inducible Factor-1Î± Expression Induced by High Single-Dose Irradiation in a Pancreatic Tumor Model. International Journal of Radiation Oncology Biology Physics, 2017, 97, 184-194.	0.4	32
860	The changing paradigm of tumour response to irradiation. British Journal of Radiology, 2017, 90, 20160474.	1.0	30
861	Leveraging Physiology for Precision Drug Delivery. Physiological Reviews, 2017, 97, 189-225.	13.1	125
862	Fluorinated benzenesulfonamide anticancer inhibitors of carbonic anhydrase IX exhibit lower toxic effects on zebrafish embryonic development than ethoxzolamide. Drug and Chemical Toxicology, 2017, 40, 309-319.	1.2	13
863	Radiotherapy and Glioma Stem Cells: Searching for Chinks in Cellular Armor. Current Stem Cell Reports, 2017, 3, 348-357.	0.7	16
864	Opposite response to hypoxia by breast cancer cells between cell proliferation and cell migration: A clue from microRNA expression profile. Oncology Letters, 2018, 15, 2771-2780.	0.8	10
865	The development of ruthenium(<scp>ii</scp>) polypyridyl complexes and conjugates forin vitrocellular andin vivoapplications. Chemical Society Reviews, 2017, 46, 7706-7756.	18.7	326
866	The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget, 2017, 8, 55684-55714.	0.8	141
867	BMPR2 and HIF1-Î± overexpression in resected osteosarcoma correlates with distant metastasis and patient survival. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 447-454.	0.7	23
868	Hypoxic Upregulation of ARNT (HIF-1Î²): A Cell-Specific Attribute with Clinical Implications. , 2017, , .		0
869	The Critical Role of Hypoxia in Tumor-Mediated Immunosuppression. , 0, , .		1
870	Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice. Frontiers in Pharmacology, 2017, 8, 531.	1.6	16
871	Cooperative Oxygen Sensing by the Kidney and Carotid Body in Blood Pressure Control. Frontiers in Physiology, 2017, 8, 752.	1.3	14
872	Loss of LKB1 Expression Decreases the Survival and Promotes Laryngeal Cancer Metastasis. Journal of Cancer, 2017, 8, 3548-3554.	1.2	3
873	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
874	Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics, 2017, 7, 538-558.	4.6	260
875	Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells. Viruses, 2017, 9, 174.	1.5	9
876	Role of Aquaporin 1 Signalling in Cancer Development and Progression. International Journal of Molecular Sciences, 2017, 18, 299.	1.8	95

#	Article	IF	Citations
877	Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies. International Journal of Molecular Sciences, 2017, 18, 1258.	1.8	2
878	The Role of Pontin and Reptin in Cellular Physiology and Cancer Etiology. Frontiers in Molecular Biosciences, 2017, 4, 58.	1.6	97
879	The Importance of Histology and Pathology in Mass Spectrometry Imaging. Advances in Cancer Research, 2017, 134, 1-26.	1.9	19
880	The eIF4E2-Directed Hypoxic Cap-Dependent Translation Machinery Reveals Novel Therapeutic Potential for Cancer Treatment. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-12.	1.9	20
881	Electric Cell-Substrate Impedance Sensing of Cellular Effects under Hypoxic Conditions and Carbonic Anhydrase Inhibition. Journal of Sensors, 2017, 2017, 1-10.	0.6	2
882	Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	65
883	Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy. Yonsei Medical Journal, 2017, 58, 489.	0.9	157
884	Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. International Journal of Nanomedicine, 2017, Volume 12, 1065-1083.	3.3	61
885	Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics, 2017, 7, 4322-4339.	4.6	59
886	The Bidirectional Regulation between MYL5 and HIF-1Î± Promotes Cervical Carcinoma Metastasis. Theranostics, 2017, 7, 3768-3780.	4.6	17
887	Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. PLoS ONE, 2017, 12, e0181340.	1.1	37
888	Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model. PLoS ONE, 2017, 12, e0188960.	1.1	16
890	A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer. BMC Cancer, 2017, 17, 844.	1.1	14
891	Microencapsulation of low-passage poorly-differentiated human mucoepidermoid carcinoma cells by alginate microcapsules: in vitro profiling of angiogenesis-related molecules. Cancer Cell International, 2017, 17, 106.	1.8	6
892	Hypoxia-inducible factor-2Î± promotes tumor progression and has crosstalk with Wnt/Î²-catenin signaling in pancreatic cancer. Molecular Cancer, 2017, 16, 119.	7.9	97
893	Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids. Journal of Experimental and Clinical Cancer Research, 2017, 36, 102.	3.5	140
894	Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Molecular Cancer, 2017, 16, 143.	7.9	262
895	Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. Cancers, 2017, 9, 152.	1.7	41

#	Article	IF	Citations
896	Mutual Regulation of MiR-199a-5p and HIF-1Î± Modulates the Warburg Effect in Hepatocellular Carcinoma. Journal of Cancer, 2017, 8, 940-949.	1.2	35
897	Functions of the AP-2Î± gene in activating apoptosis and inhibiting proliferation of gastric cancer cells both in vitro and in vivo. Archives of Medical Science, 2017, 6, 1255-1261.	0.4	5
898	Redox activated polymeric nanoparticles in tumor therapy. , 2017, , 327-354.		4
899	An update on anticancer drug development and delivery targeting carbonic anhydrase IX. PeerJ, 2017, 5, e4068.	0.9	18
900	Discovery of the Hypoxia-Activated Prodrug SN30000. , 2017, , 58-94.		4
901	Synergistic Activities of Nitric Oxide and Various Drugs. , 2017, , 293-312.		3
902	Magnetic resonance imaging in precision radiation therapy for lung cancer. Translational Lung Cancer Research, 2017, 6, 689-707.	1.3	56
903	Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget, 2017, 8, 62742-62758.	0.8	186
904	Targeting tumour hypoxia: shifting focus from oxygen supply to demand. British Journal of Radiology, 2019, 92, 20170843.	1.0	12
905	Molybdenum cluster loaded PLGA nanoparticles: An innovative theranostic approach for the treatment of ovarian cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 95-105.	2.0	55
906	Responsive triggering systems for delivery in chronic wound healing. Advanced Drug Delivery Reviews, 2018, 129, 169-193.	6.6	51
907	Translational models of tumor angiogenesis: A nexus of in silico and in vitro models. Biotechnology Advances, 2018, 36, 880-893.	6.0	39
908	Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs. Journal of Organic Chemistry, 2018, 83, 3126-3131.	1.7	12
909	Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2018, 24, 2116-2127.	3.2	20
910	Ultrasound beam steering of oxygen nanobubbles for enhanced bladder cancer therapy. Scientific Reports, 2018, 8, 3112.	1.6	39
911	Probing characteristics of cancer cells cultured on engineered platforms simulating different microenvironments. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 1170-1179.	1.9	6
912	Application of Bld-1-Embedded Elastin-Like Polypeptides in Tumor Targeting. Scientific Reports, 2018, 8, 3892.	1.6	14
913	Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1Râ€“YAP Axis. Cancer Research, 2018, 78, 3995-4006.	0.4	29

#	Article	IF	Citations
914	A Novel Target of p53, TCF21, Can Respond to Hypoxia by MAPK Pathway Inactivation in Uterine Corpus Endometrial Carcinoma. DNA and Cell Biology, 2018, 37, 473-480.	0.9	13
915	Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. International Journal of Biological Markers, 2018, 33, 109-115.	0.7	29
916	T Cell Dysfunction in Cancer. Cancer Cell, 2018, 33, 547-562.	7.7	787
917	Stress alleviation strategy in cancer treatment: Insights from a mathematical model. ZAMM Zeitschrift Fur Angewandte Mathematik Und Mechanik, 2018, 98, 2295-2306.	0.9	13
918	Modified Shenlingbaizhu decoction reduces intestinal adenoma formation in adenomatous polyposis coli multiple intestinal neoplasia mice by suppression of hypoxia-inducible factor 1Î±-induced CD4 + CD25+ forkhead box P3 regulatory T cells. Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine, 2018, 38, 22-32.	0.4	4
919	Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy. Biomaterials, 2018, 162, 123-131.	5.7	196
920	Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy. Coordination Chemistry Reviews, 2018, 360, 34-76.	9.5	214
921	Acetazolamide-based [18 F]-PET tracer: In vivo validation of carbonic anhydrase IX as a sole target for imaging of CA-IX expressing hypoxic solid tumors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 915-921.	1.0	11
922	Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. Translational Oncology, 2018, 11, 250-258.	1.7	57
923	Genetically-encoded fluorescent probe for imaging of oxygenation gradients in living Drosophila. Development (Cambridge), 2018, 145, .	1.2	15
924	Transcriptional Regulation of the Warburg Effect in Cancer by SIX1. Cancer Cell, 2018, 33, 368-385.e7.	7.7	268
925	Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling. Cell Death and Disease, 2018, 9, 217.	2.7	87
926	Nano-graphene oxide-manganese dioxide nanocomposites for overcoming tumor hypoxia and enhancing cancer radioisotope therapy. Nanoscale, 2018, 10, 5114-5123.	2.8	62
927	Synthetic torpor: A method for safely and practically transporting experimental animals aboard spaceflight missions to deep space. Life Sciences in Space Research, 2018, 16, 101-107.	1.2	18
928	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. Advanced Healthcare Materials, 2018, 7, 1701174.	3.9	66
929	Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer. International Journal of Cancer, 2018, 143, 1017-1028.	2.3	39
930	Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factorâ€‘1Î±. International Journal of Oncology, 2018, 52, 679-686.	1.4	12
931	Reduction-sensitive fluorescence enhanced polymeric prodrug nanoparticles for combinational photothermal-chemotherapy. Biomaterials, 2018, 163, 14-24.	5.7	109

#	Article	IF	Citations
932	A simple umbelliferone based fluorescent probe for the detection of nitroreductase. Frontiers of Chemical Science and Engineering, 2018, 12, 311-314.	2.3	13
933	Matrix Metalloproteinase-9-Responsive Nanogels for Proximal Surface Conversion and Activated Cellular Uptake. Biomacromolecules, 2018, 19, 860-871.	2.6	27
934	Sounding Out Dysfunctional Oxygen Metabolism: A Small-Molecule Probe for Photoacoustic Imaging of Hypoxia. Biochemistry, 2018, 57, 893-894.	1.2	3
935	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angewandte Chemie - International Edition, 2018, 57, 1510-1513.	7.2	168
936	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angewandte Chemie, 2018, 130, 1526-1529.	1.6	29
937	Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery. Nanoscale, 2018, 10, 2856-2865.	2.8	81
938	Tumor Microenvironmentâ€Enabled Nanotherapy. Advanced Healthcare Materials, 2018, 7, e1701156.	3.9	158
939	Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides. Journal of Medicinal Chemistry, 2018, 61, 1241-1254.	2.9	52
940	Synthesis and evaluation of an ¹⁸Fâ€labeled trifluoroborate derivative of 2â€nitroimidazole for imaging tumor hypoxia with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 370-379.	0.5	6
941	The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. British Journal of Cancer, 2018, 118, 698-704.	2.9	20
942	Nano-functionalized long-period fiber grating probe for disease-specific protein detection. Journal of Materials Chemistry B, 2018, 6, 386-392.	2.9	18
943	Facile Deposition of Manganese Dioxide to Albumin-Bound Paclitaxel Nanoparticles for Modulation of Hypoxic Tumor Microenvironment To Improve Chemoradiation Therapy. Molecular Pharmaceutics, 2018, 15, 447-457.	2.3	53
944	Characteristics of new bioreductive fluorescent probes based on the xanthene fluorophore: Detection of nitroreductase and imaging of hypoxic cells. Dyes and Pigments, 2018, 151, 245-253.	2.0	19
946	Non-coding RNAs predict recurrence-free survival of patients with hypoxic tumours. Scientific Reports, 2018, 8, 152.	1.6	10
947	Hypoxia-Mediated In Vivo Tumor Glucose Uptake Measurement and Analysis. Methods in Molecular Biology, 2018, 1742, 107-113.	0.4	8
948	Nearâ€Infrared Upconversion Mesoporous Cerium Oxide Hollow Biophotocatalyst for Concurrent pHâ€/H₂O₂â€Responsive O₂â€Evolving Synergetic Cancer Therapy. Advanced Materials, 2018, 30, 1704833.	11.1	350
949	Metabolic Barriers to T Cell Function in Tumors. Journal of Immunology, 2018, 200, 400-407.	0.4	144
950	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	3.0	76

#	Article	IF	Citations
951	A dual-function fluorescent probe for monitoring the degrees of hypoxia in living cells via the imaging of nitroreductase and adenosine triphosphate. Chemical Communications, 2018, 54, 5454-5457.	2.2	106
953	A history of exploring cancer in context. Nature Reviews Cancer, 2018, 18, 359-376.	12.8	361
954	Development of Protecting Groups for Prodrug-Type Oligonucleotide Medicines. Chemical and Pharmaceutical Bulletin, 2018, 66, 147-154.	0.6	7
955	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. Cell Proliferation, 2018, 51, e12456.	2.4	22
956	A nitroreductase and acidity detecting dual functional ratiometric fluorescent probe for selectively imaging tumor cells. Organic and Biomolecular Chemistry, 2018, 16, 3266-3272.	1.5	20
957	An upconverting nanotheranostic agent activated by hypoxia combined with NIR irradiation for selective hypoxia imaging and tumour therapy. Journal of Materials Chemistry B, 2018, 6, 2747-2757.	2.9	26
958	Extracellular Vesicles in Cancer. Cancer Journal (Sudbury, Mass), 2018, 24, 65-69.	1.0	22
959	Phosphorescent ruthenium complexes with bromopyrene unit that enhance oxygen sensitivity. Bioorganic and Medicinal Chemistry, 2018, 26, 4595-4601.	1.4	5
960	Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy. Acta Biomaterialia, 2018, 71, 351-362.	4.1	41
961	Integrated omics profiling identifies hypoxia-regulated genes in HCT116 colon cancer cells. Journal of Proteomics, 2018, 188, 139-151.	1.2	13
962	Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends in Cancer, 2018, 4, 292-319.	3.8	389
963	Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncology, 2018, 80, 23-32.	0.8	210
964	Upregulation of IL-11, an IL-6 Family Cytokine, Promotes Tumor Progression and Correlates with Poor Prognosis in Non-Small Cell Lung Cancer. Cellular Physiology and Biochemistry, 2018, 45, 2213-2224.	1.1	49
965	The tumour microenvironment links complement system dysregulation and hypoxic signallingï»¿. British Journal of Radiology, 2019, 92, 20180069.	1.0	10
966	Association of PD-L1 and HIF-1Î± Coexpression with Poor Prognosis in Hepatocellular Carcinoma. Translational Oncology, 2018, 11, 559-566.	1.7	52
967	Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapiesâ€"A review. Medicinal Research Reviews, 2018, 38, 1769-1798.	5.0	51
968	PERK/eIF2Î± signaling inhibits HIF-induced gene expression during the unfolded protein response via YB1-dependent regulation of HIF1Î± translation. Nucleic Acids Research, 2018, 46, 3878-3890.	6.5	38
969	Structural Diversity, Electrochemical, and DNA-Binding Properties of Copper(II) Carboxylates. Iranian Journal of Science and Technology, Transaction A: Science, 2018, 42, 1859-1871.	0.7	3

#	Article	IF	Citations
970	Separation of two sub-groups with different DNA content after treatment of T-47D breast cancer cells with low dose-rate irradiation and intermittent hypoxia. Acta Radiologica, 2018, 59, 26-33.	0.5	5
971	Hypoxia driven glycation: Mechanisms and therapeutic opportunities. Seminars in Cancer Biology, 2018, 49, 75-82.	4.3	37
972	Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. Antioxidants and Redox Signaling, 2018, 28, 131-140.	2.5	27
973	Targeting Hypoxia to Improve Nonâ€“Small Cell Lung Cancer Outcome. Journal of the National Cancer Institute, 2018, 110, 14-30.	3.0	177
974	A prodrug of green tea polyphenol (â€“)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer. Cancer Letters, 2018, 412, 10-20.	3.2	86
975	The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. Trends in Microbiology, 2018, 26, 158-168.	3.5	272
976	Hypoxiaâ€inducible factorâ€1Î±/interleukinâ€1Î² signaling enhances hepatoma epithelialâ€“mesenchymal transition through macrophages in a hypoxicâ€inflammatory microenvironment. Hepatology, 2018, 67, 1872-1889.	3.6	216
977	Hypoxic Induction of Vasorin Regulates Notch1 Turnover to Maintain Glioma Stem-like Cells. Cell Stem Cell, 2018, 22, 104-118.e6.	5.2	127
978	A coelenterazine-type bioluminescent probe for nitroreductase imaging. Organic and Biomolecular Chemistry, 2018, 16, 146-151.	1.5	16
979	Nanoscale covalent organic polymers as a biodegradable nanomedicine for chemotherapy-enhanced photodynamic therapy of cancer. Nano Research, 2018, 11, 3244-3257.	5.8	74
980	Lesion magnetic susceptibility response to hyperoxic challenge: A biomarker for malignant brain tumor microenvironment?. Magnetic Resonance Imaging, 2018, 47, 147-153.	1.0	4
981	Advances in Stimulusâ€Responsive Polymeric Materials for Systemic Delivery of Nucleic Acids. Advanced Healthcare Materials, 2018, 7, 1701070.	3.9	33
982	Linkers: The key elements for the creation of efficient nanotherapeutics. Journal of Controlled Release, 2018, 270, 260-267.	4.8	24
983	Oxidative activation of leinamycin E1 triggers alkylation of guanine residues in double-stranded DNA. Chemical Communications, 2018, 54, 256-259.	2.2	5
984	Hyperbaric Oxygen Reduces Aspergillus fumigatus Proliferation In Vitro and Influences In Vivo Disease Outcomes. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
985	Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene, 2018, 37, 1107-1118.	2.6	71
986	Manganese Dioxide Coated WS₂@Fe₃O₄/sSiO₂ Nanocomposites for pHâ€Responsive MR Imaging and Oxygenâ€Elevated Synergetic Therapy. Small, 2018, 14, 1702664.	5.2	116
987	The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 1-15.	1.1	36

#	Article	IF	Citations
988	Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery. International Journal of Biological Macromolecules, 2018, 110, 399-405.	3.6	57
989	Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents. Chemical Biology and Drug Design, 2018, 91, 681-690.	1.5	88
990	Applying Precision Oncology Principles in Radiation Oncology. JCO Precision Oncology, 2018, 2, 1-23.	1.5	12
991	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. Oncotarget, 2018, 9, 3946-3955.	0.8	35
992	Comparative Assay of 2D and 3D Cell Culture Models: Proliferation, Gene Expression and Anticancer Drug Response. Current Pharmaceutical Design, 2018, 24, 1689-1694.	0.9	109
993	Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells. Oncotarget, 2018, 9, 26800-26816.	0.8	25
994	Gasâ€€Generating Nanoplatforms: Material Chemistry, Multifunctionality, and Gas Therapy. Advanced Materials, 2018, 30, e1801964.	11.1	225
995	The HIFâ€1Î±/miRâ€224â€3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxiaâ€induced protective autophagy in glioblastoma and astrocytoma. Oncology Reports, 2018, 41, 1759-1768.	1.2	33
996	Is 'Hanging Dropâ€™ a Useful Method to Form Spheroids of Jimt, Mcf-7, T-47d, Bt-474 That are Breast Cancer Cell Lines. Single Cell Biology, 2018, 07, .	0.2	5
997	Light-enhanced hypoxia-responsive nanoparticles for deep tumor penetration and combined chemo-photodynamic therapy. Chemical Communications, 2018, 54, 13127-13130.	2.2	41
998	Interaction study of cancer cells and fibroblasts on a spatially confined oxygen gradient microfluidic chip to investigate the tumor microenvironment. Analyst, The, 2018, 143, 5431-5437.	1.7	15
999	Therapeutic targeting of tumor hypoxia and necrosis with antibody Î±-radioconjugates. Antibody Therapeutics, 2018, 1, 55-63.	1.2	15
1001	Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination. PLoS ONE, 2018, 13, e0206706.	1.1	15
1002	The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nature Communications, 2018, 9, 4728.	5.8	125
1003	Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma. BMC Cancer, 2018, 18, 1114.	1.1	26
1004	Hypoxia-Activated, Small-Molecule-Induced Gene Expression. ACS Chemical Biology, 2018, 13, 3354-3360.	1.6	11
1005	Hypoxia-triggered single molecule probe for high-contrast NIR II/PA tumor imaging and robust photothermal therapy. Theranostics, 2018, 8, 6025-6034.	4.6	171
1006	4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles. Journal of Medicinal Chemistry, 2018, 61, 10860-10874.	2.9	48

#	Article	IF	Citations
1008	Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development. Theranostics, 2018, 8, 5259-5275.	4.6	138
1009	Hypoxia Stimulates the Epithelialâ€“toâ€“Mesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear Î²-Catenin. Anticancer Research, 2018, 38, 6299-6308.	0.5	26
1010	Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo. International Journal of Nanomedicine, 2019, Volume 14, 195-204.	3.3	6
1011	MicroRNAâ€101 protects bladder of BOO from hypoxiaâ€induced fibrosis by attenuating TGFâ€Î²â€smad2/3 signaling. IUBMB Life, 2019, 71, 235-243.	1.5	17
1012	Squaramide-Based Pt(II) Complexes as Potential Oxygen-Regulated Light-Triggered Photocages. Inorganic Chemistry, 2018, 57, 15517-15525.	1.9	7
1013	NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development. Frontiers in Immunology, 2018, 9, 2918.	2.2	77
1014	Repurposing drugs in oncology (ReDO)â€”selective PDE5 inhibitors as. Ecancermedicalscience, 2018, 12, 824.	0.6	41
1015	Salvianolic acid B renders glioma cells more sensitive to radiation via Fis-1-mediated mitochondrial dysfunction. Biomedicine and Pharmacotherapy, 2018, 107, 1230-1236.	2.5	12
1016	Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9640-E9648.	3.3	116
1017	Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. International Journal of Molecular Sciences, 2018, 19, 2922.	1.8	30
1018	Bioresponsive polyplexes â€“ chemically programmed for nucleic acid delivery. Expert Opinion on Drug Delivery, 2018, 15, 1067-1083.	2.4	22
1019	Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy. ACS Nano, 2018, 12, 9894-9902.	7.3	61
1020	A Multimodal Molecular Imaging Study Evaluates Pharmacological Alteration of the Tumor Microenvironment to Improve Radiation Response. Cancer Research, 2018, 78, 6828-6837.	0.4	16
1021	Effect of exosomal miRNA on cancer biology and clinical applications. Molecular Cancer, 2018, 17, 147.	7.9	531
1022	Photo-Enhanced Singlet Oxygen Generation of Prussian Blue-Based Nanocatalyst for Augmented Photodynamic Therapy. IScience, 2018, 9, 14-26.	1.9	46
1023	An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids. PLoS Computational Biology, 2018, 14, e1006469.	1.5	33
1024	Redox regulation of EGFR steers migration of hypoxic mammary cells towards oxygen. Nature Communications, 2018, 9, 4545.	5.8	24
1025	A Novel <scp>PBPK</scp> Modeling Approach to Assess Cytochrome P450 Mediated Drugâ€Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 829-837.	1.3	2

#	Article	IF	Citations
1026	Hypoxia-activated prodrugs and redox-responsive nanocarriers. International Journal of Nanomedicine, 2018, Volume 13, 6551-6574.	3.3	56
1027	Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity. International Journal of Molecular Sciences, 2018, 19, 3044.	1.8	64
1028	Metformin suppresses hypoxiaâ€'induced migration via the HIFâ€'1Î±/VEGF pathway in gallbladder cancer inï¿½vitro and inï¿½vivo. Oncology Reports, 2018, 40, 3501-3510.	1.2	30
1029	Advanced nanomaterials targeting hypoxia to enhance radiotherapy. International Journal of Nanomedicine, 2018, Volume 13, 5925-5936.	3.3	42
1030	Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer. Journal of Controlled Release, 2018, 291, 169-183.	4.8	20
1031	Mechanical Forces in Tumor Angiogenesis. Advances in Experimental Medicine and Biology, 2018, 1092, 91-112.	0.8	93
1032	Activated hepatic stellate cells promote epithelial-to-mesenchymal transition in hepatocellular carcinoma through transglutaminase 2-induced pseudohypoxia. Communications Biology, 2018, 1, 168.	2.0	25
1033	Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands. Bioinorganic Chemistry and Applications, 2018, 2018, 1-18.	1.8	54
1034	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics, 2018, 9, 427.	1.1	88
1035	Photodynamic Therapy Based on Nanoscale Metalâ€"Organic Frameworks: From Material Design to Cancer Nanotherapeutics. Chemistry - an Asian Journal, 2018, 13, 3122-3149.	1.7	71
1036	p53 and metabolism: from mechanism to therapeutics. Oncotarget, 2018, 9, 23780-23823.	0.8	103
1037	A three-dimensional engineered heterogeneous tumor model for assessing cellular environment and response. Nature Protocols, 2018, 13, 1917-1957.	5.5	31
1038	A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. Journal of Biological Engineering, 2018, 12, 12.	2.0	37
1039	Transcriptomic analysis reveals key lncRNAs associated with ribosomal biogenesis and epidermis differentiation in head and neck squamous cell carcinoma. Journal of Zhejiang University: Science B, 2018, 19, 674-688.	1.3	20
1040	Delivering Functional Imaging on the MRI-Linac: Current Challenges and Potential Solutions. Clinical Oncology, 2018, 30, 702-710.	0.6	39
1041	Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors. Accounts of Chemical Research, 2018, 51, 2502-2511.	7.6	230
1042	Recent updates on cancer immunotherapy. Precision Clinical Medicine, 2018, 1, 65-74.	1.3	95
1043	Biologically activatable azobenzene polymers targeted at drug delivery and imaging applications. Biomaterials, 2018, 185, 333-347.	5.7	54

#	Article	IF	Citations
1044	Reduction-Responsive DNA Duplex Containing O⁶-Nitrobenzyl-Guanine. ACS Omega, 2018, 3, 9267-9275.	1.6	9
1045	COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models. Biomaterials, 2018, 185, 63-72.	5.7	39
1046	Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models. Oncotarget, 2018, 9, 2158-2174.	0.8	56
1047	Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. Biomaterials Research, 2018, 22, 22.	3.2	135
1048	Synthesis of unsymmetrical Si-rhodamine fluorophores and application to a far-red to near-infrared fluorescence probe for hypoxia. Chemical Communications, 2018, 54, 6939-6942.	2.2	36
1049	Optical oxygen sensing with quantum dot conjugates. Pure and Applied Chemistry, 2018, 90, 1359-1377.	0.9	7
1050	A Tumor Vasculaâ€Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia. Advanced Science, 2018, 5, 1800034.	5.6	38
1051	Development and MPI tracking of novel hypoxia-targeted theranostic exosomes. Biomaterials, 2018, 177, 139-148.	5.7	155
1052	Advances in Radiation Biology of Particle Irradiation. Progress in Tumor Research, 2018, , 105-121.	0.1	1
1053	Smart Magnetic Nanoaptamer: Construction, Subcellular Distribution, and Silencing HIF for Cancer Gene Therapy. ACS Biomaterials Science and Engineering, 2018, 4, 2606-2613.	2.6	13
1054	Targeting Tumor Microenvironment and Metabolism to Overcome Radiation Resistance. Progress in Tumor Research, 2018, , 25-40.	0.1	0
1055	Normalizing Tumor Microenvironment Based on Photosynthetic Abiotic/Biotic Nanoparticles. ACS Nano, 2018, 12, 6218-6227.	7.3	73
1056	Stepwise Degradable Nanocarriers Enabled Cascade Delivery for Synergistic Cancer Therapy. Advanced Functional Materials, 2018, 28, 1800706.	7.8	96
1057	Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases. Biomaterials, 2018, 177, 149-160.	5.7	235
1058	Oxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor. Nature Communications, 2018, 9, 2053.	5.8	219
1059	Impact of Poreâ€"Walls Ligand Assembly on the Biodegradation of Mesoporous Organosilica Nanoparticles for Controlled Drug Delivery. ACS Omega, 2018, 3, 5195-5201.	1.6	14
1060	Targeting Photoinduced DNA Destruction by Ru(II) Tetraazaphenanthrene in Live Cells by Signal Peptide. Journal of the American Chemical Society, 2018, 140, 6945-6955.	6.6	69
1061	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661.	2.6	219

#	Article	IF	Citations
1062	CO2-sensitive tRNA modification associated with human mitochondrial disease. Nature Communications, 2018, 9, 1875.	5.8	87
1063	Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells. Advanced Science, 2018, 5, 1700859.	5.6	54
1064	DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts. Neoplasia, 2018, 20, 734-744.	2.3	18
1065	Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models. Translational Oncology, 2018, 11, 911-919.	1.7	11
1066	Harnessing Tumor Microenvironment for Nanoparticleâ€Mediated Radiotherapy. Advanced Therapeutics, 2018, 1, 1800050.	1.6	33
1067	Injectable Oxygen: Interfacing Materials Chemistry with Resuscitative Science. Chemistry - A European Journal, 2018, 24, 18820-18829.	1.7	7
1068	Tissueâ€Penetrating, Hypoxiaâ€Responsive Echogenic Polymersomes For Drug Delivery To Solid Tumors. Chemistry - A European Journal, 2018, 24, 12490-12494.	1.7	30
1069	18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer. PLoS ONE, 2018, 13, e0199970.	1.1	14
1070	A Platinum(II) Complex of Heptamethine Cyanine for Photoenhanced Cytotoxicity and Cellular Imaging in Nearâ€IR Light. Angewandte Chemie, 2018, 130, 10420-10424.	1.6	10
1071	Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways. Scientific Reports, 2018, 8, 9706.	1.6	22
1072	Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis. , 2018, 191, 92-122.		36
1073	Hypoxia-Targeting Organometallic Ru(II)â€“Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells. Inorganic Chemistry, 2018, 57, 8396-8403.	1.9	35
1074	Hypoxia-Triggered Nanoscale Metalâ€“Organic Frameworks for Enhanced Anticancer Activity. ACS Applied Materials & Interfaces, 2018, 10, 24638-24647.	4.0	91
1075	A <scp>HIF</scp> â€“ <scp>LIMD</scp> 1 negative feedback mechanism mitigates the proâ€tumorigenic effects of hypoxia. EMBO Molecular Medicine, 2018, 10, .	3.3	17
1076	A Platinum(II) Complex of Heptamethine Cyanine for Photoenhanced Cytotoxicity and Cellular Imaging in Nearâ€IR Light. Angewandte Chemie - International Edition, 2018, 57, 10263-10267.	7.2	72
1077	Mammalian Cell-Based Assays for Studying Bio-Nano Interactions. , 2018, , 129-166.		1
1078	Cancer Metabolism: Current Understanding and Therapies. Chemical Reviews, 2018, 118, 6893-6923.	23.0	161
1079	Aspartate is an endogenous metabolic limitation for tumour growth. Nature Cell Biology, 2018, 20, 782-788.	4.6	240

#	Article	IF	Citations
1080	Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. Cell Metabolism, 2018, 28, 69-86.e6.	7.2	284
1081	Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clinical Cancer Research, 2018, 24, 4798-4807.	3.2	65
1082	Regulation of Tumor Progression by Programmed Necrosis. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-28.	1.9	140
1083	18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry. Current Radiopharmaceuticals, 2018, 11, 50-57.	0.3	7
1084	Increased expression of hypoxia-inducible factor-1 alpha and its impact on transcriptional changes and prognosis in malignant tumours of the ocular adnexa. Eye, 2018, 32, 1772-1782.	1.1	21
1085	Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008â€“2018). Expert Opinion on Therapeutic Patents, 2018, 28, 729-740.	2.4	160
1086	Coordinationâ€Responsive Longitudinal Relaxation Tuning as a Versatile MRI Sensing Protocol for Malignancy Targets. Advanced Science, 2018, 5, 1800021.	5.6	37
1087	ERO1L promotes pancreatic cancer cell progression through activating the Wnt/catenin pathway. Journal of Cellular Biochemistry, 2018, 119, 8996-9005.	1.2	21
1088	Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Frontiers in Pharmacology, 2018, 9, 536.	1.6	160
1089	Geneâ€expression signature predicts survival benefit from postoperative chemoradiotherapy in head and neck squamous cell carcinoma. Oncology Letters, 2018, 16, 2565-2578.	0.8	7
1090	The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends in Cell Biology, 2018, 28, 941-956.	3.6	83
1091	Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose. Theranostics, 2018, 8, 3584-3596.	4.6	98
1092	Scintillator-Based Nanohybrids with Sacrificial Electron Prodrug for Enhanced X-ray-Induced Photodynamic Therapy. Nano Letters, 2018, 18, 5768-5774.	4.5	104
1093	Cancer radiotheranostics targeting carbonic anhydrase-IX with ¹¹¹In- and ⁹⁰Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy. Theranostics, 2018, 8, 2992-3006.	4.6	42
1094	Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma. International Journal of Nanomedicine, 2018, Volume 13, 1505-1524.	3.3	47
1095	Hypoxia-responsive block copolymer radiosensitizers as anticancer drug nanocarriers for enhanced chemoradiotherapy of bulky solid tumors. Biomaterials, 2018, 181, 360-371.	5.7	57
1096	Context-dependent AMPK activation distinctly regulates TAp73 stability and transcriptional activity. Signal Transduction and Targeted Therapy, 2018, 3, 20.	7.1	2
1097	Dual-Responsive Core Crosslinking Glycopolymer-Drug Conjugates Nanoparticles for Precise Hepatocarcinoma Therapy. Frontiers in Pharmacology, 2018, 9, 663.	1.6	28

#	Article	IF	Citations
1098	Emerging Functions of Regulatory T Cells in Tissue Homeostasis. Frontiers in Immunology, 2018, 9, 883.	2.2	201
1099	Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity. Frontiers in Immunology, 2018, 9, 887.	2.2	63
1100	Commentary: Induction of Dormancy in Hypoxic Human Papillomavirus-Positive Cancer Cells. Frontiers in Oncology, 2018, 8, 77.	1.3	2
1101	â€œSmartâ€•Nanoprobes for Visualization of Tumor Microenvironments. Advanced Healthcare Materials, 2018, 7, e1800391.	3.9	47
1102	The Emerging Role of Multifunctional Theranostic Materials in Cancer Nanomedicine. , 2018, , 1-31.		8
1103	Recent Progress in the Design of Hypoxiaâ€Specific Nano Drug Delivery Systems for Cancer Therapy. Advanced Therapeutics, 2018, 1, 1800026.	1.6	44
1104	A Complex Scenario and Underestimated Challenge: The Tumor Microenvironment, ER Stress, and Cancer Treatment. Current Medicinal Chemistry, 2018, 25, 2465-2502.	1.2	20
1105	Mesoporous silica nanoparticles in recent photodynamic therapy applications. Photochemical and Photobiological Sciences, 2018, 17, 1651-1674.	1.6	47
1106	Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models. International Journal of Molecular Sciences, 2018, 19, 147.	1.8	102
1107	Kv3.1 and Kv3.4, Are Involved in Cancer Cell Migration and Invasion. International Journal of Molecular Sciences, 2018, 19, 1061.	1.8	28
1108	Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. International Journal of Molecular Sciences, 2018, 19, 1512.	1.8	16
1109	Carbonic Anhydrases: Role in pH Control and Cancer. Metabolites, 2018, 8, 19.	1.3	180
1110	Hypoxia-Responsive Mesoporous Nanoparticles for Doxorubicin Delivery. Polymers, 2018, 10, 390.	2.0	23
1111	The specific role of O⁶-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy. Future Medicinal Chemistry, 2018, 10, 1971-1996.	1.1	33
1112	A Versatile Ptâ€Based Coreâ€“Shell Nanoplatform as a Nanofactory for Enhanced Tumor Therapy. Advanced Functional Materials, 2018, 28, 1801783.	7.8	106
1113	A Bioenvironment-Responsive Versatile Nanoplatform Enabling Rapid Clearance and Effective Tumor Homing for Oxygen-Enhanced Radiotherapy. Chemistry of Materials, 2018, 30, 5412-5421.	3.2	17
1114	Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIFâ€1Î± pathway. International Journal of Oncology, 2018, 53, 1160-1170.	1.4	21
1115	Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. Frontiers in Oncology, 2018, 8, 81.	1.3	86

#	Article	IF	Citations
1116	The phenotype control kernel of a biomolecular regulatory network. BMC Systems Biology, 2018, 12, 49.	3.0	13
1117	Chitin synthesis inhibitors promote liver cancer cell metastasis via interfering with hypoxia-inducible factor 1Î±. Chemosphere, 2018, 206, 231-237.	4.2	19
1118	Efficacy of the hypoxiaâ€activated prodrug evofosfamide (THâ€302) in nasopharyngeal carcinoma in vitro and in vivo. Cancer Communications, 2018, 38, 1-9.	3.7	23
1119	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
1120	Biological evaluation and SPECT imaging of tumor hypoxia using a novel technetium-99m labeled tracer with 2-nitroimidazole moiety. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 1463-1468.	0.7	7
1121	SRGN Promotes Colorectal Cancer Metastasis as a Critical Downstream Target of HIF-1Î±. Cellular Physiology and Biochemistry, 2018, 48, 2429-2440.	1.1	40
1122	Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance. Biomaterials, 2018, 182, 145-156.	5.7	93
1123	Hypoxia-inducible factor 2Î±: a novel target in gliomas. Future Medicinal Chemistry, 2018, 10, 2227-2236.	1.1	28
1124	Total synthesis of BE-43547A2. Tetrahedron, 2018, 74, 5955-5964.	1.0	7
1125	Recent progresses in small-molecule enzymatic fluorescent probes for cancer imaging. Chemical Society Reviews, 2018, 47, 7140-7180.	18.7	689
1126	Cancer cell adaptation to hypoxia involves a HIFâ€GPRC5Aâ€YAP axis. EMBO Molecular Medicine, 2018, 10, .	3.3	72
1127	Near-Infrared-Triggered in Situ Gelation System for Repeatedly Enhanced Photothermal Brachytherapy with a Single Dose. ACS Nano, 2018, 12, 9412-9422.	7.3	95
1128	Synthesis of New Branched 2-Nitroimidazole as a Hypoxia Sensitive Linker for Ligand-Targeted Drugs of Paclitaxel. ACS Omega, 2018, 3, 8813-8818.	1.6	7
1129	APD-Containing Cyclolipodepsipeptides Target Mitochondrial Function in Hypoxic Cancer Cells. Cell Chemical Biology, 2018, 25, 1337-1349.e12.	2.5	27
1130	Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs. Molecules, 2018, 23, 2041.	1.7	8
1131	Near-infrared off-on fluorescence probe activated by NTR for in vivo hypoxia imaging. Biosensors and Bioelectronics, 2018, 119, 141-148.	5.3	80
1132	Lipid Droplets in Cancer: Guardians of Fat in a Stressful World. Molecules, 2018, 23, 1941.	1.7	240
1133	Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects. Biochemical Pharmacology, 2018, 156, 265-280.	2.0	22

#	Article	IF	Citations
1134	Dimeric BODIPY-loaded liposomes for dual hypoxia marker imaging and activatable photodynamic therapy against tumors. Journal of Materials Chemistry B, 2018, 6, 4351-4359.	2.9	37
1135	Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncology, 2018, 14, 1409-1421.	1.1	38
1136	Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. Radiology, 2018, 288, 739-747.	3.6	34
1137	Dual-Phosphorescent Iridium(III) Complexes Extending Oxygen Sensing from Hypoxia to Hyperoxia. Journal of the American Chemical Society, 2018, 140, 7827-7834.	6.6	151
1138	CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1024-1033.	2.5	15
1139	A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PDâ€1/PDâ€L1 Axis. Small, 2018, 14, e1801120.	5.2	126
1140	The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma and Preclinical Models to Study It. , 2018, , 735-748.		0
1141	Hypoxic tumor microenvironment activates GLI2 via HIF-1Î± and TGF-Î²2 to promote chemoresistance in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5990-E5999.	3.3	203
1142	Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Cell Reports, 2018, 23, 3312-3326.	2.9	61
1143	Synergy between peroxisome proliferatorâ€activated receptor Î³ agonist and radiotherapy in cancer. Cancer Science, 2018, 109, 2243-2255.	1.7	14
1144	PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. PLoS Computational Biology, 2018, 14, e1005991.	1.5	303
1145	Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE, 2018, 13, e0192136.	1.1	9
1146	Obesity-Induced Defects in Dendritic Cell and T Cell Functions. , 2018, , 171-181.		1
1147	An azobenzene-based heteromeric prodrug for hypoxia-activated chemotherapy by regulating subcellular localization. Chemical Communications, 2018, 54, 7983-7986.	2.2	35
1148	A dual-analyte probe: hypoxia activated nitric oxide detection with phototriggered drug release ability. Chemical Communications, 2018, 54, 7940-7943.	2.2	17
1149	Bioenergetic and proteomic profiling to screen small molecule inhibitors that target cancer metabolisms. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 28-37.	1.1	18
1150	DCE-MRI in Human Gliomas. Academic Radiology, 2019, 26, 179-187.	1.3	8
1151	A Novel PET Probe â€œ[18F]DiFAâ€•Accumulates in Hypoxic Region via Glutathione Conjugation Following Reductive Metabolism. Molecular Imaging and Biology, 2019, 21, 122-129.	1.3	22

#	Article	IF	Citations
1152	Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice. Acta Pharmacologica Sinica, 2019, 40, 556-562.	2.8	27
1153	Oxygen self-sufficient NIR-activatable liposomes for tumor hypoxia regulation and photodynamic therapy. Chemical Science, 2019, 10, 9091-9098.	3.7	81
1154	Long non-coding RNA HOTTIP promotes hypoxia-induced glycolysis through targeting miR-615-3p/HMGB3 axis in non-small cell lung cancer cells. European Journal of Pharmacology, 2019, 862, 172615.	1.7	39
1155	Nanoparticle Interactions with the Tumor Microenvironment. Bioconjugate Chemistry, 2019, 30, 2247-2263.	1.8	66
1156	LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1Î±. Theranostics, 2019, 9, 5298-5314.	4.6	61
1157	Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells. Oncogene, 2019, 38, 6970-6984.	2.6	60
1158	Hypoxic Glioma Cell-Secreted Exosomal miR-301a Activates Wnt/Î²-catenin Signaling and Promotes Radiation Resistance by Targeting TCEAL7. Molecular Therapy, 2019, 27, 1939-1949.	3.7	129
1159	Organosilica-Based Hollow Mesoporous Bilirubin Nanoparticles for Antioxidation-Activated Self-Protection and Tumor-Specific Deoxygenation-Driven Synergistic Therapy. ACS Nano, 2019, 13, 8903-8916.	7.3	70
1160	Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models. EJNMMI Research, 2019, 9, 51.	1.1	11
1161	Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors. Molecules, 2019, 24, 2524.	1.7	3
1162	Bacteriaâ€Assisted Selective Photothermal Therapy for Precise Tumor Inhibition. Advanced Functional Materials, 2019, 29, 1904093.	7.8	58
1163	Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation. Physica Medica, 2019, 64, 145-156.	0.4	15
1164	Modeling the regulation of p53 activation by HIFâ€1 upon hypoxia. FEBS Letters, 2019, 593, 2596-2611.	1.3	39
1165	Nanocatalytic Medicine. Advanced Materials, 2019, 31, e1901778.	11.1	396
1166	Synthesis and bioevaluation of novel radioiodinated PEG-modified 2-nitroimidazole derivatives for tumor hypoxia imaging. Journal of Radioanalytical and Nuclear Chemistry, 2019, 321, 943-954.	0.7	6
1167	Detection of cellular hypoxia by pimonidazole adduct immunohistochemistry in kidney disease: methodological pitfalls and their solution. American Journal of Physiology - Renal Physiology, 2019, 317, F322-F332.	1.3	10
1168	Autoinhibitory Feedback Control over Photodynamic Action. ACS Omega, 2019, 4, 12293-12299.	1.6	10
1169	Optical coherence tomography complements confocal microscopy for investigation of multicellular tumour spheroids. Scientific Reports, 2019, 9, 10601.	1.6	17

#	Article	IF	Citations
1170	Intelligent protein-coated bismuth sulfide and manganese oxide nanocomposites obtained by biomineralization for multimodal imaging-guided enhanced tumor therapy. Journal of Materials Chemistry B, 2019, 7, 5170-5181.	2.9	31
1171	Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models. Cells, 2019, 8, 717.	1.8	14
1172	Double signal amplification strategy for ultrasensitive electrochemical biosensor based on nuclease and quantum dot-DNA nanocomposites in the detection of breast cancer 1 gene mutation. Biosensors and Bioelectronics, 2019, 142, 111544.	5.3	44
1173	Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology, 2019, 157, 823-837.	0.6	153
1174	Harnessing combinational phototherapy via post-synthetic PpIX conjugation on nanoscale metalâ€“organic frameworks. Journal of Materials Chemistry B, 2019, 7, 4763-4770.	2.9	11
1175	Size-Tunable Assemblies Based on Ferrocene-Containing DNA Polymers for Spatially Uniform Penetration. CheM, 2019, 5, 1775-1792.	5.8	78
1176	YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nature Communications, 2019, 10, 4892.	5.8	256
1177	Photo-Uncaging of a Microtubule-Targeted Rigidin Analogue in Hypoxic Cancer Cells and in a Xenograft Mouse Model. Journal of the American Chemical Society, 2019, 141, 18444-18454.	6.6	84
1178	Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. Life Sciences, 2019, 237, 116952.	2.0	69
1179	Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical Pharmacology, 2019, 169, 113641.	2.0	19
1180	Exploring the Phototoxicity of Hypoxic Active Iridium(III)-Based Sensitizers in 3D Tumor Spheroids. Journal of the American Chemical Society, 2019, 141, 18486-18491.	6.6	80
1181	Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. Advanced Materials, 2020, 32, e1904337.	11.1	130
1183	Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Frontiers in Oncology, 2019, 9, 1104.	1.3	69
1184	Sensitization of Hypoxic Tumor to Photodynamic Therapy via Oxygen Self-Supply of Fluorinated Photosensitizers. Biomacromolecules, 2019, 20, 4563-4573.	2.6	41
1185	Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Molecular Cancer, 2019, 18, 157.	7.9	1,121
1186	Platelet-Mimicking Biotaxis Targeting Vasculature-Disrupted Tumors for Cascade Amplification of Hypoxia-Sensitive Therapy. ACS Nano, 2019, 13, 14230-14240.	7.3	60
1187	Potentialization of anticancer agents by identification of new chemosensitizers active under hypoxia. Biochemical Pharmacology, 2019, 162, 224-236.	2.0	4
1188	A novel signature derived from immunoregulatory and hypoxia genes predicts prognosis in liver and five other cancers. Journal of Translational Medicine, 2019, 17, 14.	1.8	44

#	Article	IF	Citations
1189	Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancerâ€"How We Can Rise to the Challenge. Cells, 2019, 8, 957.	1.8	467
1190	Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. International Journal of Pharmaceutics, 2019, 570, 118636.	2.6	24
1191	Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clinical and Translational Medicine, 2019, 8, 10.	1.7	155
1192	Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1Î± expression. PLoS ONE, 2019, 14, e0221340.	1.1	14
1193	On the optimal design of metabolic RNA labeling experiments. PLoS Computational Biology, 2019, 15, e1007252.	1.5	16
1194	What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resistance Updates, 2019, 46, 100643.	6.5	52
1195	New power of self-assembling carbonic anhydrase inhibitor: Short peptideâ€"constructed nanofibers inspire hypoxic cancer therapy. Science Advances, 2019, 5, eaax0937.	4.7	100
1196	P4HB, a Novel Hypoxia Target Gene Related to Gastric Cancer Invasion and Metastasis. BioMed Research International, 2019, 2019, 1-13.	0.9	35
1197	Biofluids in hypobaric hypoxia: best possible use, investigative strategies and putative markers. Journal of Proteins and Proteomics, 2019, 10, 191-206.	1.0	1
1198	Design, synthesis, and biological study of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia . Drug Design, Development and Therapy, 2019, Volume 13, 3079-3089.	2.0	10
1199	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells, 2019, 8, 1083.	1.8	153
1200	Assessing for Enhanced Radiosensitivity in Hypoxic Tumors by Blocking Oxidative Phosphorylation Using IACS-010759. International Journal of Radiation Oncology Biology Physics, 2019, 103, E22.	0.4	0
1201	Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy. Nano-Micro Letters, 2019, 11, 74.	14.4	66
1202	New Self-assembled Supramolecular Bowls as Potent Anticancer Agents for Human Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 242.	1.6	4
1203	Nanomedicines for cancer therapy: current status, challenges and future prospects. Therapeutic Delivery, 2019, 10, 113-132.	1.2	102
1204	In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia. Molecular Pharmaceutics, 2019, 16, 1156-1166.	2.3	9
1205	Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics. Frontiers in Pharmacology, 2019, 10, 79.	1.6	30
1206	Hypoxia-induced LncRNA PCGEM1 promotes invasion and metastasis of gastric cancer through regulating SNAI1. Clinical and Translational Oncology, 2019, 21, 1142-1151.	1.2	58

#	Article	IF	Citations
1207	Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxiaâ€Activated Prodrug Tirapazamine Therapy for Metastatic Tumors. Advanced Materials, 2019, 31, e1805955.	11.1	154
1208	HER2 regulates HIF-2Î± and drives an increased hypoxic response in breast cancer. Breast Cancer Research, 2019, 21, 10.	2.2	48
1209	Photothermal-Controlled Generation of Alkyl Radical from Organic Nanoparticles for Tumor Treatment. ACS Applied Materials & Interfaces, 2019, 11, 5782-5790.	4.0	37
1210	Vanillic Acid Suppresses HIF-1Î± Expression via Inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK Pathways in Human Colon Cancer HCT116 Cells. International Journal of Molecular Sciences, 2019, 20, 465.	1.8	71
1211	Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy. Cell Biology and Toxicology, 2019, 35, 407-421.	2.4	43
1212	Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Rasâ€“ERK Pathway Activation in Hypoxia. Molecular Cancer Research, 2019, 17, 1220-1232.	1.5	22
1213	A near-infrared frequency upconversion probe for nitroreductase detection and hypoxia tumor in vivo imaging. Sensors and Actuators B: Chemical, 2019, 286, 337-345.	4.0	33
1214	Unprecedented O:â‡”:O compression and Hâ†”H fragilization in Lewis solutions. Physical Chemistry Chemical Physics, 2019, 21, 2234-2250.	1.3	27
1215	Microfluidic modelling of the tumor microenvironment for anti-cancer drug development. Lab on A Chip, 2019, 19, 369-386.	3.1	182
1216	Development of a red-light emission hypoxia-sensitive two-photon fluorescent probe for in vivo nitroreductase imaging. Journal of Materials Chemistry B, 2019, 7, 408-414.	2.9	47
1217	A sensitive and fast responsive fluorescent probe for imaging hypoxic tumors. Analyst, The, 2019, 144, 284-289.	1.7	12
1218	Thiolated plastoquinone analogs: Synthesis, characterization, and antimicrobial evaluation. Journal of Molecular Structure, 2019, 1195, 681-688.	1.8	10
1219	Therapeutic Strategies to Block the Hypoxic Response. Advances in Experimental Medicine and Biology, 2019, 1136, 141-157.	0.8	8
1220	Oxygenâ€sensitive MRI assessment of tumor response to hypoxic gas breathing challenge. NMR in Biomedicine, 2019, 32, e4101.	1.6	19
1221	Working with Hypoxia. Methods in Molecular Biology, 2019, 1990, 109-133.	0.4	4
1222	Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer. Scientific Reports, 2019, 9, 8972.	1.6	21
1223	Hypoxia-active nanoparticles used in tumor theranostic . International Journal of Nanomedicine, 2019, Volume 14, 3705-3722.	3.3	48
1224	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Experimental and Molecular Medicine, 2019, 51, 1-17.	3.2	118

#	Article	IF	Citations
1225	A novel method to establish glucocorticoid resistant acute lymphoblastic leukemia cell lines. Journal of Experimental and Clinical Cancer Research, 2019, 38, 269.	3.5	17
1226	Reactive oxygen species-responsive theranostic nanoparticles for enhanced hypoxic tumor photodynamic therapyviasynchronous HIF-1Î± inhibition and ATP depletion. Materials Chemistry Frontiers, 2019, 3, 1793-1799.	3.2	14
1227	A Nanozyme with Photoâ€Enhanced Dual Enzymeâ€Like Activities for Deep Pancreatic Cancer Therapy. Angewandte Chemie, 2019, 131, 12754-12761.	1.6	71
1228	A Nanozyme with Photoâ€Enhanced Dual Enzymeâ€Like Activities for Deep Pancreatic Cancer Therapy. Angewandte Chemie - International Edition, 2019, 58, 12624-12631.	7.2	345
1229	Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1Î±-mediated epithelial-mesenchymal transition. International Journal of Biological Macromolecules, 2019, 137, 32-44.	3.6	16
1230	Evaluation of 5-hydroxy-1,4-naphthoquinone-cobalt(III) complexes for hypoxia-activated drug delivery. Journal of Inorganic Biochemistry, 2019, 199, 110756.	1.5	8
1231	Luminescent, Oxygenâ€Supplying, Hemoglobinâ€Linked Conjugated Polymer Nanoparticles for Photodynamic Therapy. Angewandte Chemie - International Edition, 2019, 58, 10660-10665.	7.2	188
1232	Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. Clinical Breast Cancer, 2019, 19, 383-391.	1.1	20
1233	Dependency of the blood oxygen level dependent-response to hyperoxic challenges on the order of gas administration in intracranial malignancies. Neuroradiology, 2019, 61, 783-793.	1.1	1
1234	Copper trafficking in eukaryotic systems: current knowledge from experimental and computational efforts. Current Opinion in Structural Biology, 2019, 58, 26-33.	2.6	39
1235	Radiation Damage Mechanisms of Chemotherapeutically Active Nitroimidazole Derived Compounds. Frontiers in Chemistry, 2019, 7, 329.	1.8	10
1236	Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy. Chemical Science, 2019, 10, 6932-6943.	3.7	111
1237	Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment. Theranostics, 2019, 9, 3134-3149.	4.6	82
1238	Tumor Reoxygenation and Blood Perfusion Enhanced Photodynamic Therapy using Ultrathin Graphdiyne Oxide Nanosheets. Nano Letters, 2019, 19, 4060-4067.	4.5	118
1239	Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000. Cancer Biology and Therapy, 2019, 20, 1258-1269.	1.5	7
1240	Metabolite Responsive Nanoparticleâ€“Protein Complex. Biomacromolecules, 2019, 20, 2703-2712.	2.6	11
1241	Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Biochemical and Biophysical Research Communications, 2019, 515, 275-281.	1.0	8
1242	Luminescent, Oxygenâ€Supplying, Hemoglobinâ€Linked Conjugated Polymer Nanoparticles for Photodynamic Therapy. Angewandte Chemie, 2019, 131, 10770-10775.	1.6	42

#	Article	IF	Citations
1243	ROS-sensitive biomimetic nanocarriers modulate tumor hypoxia for synergistic photodynamic chemotherapy. Biomaterials Science, 2019, 7, 3706-3716.	2.6	53
1244	A dual-responsive probe for detecting cellular hypoxia using ¹⁹F magnetic resonance and fluorescence. Chemical Communications, 2019, 55, 8860-8863.	2.2	21
1245	Hypoxia and Cancer Metastasis. Advances in Experimental Medicine and Biology, 2019, , .	0.8	5
1246	Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity. Advances in Experimental Medicine and Biology, 2019, 1136, 43-55.	0.8	49
1247	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. International Journal of Molecular Sciences, 2019, 20, 2469.	1.8	14
1248	Limitations of Anti-Angiogenic Treatment of Tumors. Translational Oncology, 2019, 12, 981-986.	1.7	89
1249	Naphthalimides in fluorescent imaging of tumor hypoxia â€“ An up-to-date review. Bioorganic Chemistry, 2019, 88, 102979.	2.0	42
1250	PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 2188.	1.8	71
1251	A Hypoxiaâ€Responsive Albuminâ€Based Nanosystem for Deep Tumor Penetration and Excellent Therapeutic Efficacy. Advanced Materials, 2019, 31, e1901513.	11.1	263
1252	Effect of resveratrol on the radiosensitivity of 5â€FU in human breast cancer MCFâ€7 cells. Journal of Cellular Biochemistry, 2019, 120, 15671-15677.	1.2	14
1253	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 3818-3829.	3.2	51
1254	Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy. Chemical Engineering Journal, 2019, 373, 720-733.	6.6	68
1255	Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment. Molecular Pharmaceutics, 2019, 16, 2966-2979.	2.3	29
1256	The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opinion on Drug Discovery, 2019, 14, 667-682.	2.5	204
1257	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.5	9
1258	Volumetric Optoacoustic Imaging Unveils High-Resolution Patterns of Acute and Cyclic Hypoxia in a Murine Model of Breast Cancer. Cancer Research, 2019, 79, 4767-4775.	0.4	47
1259	Towards an evolvable cancer treatment simulator. BioSystems, 2019, 182, 1-7.	0.9	21
1260	Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors. Molecules, 2019, 24, 1559.	1.7	11

#	Article	IF	Citations
1261	Kinetics-Based Measurement of Hypoxia in Living Cells and Animals Using an Acetoxymethyl Ester Chemiluminescent Probe. ACS Sensors, 2019, 4, 1391-1398.	4.0	38
1262	A Review on the Special Radiotherapy Techniques of Colorectal Cancer. Frontiers in Oncology, 2019, 9, 208.	1.3	44
1263	Colloids, nanoparticles, and materials for imaging, delivery, ablation, and theranostics by focused ultrasound (FUS). Theranostics, 2019, 9, 2572-2594.	4.6	42
1264	Reduction and pH dualâ€responsive block copolymers containing pendent p â€nitrobenzyl carbamate functionalities: Synthesis and selfâ€assembly behavior. Journal of Polymer Science Part A, 2019, 57, 1333-1343.	2.5	7
1265	Polymeric Micelles for Tumor Theranostics. , 2019, , 289-302.		3
1266	Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex . International Journal of Nanomedicine, 2019, Volume 14, 2637-2653.	3.3	21
1267	An oxygen self-sufficient NIR-responsive nanosystem for enhanced PDT and chemotherapy against hypoxic tumors. Chemical Science, 2019, 10, 5766-5772.	3.7	91
1268	Azodyes as markers for tumor hypoxia imaging and therapy: An up-to-date review. Chemico-Biological Interactions, 2019, 307, 91-104.	1.7	33
1269	The role of caveolin-1 in tumors of the brain - functional and clinical implications. Cellular Oncology (Dordrecht), 2019, 42, 423-447.	2.1	10
1270	Development of the ^{99m}Tc-Hydroxamamide Complex as a Probe Targeting Carbonic Anhydrase IX. Molecular Pharmaceutics, 2019, 16, 1489-1497.	2.3	10
1271	Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection. American Journal of Roentgenology, 2019, 212, 1060-1069.	1.0	12
1272	Perfluorocarbon nanodroplets can reoxygenate hypoxic tumors in vivo without carbogen breathing. Nanotheranostics, 2019, 3, 135-144.	2.7	29
1273	miRâ€20a inhibits hypoxiaâ€induced autophagy by targeting ATG5/FIP200 in colorectal cancer. Molecular Carcinogenesis, 2019, 58, 1234-1247.	1.3	30
1274	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nature Metabolism, 2019, 1, 431-444.	5.1	158
1275	shRNAâ€mediated knockdown of KNTC1 suppresses cell viability and induces apoptosis in esophageal squamous cell carcinoma. International Journal of Oncology, 2019, 54, 1053-1060.	1.4	13
1276	Hypoxiaâ€inducible factor-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib. Oncology Letters, 2019, 17, 4034-4043.	0.8	6
1277	Mitochondria-targeting cyclometalated iridium(<scp>iii</scp>) complexes for tumor hypoxic imaging and therapy. Inorganic Chemistry Frontiers, 2019, 6, 1003-1010.	3.0	35
1278	The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression. Nature Communications, 2019, 10, 1034.	5.8	56

#	Article	IF	Citations
1279	In vivo imaging of hypoxia generation stimulated by testosterone using a micelle-based near-infrared fluorescent probe. Sensors and Actuators B: Chemical, 2019, 288, 543-551.	4.0	12
1280	Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1232-1235.	1.0	6
1281	Fabrication of Red Blood Cell-Based Multimodal Theranostic Probes for Second Near-Infrared Window Fluorescence Imaging-Guided Tumor Surgery and Photodynamic Therapy. Theranostics, 2019, 9, 369-380.	4.6	93
1283	ATF4, Hypoxia and Treatment Resistance in Cancer. Cancer Drug Discovery and Development, 2019, , 75-108.	0.2	1
1284	Biomaterial Platform To Establish a Hypoxic Metastatic Niche in Vivo. ACS Applied Bio Materials, 2019, 2, 1549-1560.	2.3	10
1285	Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging. Scientific Reports, 2019, 9, 4907.	1.6	30
1286	Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs. Clinical Oncology, 2019, 31, 290-302.	0.6	22
1287	Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene, 2019, 38, 5158-5173.	2.6	212
1288	Modeling genotypes in their microenvironment to predict single- and multi-cellular behavior. GigaScience, 2019, 8, .	3.3	14
1289	Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Molecular Cancer, 2019, 18, 40.	7.9	350
1290	Hydrangea-structured tumor microenvironment responsive degradable nanoplatform for hypoxic tumor multimodal imaging and therapy. Biomaterials, 2019, 205, 1-10.	5.7	70
1291	Enzyme-Activated Generation of Reactive Oxygen Species from Heterocyclic N-Oxides under Aerobic and Anaerobic Conditions and Its Relevance to Hypoxia-Selective Prodrugs. Chemical Research in Toxicology, 2019, 32, 348-361.	1.7	19
1292	Highly Stable and Luminescent Oxygen Nanosensor Based on Ruthenium-Containing Metallopolymer for Real-Time Imaging of Intracellular Oxygenation. ACS Sensors, 2019, 4, 984-991.	4.0	21
1293	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. Future Medicinal Chemistry, 2019, 11, 323-336.	1.1	31
1294	Routine Blood Tests Do Not Predict Survival in Patients with Glioblastomaâ€"Multivariable Analysis of 497 Patients. World Neurosurgery, 2019, 126, e1081-e1091.	0.7	13
1295	Catalase-Integrated Hyaluronic Acid as Nanocarriers for Enhanced Photodynamic Therapy in Solid Tumor. ACS Nano, 2019, 13, 4742-4751.	7.3	293
1296	Pt nanozyme for O₂ self-sufficient, tumor-specific oxidative damage and drug resistance reversal. Nanoscale Horizons, 2019, 4, 1124-1131.	4.1	48
1297	Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide. Molecular Pharmacology, 2019, 95, 638-651.	1.0	11

#	Article	IF	Citations
1298	Optimised synthesis of a nitroCBI hypoxia-activated prodrug with substantial anticancer activity. Tetrahedron, 2019, 75, 3001-3007.	1.0	2
1299	Reactive Oxygen Species (ROS)-Based Nanomedicine. Chemical Reviews, 2019, 119, 4881-4985.	23.0	1,519
1300	Drug Delivery to Hypoxic Tumors Targeting Carbonic Anhydrase IX. ACS Symposium Series, 2019, , 223-252.	0.5	1
1301	Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1215-1219.	1.0	6
1302	Programmable Therapeutic Nanodevices with Circular Amplification of H₂O₂ in the Tumor Microenvironment for Synergistic Cancer Therapy. Advanced Healthcare Materials, 2019, 8, e1801627.	3.9	27
1303	Hypomethylation at non-CpG/CpG sites in the promoter of HIF-1Î± gene combined with enhanced H3K9Ac modification contribute to maintain higher HIF-1Î± expression in breast cancer. Oncogenesis, 2019, 8, 26.	2.1	22
1304	The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells. Reports on Progress in Physics, 2019, 82, 064602.	8.1	157
1305	Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. Nature Communications, 2019, 10, 1580.	5.8	85
1306	Breaking the Depth Dependence by Nanotechnologyâ€Enhanced Xâ€Rayâ€Excited Deep Cancer Theranostics. Advanced Materials, 2019, 31, e1806381.	11.1	125
1307	Stimuli-responsive polymeric micelles for extracellular and intracellular drug delivery. , 2019, , 269-304.		5
1308	Mesoporous silica/organosilica nanoparticles: Synthesis, biological effect and biomedical application. Materials Science and Engineering Reports, 2019, 137, 66-105.	14.8	119
1309	Structural Simplification of Natural Products. Chemical Reviews, 2019, 119, 4180-4220.	23.0	157
1310	Tissue acidosis does not mediate the hypoxia selectivity of [64Cu][Cu(ATSM)] in the isolated perfused rat heart. Scientific Reports, 2019, 9, 499.	1.6	6
1311	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clinical and Translational Radiation Oncology, 2019, 15, 62-69.	0.9	86
1312	Development of [131I]I-EOE-TPZ and [131I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia. Pharmaceuticals, 2019, 12, 3.	1.7	3
1313	Ultrasound Hyperthermia Technology for Radiosensitization. Ultrasound in Medicine and Biology, 2019, 45, 1025-1043.	0.7	78
1314	Coordination of Timers and Sensors in Cell Signaling. BioEssays, 2019, 41, e1800217.	1.2	8
1315	Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. Annual Review of Physiology, 2019, 81, 505-534.	5.6	303

#	Article	IF	Citations
1316	A faster PISTOL for 1 H MRâ€based quantitative tissue oximetry. NMR in Biomedicine, 2019, 32, e4076.	1.6	5
1317	Differential Oxygenation in Tumor Microenvironment Modulates Macrophage and Cancer Cell Crosstalk: Novel Experimental Setting and Proof of Concept. Frontiers in Oncology, 2019, 9, 43.	1.3	56
1318	<scp>REV</scp>7 confers radioresistance of esophagus squamous cell carcinoma by recruiting <scp>PRDX</scp>2. Cancer Science, 2019, 110, 962-972.	1.7	26
1319	Endogenous stimuli-responsive linkers in nanoliposomal systems for cancer drug targeting. International Journal of Pharmaceutics, 2019, 572, 118716.	2.6	25
1320	Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors. Journal of Clinical Medicine, 2019, 8, 1980.	1.0	23
1321	Recent Advances in Glucoseâ€Oxidaseâ€Based Nanocomposites for Tumor Therapy. Small, 2019, 15, e1903895.	5.2	187
1322	What Neuroradiologists Need to Know About Radiation Treatment for Neural Tumors. Topics in Magnetic Resonance Imaging, 2019, 28, 37-47.	0.7	1
1323	Matrine Reverses the Warburg Effect and Suppresses Colon Cancer Cell Growth via Negatively Regulating HIF-1Î±. Frontiers in Pharmacology, 2019, 10, 1437.	1.6	36
1324	Azo-based near-infrared fluorescent theranostic probe for tracking hypoxia-activated cancer chemotherapy in vivo. Chemical Communications, 2019, 55, 13172-13175.	2.2	35
1325	Recent progress in the augmentation of reactive species with nanoplatforms for cancer therapy. Nanoscale, 2019, 11, 19658-19683.	2.8	90
1326	A fluorescent probe for simultaneously sensing NTR and hNQO1 and distinguishing cancer cells. Journal of Materials Chemistry B, 2019, 7, 6822-6827.	2.9	23
1327	Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia. Scientific Reports, 2019, 9, 17782.	1.6	48
1328	A Near-Infrared Phosphorescent Nanoprobe Enables Quantitative, Longitudinal Imaging of Tumor Hypoxia Dynamics during Radiotherapy. Cancer Research, 2019, 79, 4787-4797.	0.4	20
1329	99mTc Labelling Strategies for the Development of Potential Nitroimidazolic Hypoxia Imaging Agents. Inorganics, 2019, 7, 128.	1.2	13
1330	The Roles of Hypoxia-Inducible Factors and Non-Coding RNAs in Gastrointestinal Cancer. Genes, 2019, 10, 1008.	1.0	14
1331	Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 455-466.	3.3	59
1332	A Highly Sensitive Chemiluminescent Probe for Detecting Nitroreductase and Imaging in Living Animals. Analytical Chemistry, 2019, 91, 1384-1390.	3.2	50
1333	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. Theranostics, 2019, 9, 126-151.	4.6	128

#	Article	IF	Citations
1334	Targeting Cancer Stem Cell Redox Metabolism to Enhance Therapy Responses. Seminars in Radiation Oncology, 2019, 29, 42-54.	1.0	57
1335	A Flexible Synthesis of 68Ga-Labeled Carbonic Anhydrase IX (CAIX)-Targeted Molecules via CBT/1,2-Aminothiol Click Reaction. Molecules, 2019, 24, 23.	1.7	27
1336	Hibernating astronautsâ€"science or fiction?. Pflugers Archiv European Journal of Physiology, 2019, 471, 819-828.	1.3	40
1337	LINE-1 and EPAS1 DNA methylation associations with high-altitude exposure. Epigenetics, 2019, 14, 1-15.	1.3	44
1338	A two-photon excited O2-evolving nanocomposite for efficient photodynamic therapy against hypoxic tumor. Biomaterials, 2019, 194, 84-93.	5.7	88
1339	Design, synthesis, and screening of novel ursolic acid derivatives as potential anti-cancer agents that target the HIF-1Î± pathway. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 853-858.	1.0	16
1340	Chlorella-gold nanorods hydrogels generating photosynthesis-derived oxygen and mild heat for the treatment of hypoxic breast cancer. Journal of Controlled Release, 2019, 294, 77-90.	4.8	44
1341	Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Review of Anticancer Therapy, 2019, 19, 105-119.	1.1	107
1342	Nanostars on Nanopipette Tips: A Raman Probe for Quantifying Oxygen Levels in Hypoxic Single Cells and Tumours. Angewandte Chemie - International Edition, 2019, 58, 2710-2714.	7.2	53
1343	Synthesis, Characterization and inâ€...vitro Studies of a Cathepsin Bâ€Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. Chemistry and Biodiversity, 2019, 16, e1800520.	1.0	9
1344	3D-porous Î²-tricalcium phosphateâ€"alginateâ€"gelatin scaffold with DMOG delivery promotes angiogenesis and bone formation in rat calvarial defects. Journal of Materials Science: Materials in Medicine, 2019, 30, 1.	1.7	33
1345	Hypoxia-tropic Protein Nanocages for Modulation of Tumor- and Chemotherapy-Associated Hypoxia. ACS Nano, 2019, 13, 236-247.	7.3	64
1346	Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions. Biomedicine and Pharmacotherapy, 2019, 109, 39-46.	2.5	47
1347	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 2019, 68, 742-758.	6.1	68
1348	Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2â€•mutant lung cancer. International Journal of Cancer, 2019, 144, 788-801.	2.3	16
1349	Design of a multifunctional biotinylated copper complex for visualization and quantification of cancer hypoxia levels. Sensors and Actuators B: Chemical, 2019, 282, 541-548.	4.0	16
1350	Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IÎºBÎ±. Inflammation Research, 2019, 68, 157-166.	1.6	21
1351	Hypoxiaâ€Activated Prodrugs of PERK Inhibitors. Chemistry - an Asian Journal, 2019, 14, 1238-1248.	1.7	10

#	Article	IF	Citations
1352	An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect. Neoplasia, 2019, 21, 159-171.	2.3	22
1353	Nanostars on Nanopipette Tips: A Raman Probe for Quantifying Oxygen Levels in Hypoxic Single Cells and Tumours. Angewandte Chemie, 2019, 131, 2736-2740.	1.6	6
1354	Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary inÂvitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs). European Journal of Medicinal Chemistry, 2019, 165, 216-224.	2.6	2
1355	Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics, 2019, 51, 308-318.	9.4	480
1356	Antitumor effects of circâ€EPHB4 in hepatocellular carcinoma via inhibition of HIFâ€1Î±. Molecular Carcinogenesis, 2019, 58, 875-886.	1.3	26
1357	A platinum(II)-acetylide-based conjugated polyelectrolyte for hypoxia imaging via ratiometric and time-resolved luminescence microscopy. Journal of Organometallic Chemistry, 2019, 879, 144-149.	0.8	6
1358	Hypoxiaâ€induced tRNAâ€derived fragments, novel regulatory factor for doxorubicin resistance in tripleâ€negative breast cancer. Journal of Cellular Physiology, 2019, 234, 8740-8751.	2.0	65
1359	3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnology and Bioengineering, 2019, 116, 206-226.	1.7	464
1360	Fast and sensitive dynamic oxygenâ€enhanced MRI with a cycling gas challenge and independent component analysis. Magnetic Resonance in Medicine, 2019, 81, 2514-2525.	1.9	8
1361	HIF-1Î±-induced miR-23aâ¼27aâ¼24 cluster promotes colorectal cancer progression via reprogramming metabolism. Cancer Letters, 2019, 440-441, 211-222.	3.2	45
1362	Multifunctional Two-Dimensional Coreâ€“Shell MXene@Gold Nanocomposites for Enhanced Photoâ€“Radio Combined Therapy in the Second Biological Window. ACS Nano, 2019, 13, 284-294.	7.3	232
1363	Functionalized Holmiumâ€Doped Hollow Silica Nanospheres for Combined Sonodynamic and Hypoxiaâ€Activated Therapy. Advanced Functional Materials, 2019, 29, 1805764.	7.8	79
1364	Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433. Chemical Reviews, 2019, 119, 797-828.	23.0	899
1365	Hypoxia-induced autophagy promotes EGFR loss in specific cell contexts, which leads to cell death and enhanced radiosensitivity. International Journal of Biochemistry and Cell Biology, 2019, 111, 12-18.	1.2	12
1366	Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. British Journal of Radiology, 2019, 92, 20180642.	1.0	111
1367	Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bulletin of Mathematical Biology, 2019, 81, 3623-3641.	0.9	19
1368	Design, synthesis and biological evaluation of a novel platinum(II) complex possessing bioreductive groups for cancer therapy. Chinese Chemical Letters, 2019, 30, 243-246.	4.8	4
1369	Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology. Seminars in Cell and Developmental Biology, 2020, 98, 202-210.	2.3	23

#	Article	IF	Citations
1370	Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies. Journal of Biomolecular Structure and Dynamics, 2020, 38, 2156-2170.	2.0	13
1371	Treasure hunt for peptides with undefined chemical modifications: Proteomics identification of differential albumin adducts of 2â€nitroimidazoleâ€indocyanine green in hypoxic tumor. Journal of Mass Spectrometry, 2020, 55, e4376.	0.7	1
1372	Activatable Small-Molecule Hydrogen Sulfide Donors. Antioxidants and Redox Signaling, 2020, 32, 96-109.	2.5	71
1373	Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. Acta Biomaterialia, 2020, 101, 43-68.	4.1	215
1374	Exosomes: New insights into cancer mechanisms. Journal of Cellular Biochemistry, 2020, 121, 7-16.	1.2	41
1375	In vivo three-dimensional evaluation of tumour hypoxia in nasopharyngeal carcinomas using FMT-CT and MSOT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1027-1038.	3.3	17
1376	A novel LncRNA HITT forms a regulatory loop with HIF-1Î± to modulate angiogenesis and tumor growth. Cell Death and Differentiation, 2020, 27, 1431-1446.	5.0	66
1377	Nanomedicineâ€Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy. Advanced Therapeutics, 2020, 3, 1900083.	1.6	21
1378	Cellular Plasticity during Metastasis: New Insights Provided by Intravital Microscopy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037267.	2.9	10
1379	Exploration of nitroimidazoles as radiosensitizers: application of multilayered feature selection approach in QSAR modeling. Structural Chemistry, 2020, 31, 1043-1055.	1.0	7
1380	Hollow Mesoporous Tantalum Oxide Based Nanospheres for Triple Sensitization of Radiotherapy. ACS Applied Materials & Interfaces, 2020, 12, 5520-5530.	4.0	24
1381	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. Seminars in Cancer Biology, 2020, 65, 140-154.	4.3	66
1382	Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer. Frontiers in Oncology, 2019, 9, 1452.	1.3	9
1383	Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation. Biomedicine and Pharmacotherapy, 2020, 122, 109461.	2.5	28
1384	Bacterial particles retard tumor growth as a novel vascular disrupting agent. Biomedicine and Pharmacotherapy, 2020, 122, 109757.	2.5	6
1385	Identification of key HIF-1Î± target genes that regulate adaptation to hypoxic conditions in Tibetan chicken embryos. Gene, 2020, 729, 144321.	1.0	8
1386	Microenvironment-activated nanoparticles for oxygen self-supplemented photodynamic cancer therapy. Biomaterials Science, 2020, 8, 370-378.	2.6	17
1387	Tirapazamine-embedded polyplatinum(<scp>iv</scp>) complex: a prodrug combo for hypoxia-activated synergistic chemotherapy. Biomaterials Science, 2020, 8, 694-701.	2.6	26

#	Article	IF	Citations
1388	Imaging for Response Assessment in Radiation Oncology. Hematology/Oncology Clinics of North America, 2020, 34, 293-306.	0.9	11
1389	Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review. Journal of Controlled Release, 2020, 319, 135-156.	4.8	160
1390	Oxygen-Dependent Regulation of Excited-State Deactivation Process of Rational Photosensitizer for Smart Phototherapy. Journal of the American Chemical Society, 2020, 142, 1510-1517.	6.6	167
1391	Macrophageâ€Mediated Delivery of Hypoxiaâ€Activated Prodrug Nanoparticles. Advanced Therapeutics, 2020, 3, 1900162.	1.6	22
1392	Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics. Biomaterials, 2020, 230, 119635.	5.7	61
1393	Genetically Encoded Activators of Small Molecules for Imaging and Drug Delivery. Angewandte Chemie, 2020, 132, 7741-7749.	1.6	1
1394	Genetically Encoded Activators of Small Molecules for Imaging and Drug Delivery. Angewandte Chemie - International Edition, 2020, 59, 7669-7677.	7.2	6
1395	Anti-LDLR modified TPZ@Ce6-PEG complexes for tumor hypoxia-targeting chemo-/radio-/photodynamic/photothermal therapy. Journal of Materials Chemistry B, 2020, 8, 648-654.	2.9	34
1396	Convergent genomic signatures of high-altitude adaptation among domestic mammals. National Science Review, 2020, 7, 952-963.	4.6	52
1397	Photodynamic Therapy and the Biophysics of the Tumor Microenvironment. Photochemistry and Photobiology, 2020, 96, 232-259.	1.3	55
1398	Cell and Tissue Destruction in Selected Disorders. , 2020, , 249-287.		0
1399	Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy. Journal of Controlled Release, 2020, 319, 25-45.	4.8	80
1400	Dual-amplified strategy for ultrasensitive electrochemical biosensor based on click chemistry-mediated enzyme-assisted target recycling and functionalized fullerene nanoparticles in the detection of microRNA-141. Biosensors and Bioelectronics, 2020, 150, 111964.	5.3	53
1401	¹⁹F Magnetic Resonance Activity-Based Sensing Using Paramagnetic Metals. Accounts of Chemical Research, 2020, 53, 2-10.	7.6	69
1402	Synthesis and evaluation of the HIF-1Î± inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126822.	1.0	9
1403	A lncRNA coordinates with Ezh2 to inhibit HIF-1Î± transcription and suppress cancer cell adaption to hypoxia. Oncogene, 2020, 39, 1860-1874.	2.6	35
1404	Targeting Tumor Microenvironment by Small-Molecule Inhibitors. Translational Oncology, 2020, 13, 57-69.	1.7	82
1405	Small molecules targeting HIF-1Î± pathway for cancer therapy in recent years. Bioorganic and Medicinal Chemistry, 2020, 28, 115235.	1.4	39

#	Article	IF	Citations
1406	MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. Journal of Zhejiang University: Science B, 2020, 21, 12-28.	1.3	31
1407	Recent Advances in Nanomaterialâ€Assisted Combinational Sonodynamic Cancer Therapy. Advanced Materials, 2020, 32, e2003214.	11.1	333
1408	Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1Î± inhibitors with strong antiestrogenic potency. Bioorganic Chemistry, 2020, 104, 104324.	2.0	8
1409	Updates on the applications of iron-based nanoplatforms in tumor theranostics. International Journal of Pharmaceutics, 2020, 589, 119815.	2.6	10
1410	PLCÎ³1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia. Nature Cell Biology, 2020, 22, 1382-1395.	4.6	16
1411	Melatonin and gastrointestinal cancers: Current evidence based on underlying signaling pathways. European Journal of Pharmacology, 2020, 886, 173471.	1.7	24
1412	Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers, 2020, 12, 2774.	1.7	20
1413	Modification of Hypoxic States in Photodynamic Therapy. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2020, 14, 184-193.	0.3	1
1414	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. Npj Breast Cancer, 2020, 6, 54.	2.3	181
1415	Inhibitory effect of glutathione Sâ€transferase A3 in the progression of cutaneous squamous cell carcinoma. Journal of Cosmetic Dermatology, 2021, 20, 2287-2295.	0.8	2
1416	Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. Journal of Experimental and Clinical Cancer Research, 2020, 39, 208.	3.5	79
1417	Activatable Offâ€on Nearâ€Infrared QCy7â€based Fluorogenic Probes for Bioimaging. Chemistry - an Asian Journal, 2020, 15, 3983-3994.	1.7	11
1418	Nanomaterials to relieve tumor hypoxia for enhanced photodynamic therapy. Nano Today, 2020, 35, 100960.	6.2	111
1419	Thionated organic compounds as emerging heavy-atom-free photodynamic therapy agents. Chemical Science, 2020, 11, 11113-11123.	3.7	49
1420	Re-engineering natural products to engage new biological targets. Natural Product Reports, 2020, 37, 1395-1403.	5.2	38
1421	Advanced nanomaterials for hypoxia tumor therapy: challenges and solutions. Nanoscale, 2020, 12, 21497-21518.	2.8	32
1422	Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129723.	1.1	14
1423	Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. International Journal of Pharmaceutics, 2020, 590, 119915.	2.6	43

#	Article	IF	Citations
1424	Conjugated Photosensitizers for Imaging and PDT in Cancer Research. Journal of Medicinal Chemistry, 2020, 63, 14119-14150.	2.9	86
1425	Enzyme production of<scp>d</scp>-gluconic acid and glucose oxidase: successful tales of cascade reactions. Catalysis Science and Technology, 2020, 10, 5740-5771.	2.1	80
1426	Responsive fluorinated nanoemulsions for ¹⁹F magnetic resonance detection of cellular hypoxia. Dalton Transactions, 2020, 49, 16419-16424.	1.6	13
1427	Development of Bioreduction Labile Protecting Groups for the 2â€²-Hydroxyl Group of RNA. Organic Letters, 2020, 22, 6006-6009.	2.4	3
1428	Targeted Myoglobin Delivery as a Strategy for Enhancing the Sensitivity of Hypoxic Cancer Cells to Radiation. IScience, 2020, 23, 101158.	1.9	15
1429	Fabrication of hypoxia-responsive and uperconversion nanoparticles-modified RBC micro-vehicles for oxygen delivery and chemotherapy enhancement. Biomaterials Science, 2020, 8, 4595-4602.	2.6	17
1430	Investigation of cobalt(<scp>iii</scp>)â€“phenylalanine complexes for hypoxia-activated drug delivery. Dalton Transactions, 2020, 49, 16425-16439.	1.6	14
1431	Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer. Cancer Letters, 2020, 492, 116-135.	3.2	67
1432	A Simple Computational Tool for Accurate, Quantitative Prediction of Oneâ€“Electron Reduction Potentials of Hypoxiaâ€“Activated Tirapazamine Analogues. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 231-242.	0.9	1
1433	Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 315-330.	1.8	31
1434	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers, 2020, 12, 3380.	1.7	71
1435	Investigating the influence of relativistic effects on absorption spectra for platinum complexes with light-activated activity against cancer cells. Physical Chemistry Chemical Physics, 2020, 22, 27013-27023.	1.3	6
1436	Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer. International Journal of Molecular Sciences, 2020, 21, 8447.	1.8	0
1437	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. Inorganic Chemistry, 2020, 59, 17794-17810.	1.9	11
1438	Tumor-Microenvironment- Responsive Size-Shrinkable Drug-Delivery Nanosystems for Deepened Penetration Into Tumors. Frontiers in Molecular Biosciences, 2020, 7, 576420.	1.6	25
1439	Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment. Cancer Cell International, 2020, 20, 570.	1.8	19
1440	Beyond energy storage: roles of glycogen metabolism in health and disease. FEBS Journal, 2021, 288, 3772-3783.	2.2	27
1441	Discovery of novel artemisinin-sulfonamide hybrids as potential carbonic anhydrase IX inhibitors with improved antiproliferative activities. Bioorganic Chemistry, 2020, 104, 104347.	2.0	12

#	Article	IF	Citations
1442	Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer . OncoTargets and Therapy, 2020, Volume 13, 12113-12129.	1.0	25
1443	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3574.	1.7	42
1444	In situ tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor. Theranostics, 2020, 10, 11998-12010.	4.6	19
1445	A Nuclear Stress Pathway that Parallels Cytoplasmic Stress Granule Formation. IScience, 2020, 23, 101664.	1.9	3
1446	Photoacoustic and Magnetic Resonance Imaging of Hybrid Manganese Dioxide-Coated Ultra-Small NaGdF4 Nanoparticles for Spatiotemporal Modulation of Hypoxia in Head and Neck Cancer. Cancers, 2020, 12, 3294.	1.7	15
1447	Theranostic Nanomedicine for Synergistic Chemodynamic Therapy and Chemotherapy of Orthotopic Glioma. Advanced Science, 2020, 7, 2003036.	5.6	65
1448	Activatable imaging probes for cancer-linked NAD(P)H:quinone oxidoreductase-1 (NQO1): Advances and future prospects. TrAC - Trends in Analytical Chemistry, 2020, 133, 116112.	5.8	13
1449	Proof-of-principle for two-stage photodynamic therapy: hypoxia triggered release of singlet oxygen. Chemical Communications, 2020, 56, 14793-14796.	2.2	34
1450	Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action. Molecules, 2020, 25, 5167.	1.7	29
1451	Multifunctional fluorescent probes "killing two birds with one stone" - recent progress and outlook. Applied Materials Today, 2020, 21, 100877.	2.3	4
1452	Injectable redox and light responsive MnO2 hybrid hydrogel for simultaneous melanoma therapy and multidrug-resistant bacteria-infected wound healing. Biomaterials, 2020, 260, 120314.	5.7	130
1453	Recent Development in Applications of Synthetic Phenoxazines and Their Related Congeners: A Miniâ€Review. ChemistrySelect, 2020, 5, 8540-8556.	0.7	9
1454	Hypoxia induced exosomal circRNA promotes metastasis of Colorectal Cancer via targeting GEF-H1/RhoA axis. Theranostics, 2020, 10, 8211-8226.	4.6	131
1455	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Frontiers in Cell and Developmental Biology, 2020, 8, 584.	1.8	40
1456	Porphyrinâ€Based Metalâ^'Organic Framework Compounds as Promising Nanomedicines in Photodynamic Therapy. ChemMedChem, 2020, 15, 1766-1775.	1.6	64
1457	Bi-directionally amplified ratiometric electrochemical aptasensor for the ultrasensitive detection of alpha-fetoprotein. Sensors and Actuators B: Chemical, 2020, 323, 128666.	4.0	32
1458	Near-Infrared Light-Initiated Upconversion Nanoplatform with Tumor Microenvironment Responsiveness for Improved Photodynamic Therapy. ACS Applied Bio Materials, 2020, 3, 5813-5823.	2.3	14
1459	Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment. European Journal of Medicinal Chemistry, 2020, 207, 112670.	2.6	45

#	Article	IF	Citations
1460	A new prognostic hypoxia biomarker consisting of imaging and gene-based data. EBioMedicine, 2020, 58, 102901.	2.7	0
1461	Nanosized zeolites as a gas delivery platform in a glioblastoma model. Biomaterials, 2020, 257, 120249.	5.7	14
1462	Molecular Engineering to Boost AIEâ€Active Free Radical Photogenerators and Enable Highâ€Performance Photodynamic Therapy under Hypoxia. Advanced Functional Materials, 2020, 30, 2002057.	7.8	208
1463	Normalizing the Tumor Microenvironment for Radiosensitization. Cancer Drug Discovery and Development, 2020, , 301-338.	0.2	4
1464	Membranous NOX5-derived ROS oxidizes and activates local Src to promote malignancy of tumor cells. Signal Transduction and Targeted Therapy, 2020, 5, 139.	7.1	25
1465	Heterocyclic N-Oxides as Small-Molecule Fluorogenic Scaffolds: Rational Design and Applications of Their â€œOnâ€“Offâ€•Fluorescence. Analytical Chemistry, 2020, 92, 12282-12289.	3.2	11
1466	Self-Delivery Photodynamic Nanoinhibitors for Tumor Targeted Therapy and Metastasis Inhibition. ACS Applied Bio Materials, 2020, 3, 6124-6130.	2.3	10
1467	Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. Cancer Letters, 2020, 492, 63-70.	3.2	60
1468	Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity. Molecules, 2020, 25, 4888.	1.7	4
1469	Nanoplatform-based cascade engineering for cancer therapy. Chemical Society Reviews, 2020, 49, 9057-9094.	18.7	109
1471	Machine learning analysis of DNA methylation in a hypoxia-immune model of oral squamous cell carcinoma. International Immunopharmacology, 2020, 89, 107098.	1.7	7
1472	Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. Molecules, 2020, 25, 3900.	1.7	21
1473	Immunotherapy on acid: opportunities and challenges. European Journal of Clinical Nutrition, 2020, 74, 3-6.	1.3	5
1474	ASC modulates HIF-1Î± stability and induces cell mobility in OSCC. Cell Death and Disease, 2020, 11, 721.	2.7	4
1475	A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients. Journal of Translational Medicine, 2020, 18, 342.	1.8	104
1476	Biomineralized Biohybrid Algae for Tumor Hypoxia Modulation and Cascade Radio-Photodynamic Therapy. ACS Applied Materials & Interfaces, 2020, 12, 44541-44553.	4.0	40
1477	A Smart Nanoparticle-Laden and Remote-Controlled Self-Destructive Macrophage for Enhanced Chemo/Chemodynamic Synergistic Therapy. ACS Nano, 2020, 14, 13894-13904.	7.3	83
1478	Identification of critical radioresistance genes in esophageal squamous cell carcinoma by whole-exome sequencing. Annals of Translational Medicine, 2020, 8, 998-998.	0.7	5

#	Article	IF	Citations
1479	Ultrasmall Ternary FePtMn Nanocrystals with Acidityâ€Triggered Dualâ€Ions Release and Hypoxia Relief for Multimodal Synergistic Chemodynamic/Photodynamic/Photothermal Cancer Therapy. Advanced Healthcare Materials, 2020, 9, e1901634.	3.9	38
1480	A multifunctional oxygen-producing MnO₂-based nanoplatform for tumor microenvironment-activated imaging and combination therapy in vitro. Journal of Materials Chemistry B, 2020, 8, 9943-9950.	2.9	20
1481	A Paclitaxel Prodrug Activatable by Irradiation in a Hypoxic Microenvironment. Angewandte Chemie, 2020, 132, 23398-23405.	1.6	10
1482	Guidelines for cell viability assays. Food Frontiers, 2020, 1, 332-349.	3.7	289
1484	A Paclitaxel Prodrug Activatable by Irradiation in a Hypoxic Microenvironment. Angewandte Chemie - International Edition, 2020, 59, 23198-23205.	7.2	94
1485	Nanoparticle Delivery of MnO₂ and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma. ACS Applied Materials & Interfaces, 2020, 12, 44407-44419.	4.0	72
1486	Nucleic Acid-Based Approaches for Tumor Therapy. Cells, 2020, 9, 2061.	1.8	40
1487	Hypoxia-Responsive, Polymeric Nanocarriers for Targeted Drug Delivery to Estrogen Receptor-Positive Breast Cancer Cell Spheroids. Molecular Pharmaceutics, 2020, 17, 4312-4322.	2.3	32
1488	Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis. Cell Communication and Signaling, 2020, 18, 120.	2.7	64
1489	CircHIPK3 Promotes Metastasis of Gastric Cancer via miR-653-5p/miR-338-3p-NRP1 Axis Under a Long-Term Hypoxic Microenvironment. Frontiers in Oncology, 2020, 10, 1612.	1.3	28
1491	Near-Infrared Upconversion Mesoporous Tin Oxide Bio-Photocatalyst for H₂O₂-Activatable O₂-Generating Magnetic Targeting Synergetic Treatment. ACS Applied Materials & Interfaces, 2020, 12, 41047-41061.	4.0	26
1492	2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche. Communications Biology, 2020, 3, 450.	2.0	24
1493	Bad neighbours: hypoxia and genomic instability in prostate cancer. British Journal of Radiology, 2020, 93, 20200087.	1.0	23
1494	Caveolin-1-Mediated Tumor Suppression Is Linked to Reduced HIF1Î± S-Nitrosylation and Transcriptional Activity in Hypoxia. Cancers, 2020, 12, 2349.	1.7	11
1495	Recent Research on Methods to Improve Tumor Hypoxia Environment. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-18.	1.9	11
1496	Long Noncoding RNA MIR210HG Promotes the Warburg Effect and Tumor Growth by Enhancing HIF-1Î± Translation in Triple-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 580176.	1.3	39
1497	Expression analysis based diagnostic potential of hypoxia-responsive genes in gastric tumorigenesis. Gene Reports, 2020, 21, 100936.	0.4	0
1498	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. Cancers, 2020, 12, 3743.	1.7	19

#	Article	IF	Citations
1499	Extracellular Vesicles Are Key Regulators of Tumor Neovasculature. Frontiers in Cell and Developmental Biology, 2020, 8, 611039.	1.8	37
1500	Biophysical and Epigenetic Regulation of Cancer Stemness, Invasiveness, and Immune Action. Current Tissue Microenvironment Reports, 2020, 1, 277-300.	1.3	7
1501	Facile Preparation of Macromolecular Prodrugs for Hypoxia-Specific Chemotherapy. ACS Macro Letters, 2020, 9, 1687-1692.	2.3	9
1502	Electron-Accepting Micelles Deplete Reduced Nicotinamide Adenine Dinucleotide Phosphate and Impair Two Antioxidant Cascades for Ferroptosis-Induced Tumor Eradication. ACS Nano, 2020, 14, 14715-14730.	7.3	118
1503	Engineering microrobots for targeted cancer therapies from a medical perspective. Nature Communications, 2020, 11, 5618.	5.8	220
1504	Microbial nitroreductases: A versatile tool for biomedical and environmental applications. Biotechnology and Applied Biochemistry, 2020, , .	1.4	12
1505	Tumor Microenvironment-Responsive and Catalytic Cascade-Enhanced Nanocomposite for Tumor Thermal Ablation Synergizing with Chemodynamic and Chemotherapy. ACS Applied Bio Materials, 2020, 3, 3880-3893.	2.3	15
1506	High-throughput screening in multicellular spheroids for target discovery in the tumor microenvironment. Expert Opinion on Drug Discovery, 2020, 15, 955-967.	2.5	11
1507	Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer. Frontiers in Oncology, 2020, 10, 530.	1.3	17
1508	Transition metal complexes as photosensitizers for integrated cancer theranostic applications. Coordination Chemistry Reviews, 2020, 418, 213355.	9.5	91
1509	Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer. Journal of Controlled Release, 2020, 324, 482-492.	4.8	16
1510	Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy. Nano Letters, 2020, 20, 4857-4863.	4.5	42
1511	The dormant cancer cell life cycle. Nature Reviews Cancer, 2020, 20, 398-411.	12.8	286
1512	Photoactivated polyprodrug nanoparticles for effective light-controlled Pt(<scp>iv</scp>) and siRNA codelivery to achieve synergistic cancer therapy. Journal of Materials Chemistry B, 2020, 8, 5903-5911.	2.9	20
1513	A ratiometric fluorescent biosensor based on conjugated polymers for sensitive detection of nitroreductase and hypoxia diagnosis in tumor cells. Sensors and Actuators B: Chemical, 2020, 318, 128257.	4.0	30
1514	Estimation of the oxygen enhancement ratio for charged particle radiation. Physics in Medicine and Biology, 2020, 65, 15NT01.	1.6	8
1515	Role of hyperoxic treatment in cancer. Experimental Biology and Medicine, 2020, 245, 851-860.	1.1	12
1516	A General Hypoxiaâ€Responsive Molecular Container for Tumorâ€Targeted Therapy. Advanced Materials, 2020, 32, e1908435.	11.1	81

#	Article	IF	Citations
1517	A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs. Bioorganic Chemistry, 2020, 101, 103975.	2.0	5
1518	Microenvironment-sensitive iridium(<scp>iii</scp>) complexes for disease theranostics. Dalton Transactions, 2020, 49, 9182-9190.	1.6	9
1519	Platinum-carbon-integrated nanozymes for enhanced tumor photodynamic and photothermal therapy. Nanoscale, 2020, 12, 13548-13557.	2.8	104
1520	In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery. PLoS Computational Biology, 2020, 16, e1007926.	1.5	12
1521	Hypoxia PET Imaging with [18F]-HX4â€"A Promising Next-Generation Tracer. Cancers, 2020, 12, 1322.	1.7	35
1522	Engineering magnetosomes with chimeric membrane and hyaluronidase for efficient delivery of HIF-1 siRNA into deep hypoxic tumors. Chemical Engineering Journal, 2020, 398, 125453.	6.6	20
1523	Co-Culturing of Endothelial and Cancer Cells in a Nanofibrous Scaffold-Based Two-Layer System. International Journal of Molecular Sciences, 2020, 21, 4128.	1.8	7
1524	Silencing of HIF-1Î±/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. European Journal of Pharmacology, 2020, 882, 173235.	1.7	48
1525	Exosomes: A Potential Therapeutic Tool Targeting Communications between Tumor Cells and Macrophages. Molecular Therapy, 2020, 28, 1953-1964.	3.7	40
1526	Hypoxia imaging in living cells, tissues and zebrafish with a nitroreductase-specific fluorescent probe. Analyst, The, 2020, 145, 5657-5663.	1.7	17
1527	The prognostic implication of pre-treatment hemoglobin levels in esophageal cancer patients: A systematic review and meta-analysis. Meta Gene, 2020, 25, 100734.	0.3	0
1528	Delayed Fluorescence, Room Temperature Phosphorescence, and Mechanofluorochromic Naphthalimides: Differential Imaging of Normoxia and Hypoxia Live Cancer Cells. Journal of Physical Chemistry B, 2020, 124, 5393-5406.	1.2	23
1529	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. British Journal of Cancer, 2020, 123, 644-656.	2.9	29
1530	CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydraseâ€...IX for the Treatment of Hypoxic Tumors. Angewandte Chemie - International Edition, 2020, 59, 18556-18562.	7.2	94
1531	Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development. Handbook of Experimental Pharmacology, 2020, 265, 269-301.	0.9	2
1532	CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydraseâ€...IX for the Treatment of Hypoxic Tumors. Angewandte Chemie, 2020, 132, 18715-18721.	1.6	16
1533	Antiâ€tumour effects of <scp>PIM</scp> kinase inhibition on progression and chemoresistance of hepatocellular carcinoma. Journal of Pathology, 2020, 252, 65-76.	2.1	9
1534	The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate. Scientific Reports, 2020, 10, 9926.	1.6	7

#	Article	IF	Citations
1535	Investigating the Physical Effects in Bacterial Therapies for Avascular Tumors. Frontiers in Microbiology, 2020, 11, 1083.	1.5	0
1536	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm, 2020, 1, 47-68.	3.1	93
1537	Identification of long noncoding RNAs involved in adaptability to chronic hypoxic by whole transcriptome sequencing. 3 Biotech, 2020, 10, 269.	1.1	2
1538	Withaferin A suppresses breast cancer cell proliferation by inhibition of the two-pore domain potassium (K2P9) channel TASK-3. Biomedicine and Pharmacotherapy, 2020, 129, 110383.	2.5	21
1539	Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. Seminars in Nuclear Medicine, 2020, 50, 562-583.	2.5	40
1541	Hypoxia-Responsive Polypeptide Nanoparticles Loaded with Doxorubicin for Breast Cancer Therapy. ACS Biomaterials Science and Engineering, 2020, 6, 2167-2174.	2.6	38
1542	Microfluidic platform for three-dimensional cell culture under spatiotemporal heterogeneity of oxygen tension. APL Bioengineering, 2020, 4, 016106.	3.3	34
1543	Combined Snail and E-cadherin Predicts Overall Survival of Cervical Carcinoma Patients: Comparison Among Various Epithelial-Mesenchymal Transition Proteins. Frontiers in Molecular Biosciences, 2020, 7, 22.	1.6	22
1544	Stepwise-activatable hypoxia triggered nanocarrier-based photodynamic therapy for effective synergistic bioreductive chemotherapy. Biomaterials, 2020, 245, 119982.	5.7	44
1545	Non-coding RNAs: Key regulators of aerobic glycolysis in breast cancer. Life Sciences, 2020, 250, 117579.	2.0	24
1546	Muscleblind-like 2 controls the hypoxia response of cancer cells. Rna, 2020, 26, 648-663.	1.6	19
1547	Reversible redox-responsive ¹H/¹⁹F MRI molecular probes. Chemical Communications, 2020, 56, 4106-4109.	2.2	30
1548	In Vivo Imaging of Hypoxia Associated with Inflammatory Bowel Disease by a Cytoplasmic Protein-Powered Fluorescence Cascade Amplifier. Analytical Chemistry, 2020, 92, 5787-5794.	3.2	26
1549	Biodegradable MnFe-hydroxide nanocapsules to enable multi-therapeutics delivery and hypoxia-modulated tumor treatment. Journal of Materials Chemistry B, 2020, 8, 3929-3938.	2.9	10
1550	Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. Journal of Natural Products, 2020, 83, 937-954.	1.5	15
1551	Application of nanotechnology for enhancing photodynamic therapy via ameliorating, neglecting, or exploiting tumor hypoxia. View, 2020, 1, e6.	2.7	51
1552	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. Bioorganic Chemistry, 2020, 99, 103778.	2.0	11
1553	Fusiform-Like Copper(II)-Based Metalâ€“Organic Framework through Relief Hypoxia and GSH-Depletion Co-Enhanced Starvation and Chemodynamic Synergetic Cancer Therapy. ACS Applied Materials & Interfaces, 2020, 12, 17254-17267.	4.0	156

#	Article	IF	Citations
1554	Role of tumor microenvironment in the regulation of PDâ€L1: A novel role in resistance to cancer immunotherapy. Journal of Cellular Physiology, 2020, 235, 6496-6506.	2.0	19
1555	Investigation of the effects of the proton transfer salts of 2-aminopyridine derivatives with 5-sulfosalicylic acid and their Cu(II) complexes on cancer-related carbonic anhydrases: CA IX and CA XII. Chemical Papers, 2020, 74, 2365-2374.	1.0	7
1556	Fluorinated-functionalized hyaluronic acid nanoparticles for enhanced photodynamic therapy of ocular choroidal melanoma by ameliorating hypoxia. Carbohydrate Polymers, 2020, 237, 116119.	5.1	47
1557	Chemo-sensitizing agents from natural origin for colorectal cancer: Pharmacodynamic and cellular pharmacokinetics approaches. , 2020, , 93-116.		2
1558	Hypoxia-responsive nanoparticles for tumor-targeted drug delivery. Cancer Letters, 2020, 490, 31-43.	3.2	52
1559	Phospholipid membrane-decorated deep-penetrated nanocatalase relieve tumor hypoxia to enhance chemo-photodynamic therapy. Acta Pharmaceutica Sinica B, 2020, 10, 2246-2257.	5.7	30
1560	Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy, 2020, 5, 113.	7.1	299
1561	Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities. Cancers, 2020, 12, 1731.	1.7	37
1562	Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas. Journal of Experimental and Clinical Cancer Research, 2020, 39, 129.	3.5	27
1563	Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition. RSC Medicinal Chemistry, 2020, 11, 923-939.	1.7	17
1564	Recent progress in the design principles, sensing mechanisms, and applications of small-molecule probes for nitroreductases. Coordination Chemistry Reviews, 2020, 421, 213460.	9.5	51
1565	A lineage-tracing tool to map the fate of hypoxic tumour cells. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	4
1566	Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study. ACS Medicinal Chemistry Letters, 2020, 11, 1484-1489.	1.3	2
1567	Macrophage HIF-1Î± Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	3.2	45
1568	A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 484-490.	0.6	141
1569	Graphdiyne-templated palladium-nanoparticle assembly as a robust oxygen generator to attenuate tumor hypoxia. Nano Today, 2020, 34, 100907.	6.2	75
1570	Multifunctional Hypoxia-Involved Gene Silencing Nanoplatform for Sensitizing Photochemotherapy. ACS Applied Materials & Interfaces, 2020, 12, 34588-34598.	4.0	20
1571	Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction. Cancer Research, 2020, 80, 3492-3506.	0.4	8

#	Article	IF	Citations
1572	Radiosynthesis and evaluation of novel [99m Tc(I)] + and [99m Tc(I)(CO) 3] + complexes with a 4â€²nitroimidazole isocyanide for imaging tumor hypoxia. Applied Organometallic Chemistry, 2020, 34, e5798.	1.7	8
1573	Triethylphosphinegold(I) Complexes with Secnidazole-Derived Thiosemicarbazones: Cytotoxic Activity against HCT-116 Colorectal Cancer Cells under Hypoxia Conditions. ACS Omega, 2020, 5, 2939-2946.	1.6	12
1574	Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma . International Journal of Nanomedicine, 2020, Volume 15, 347-361.	3.3	21
1575	Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissueâ€based research. Journal of Pathology, 2020, 250, 593-611.	2.1	23
1576	Reprogramming Tumor Associated Macrophages toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy. Advanced Therapeutics, 2020, 3, 1900181.	1.6	31
1577	Advanced Nearâ€Infrared Light for Monitoring and Modulating the Spatiotemporal Dynamics of Cell Functions in Living Systems. Advanced Science, 2020, 7, 1903783.	5.6	79
1578	Hyaluronic Acid-Modified Fluorescent Probe for Dual Color Imaging of Living Cell. ACS Applied Bio Materials, 2020, 3, 1893-1901.	2.3	1
1579	Molecular, Macromolecular, and Supramolecular Glucuronide Prodrugs: Lead Identified for Anticancer Prodrug Monotherapy. Angewandte Chemie, 2020, 132, 7460-7466.	1.6	2
1580	Hypoxia and the hypoxia inducible factor 1Î± activate protein kinase A by repressing RII beta subunit transcription. Oncogene, 2020, 39, 3367-3380.	2.6	28
1581	Fluorescence resonance energy transfer-based drug delivery systems for enhanced photodynamic therapy. Journal of Materials Chemistry B, 2020, 8, 3772-3788.	2.9	41
1582	Organic/inorganic nanohybrids rejuvenate photodynamic cancer therapy. Journal of Materials Chemistry B, 2020, 8, 4748-4763.	2.9	39
1583	Macrocycle-Based Polymer Nanocapsules for Hypoxia-Responsive Payload Delivery. , 2020, 2, 266-271.		24
1584	Ternary Co(II), Ni(II) and Cu(II) complexes containing dipyridophenazine and saccharin: Structures, reactivity, binding interactions with biomolecules and DNA damage activity. Inorganica Chimica Acta, 2020, 506, 119532.	1.2	16
1585	Molecular, Macromolecular, and Supramolecular Glucuronide Prodrugs: Lead Identified for Anticancer Prodrug Monotherapy. Angewandte Chemie - International Edition, 2020, 59, 7390-7396.	7.2	29
1586	Luminescent ruthenium(II)-containing metallopolymers with different ligands: synthesis and application as oxygen nanosensor for hypoxia imaging. Analytical and Bioanalytical Chemistry, 2020, 412, 2579-2587.	1.9	5
1587	Downâ€regulation of FOXR2 inhibits hypoxiaâ€driven ROSâ€induced migration and invasion of thyroid cancer cells via regulation of the hedgehog pathway. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1076-1082.	0.9	9
1588	Optimizing Energy Transfer in Nanostructures Enables In Vivo Cancer Lesion Tracking via Nearâ€Infrared Excited Hypoxia Imaging. Advanced Materials, 2020, 32, e1907718.	11.1	38
1589	Increased autophagy/mitophagy levels in primary tumours of patients with pancreatic neuroendocrine neoplasms. Endocrine, 2020, 68, 438-447.	1.1	11

#	Article	IF	Citations
1590	In Situ Photocatalysis of TiOâ€“Porphyrin-Encapsulated Nanosystem for Highly Efficient Oxidative Damage against Hypoxic Tumors. ACS Applied Materials & Interfaces, 2020, 12, 12573-12583.	4.0	21
1591	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	0.8	1
1592	Dynamic surveillance of tamoxifenâ€resistance in ERâ€positive breast cancer by CAIXâ€targeted ultrasound imaging. Cancer Medicine, 2020, 9, 2414-2426.	1.3	8
1593	Study on Drug Resistance to Tumor Cell in Oxygen Gradient and Co-culture Microfluidic Chip. Chinese Journal of Analytical Chemistry, 2020, 48, 180-186.	0.9	6
1594	Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines. Biomedicine and Pharmacotherapy, 2020, 125, 109988.	2.5	11
1595	Tumor-targeted nanoplatform for in situ oxygenation-boosted immunogenic phototherapy of colorectal cancer. Acta Biomaterialia, 2020, 104, 188-197.	4.1	46
1596	Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development. Acta Pharmaceutica Sinica B, 2020, 10, 1382-1396.	5.7	161
1597	Enzyme-Assisted Photodynamic Therapy Based on Nanomaterials. ACS Biomaterials Science and Engineering, 2020, 6, 2506-2517.	2.6	25
1598	Albumin-stabilized manganese-based nanocomposites with sensitive tumor microenvironment responsivity and their application for efficient SiRNA delivery in brain tumors. Journal of Materials Chemistry B, 2020, 8, 1507-1515.	2.9	23
1599	Drugging histone methyltransferases in cancer. Current Opinion in Chemical Biology, 2020, 56, 51-62.	2.8	40
1600	Less is more: Silver-AIE core@shell nanoparticles for multimodality cancer imaging and synergistic therapy. Biomaterials, 2020, 238, 119834.	5.7	48
1601	Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI. European Radiology, 2020, 30, 2171-2181.	2.3	7
1602	Size-Switchable Nanoparticles with Self-Destructive and Tumor Penetration Characteristics for Site-Specific Phototherapy of Cancer. ACS Applied Materials & Interfaces, 2020, 12, 6933-6943.	4.0	42
1603	Stress-induced lncRNA LASTR fosters cancer cell fitness by regulating the activity of the U4/U6 recycling factor SART3. Nucleic Acids Research, 2020, 48, 2502-2517.	6.5	38
1604	A fluorescent naphthalimide NADH mimic for continuous and reversible sensing of cellular redox state. Chemical Communications, 2020, 56, 2240-2243.	2.2	14
1605	Hypoxia induced changes in miRNAs and their target mRNAs in extracellular vesicles of esophageal squamous cancer cells. Thoracic Cancer, 2020, 11, 570-580.	0.8	31
1606	miRNAs as radioâ€response biomarkers for breast cancer stem cells. Molecular Oncology, 2020, 14, 556-570.	2.1	31
1607	Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 298-313.	8.2	151

#	Article	IF	Citations
1608	More bullets for PISTOL: linear and cyclic siloxane reporter probes for quantitative 1H MR oximetry. Scientific Reports, 2020, 10, 1399.	1.6	3
1609	A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs. Molecular Pharmaceutics, 2020, 17, 2072-2082.	2.3	2
1610	Minimum dose rate estimation for pulsed FLASH radiotherapy: A dimensional analysis. Medical Physics, 2020, 47, 3243-3249.	1.6	25
1611	Emerging links between endosomal pH and cancer. Cancer and Metastasis Reviews, 2020, 39, 519-534.	2.7	49
1612	Macrophage M1/M2 polarization. European Journal of Pharmacology, 2020, 877, 173090.	1.7	883
1613	Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance. Journal of Controlled Release, 2020, 322, 64-80.	4.8	37
1614	Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1Î± and STAT3 (T705) signaling pathways in hepatic cancer. Journal of Ethnopharmacology, 2020, 257, 112835.	2.0	50
1615	Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1Î± and Beyond. Frontiers in Oncology, 2020, 10, 486.	1.3	171
1616	DUB-independent regulation of pVHL by OTUD6B suppresses hepatocellular carcinoma. Protein and Cell, 2020, 11, 546-548.	4.8	4
1617	Folate pathways mediating the effects of ethanol in tumorigenesis. Chemico-Biological Interactions, 2020, 324, 109091.	1.7	8
1618	Tumor microenvironment-induced structure changing drug/gene delivery system for overcoming delivery-associated challenges. Journal of Controlled Release, 2020, 323, 203-224.	4.8	55
1619	Biomimetic nanoscale metalâ€“organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy. Chemical Science, 2020, 11, 7641-7653.	3.7	78
1620	The clinical utility of imaging methods used to measure hypoxia in cervical cancer. British Journal of Radiology, 2020, 93, 20190640.	1.0	9
1621	Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel. Biochemical and Biophysical Research Communications, 2020, 526, 321-327.	1.0	12
1622	Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia. Haematologica, 2021, 106, 1343-1353.	1.7	12
1623	Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1-14.	2.0	33
1624	Advances in nanomaterials for treatment of hypoxic tumor. National Science Review, 2021, 8, nwaa160.	4.6	58
1625	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 554-560.	3.3	10

#	Article	IF	Citations
1626	NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer. Molecular and Cellular Biology, 2021, 41, .	1.1	21
1627	Enhancement of tumor lethality of ROS in photodynamic therapy. Cancer Medicine, 2021, 10, 257-268.	1.3	70
1628	Oneâ€•and Twoâ€Photon Phototherapeutic Effects of Ru^{II} Polypyridine Complexes in the Hypoxic Centre of Large Multicellular Tumor Spheroids and Tumorâ€Bearing Mice**. Chemistry - A European Journal, 2021, 27, 362-370.	1.7	37
1629	Recent Progress in the Development of Multifunctional Nanoplatform for Precise Tumor Phototherapy. Advanced Healthcare Materials, 2021, 10, e2001207.	3.9	53
1630	A Dinuclear Persulfideâ€Bridged Ruthenium Compound is a Hypoxiaâ€Selective Hydrogen Sulfide (H₂S) Donor. Angewandte Chemie - International Edition, 2021, 60, 1588-1592.	7.2	15
1631	PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling. Annual Review of Pharmacology and Toxicology, 2021, 61, 723-743.	4.2	16
1632	A multifunctional nano system based on DNA and CeO2 for intracellular imaging of miRNA and enhancing photodynamic therapy. Talanta, 2021, 221, 121554.	2.9	7
1633	Two-channel responsive luminescent chemosensors for dioxygen species: Molecular oxygen, singlet oxygen and superoxide anion. Coordination Chemistry Reviews, 2021, 427, 213575.	9.5	36
1634	Tumor Microenvironment Sensitive Nanocarriers for Bioimaging and Therapeutics. Advanced Healthcare Materials, 2021, 10, e2000834.	3.9	40
1635	Hypoxia-degradable zwitterionic phosphorylcholine drug nanogel for enhanced drug delivery to glioblastoma. Chemical Engineering Journal, 2021, 408, 127359.	6.6	28
1636	Silica-supported dual-dye nanoprobes for ratiometric hypoxia sensing. Materials Chemistry Frontiers, 2021, 5, 458-464.	3.2	5
1637	Self-Calibrating Bipartite Fluorescent Sensor for Nitroreductase Activity and Its Application to Cancer and Hypoxic Cells. ACS Applied Bio Materials, 2021, 4, 2052-2057.	2.3	16
1638	Associations of self-reported obstructive sleep apnea with total and site-specific cancer risk in older women: a prospective study. Sleep, 2021, 44, .	0.6	17
1639	Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells. Chemico-Biological Interactions, 2021, 333, 109326.	1.7	15
1640	Oxygen self-sufficient photodynamic therapy. Coordination Chemistry Reviews, 2021, 432, 213714.	9.5	66
1641	A novel long-wavelength off-on fluorescence probe for nitroreductase analysis and hypoxia imaging. Analytica Chimica Acta, 2021, 1144, 76-84.	2.6	15
1642	Hypoxia increases the apoptotic response to betulinic acid and betulin in human non-small cell lung cancer cells. Chemico-Biological Interactions, 2021, 333, 109320.	1.7	14
1643	Platinum(IV) antitumor complexes and their nano-drug delivery. Coordination Chemistry Reviews, 2021, 429, 213640.	9.5	71

#	Article	IF	Citations
1644	Oncostatin M: A mysterious cytokine in cancers. International Immunopharmacology, 2021, 90, 107158.	1.7	35
1645	Interplay of long non-coding RNAs and HIF-1Î±: A new dimension to understanding hypoxia-regulated tumor growth and metastasis. Cancer Letters, 2021, 499, 49-59.	3.2	32
1646	Strategies to expand peptide functionality through hybridisation with a small molecule component. RSC Chemical Biology, 2021, 2, 151-165.	2.0	10
1647	Role of Regular Physical Exercise in Tumor Vasculature: Favorable Modulator of Tumor Milieu. International Journal of Sports Medicine, 2021, 42, 389-406.	0.8	9
1648	Regulating Tumor N⁶â€Methyladenosine Methylation Landscape using Hypoxiaâ€Modulating Os_x Nanoparticles. Small, 2021, 17, e2005086.	5.2	16
1649	Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans. Clinical Cancer Research, 2021, 27, 1641-1649.	3.2	21
1650	A Study on Hypoxia Susceptibility of Organ Tissues by Fluorescence Imaging with a Ratiometric Nitroreductase Probe. ACS Sensors, 2021, 6, 148-155.	4.0	47
1651	Polyoxometalateâ€Based Nanomaterials Toward Efficient Cancer Diagnosis and Therapy. Chemistry - A European Journal, 2021, 27, 6422-6434.	1.7	22
1652	Light-controlled oxygen production and collection for sustainable photodynamic therapy in tumor hypoxia. Biomaterials, 2021, 269, 120621.	5.7	68
1653	A Dinuclear Persulfideâ€Bridged Ruthenium Compound is a Hypoxiaâ€Selective Hydrogen Sulfide (H 2 S) Donor. Angewandte Chemie, 2021, 133, 1612-1616.	1.6	0
1654	Molecular engineering to accelerate cancer cell discrimination and boost AIE-active type I photosensitizer for photodynamic therapy under hypoxia. Chemical Engineering Journal, 2021, 410, 128133.	6.6	62
1655	Recent achievements of bioluminescence imaging based on firefly luciferin-luciferase system. European Journal of Medicinal Chemistry, 2021, 211, 113111.	2.6	33
1657	Roles of Ion Fluxes, Metabolism, and Redox Balance in Cancer Therapy. Antioxidants and Redox Signaling, 2021, 34, 1108-1127.	2.5	4
1658	Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics, 2021, 11, 665-683.	4.6	89
1659	Affinityâ€switchable biotin probes for the analysis of enzymes and small reactive molecules on microarray platform. Journal of the Chinese Chemical Society, 2021, 68, 291-297.	0.8	2
1660	Nanotoxicology profiling of cancer nanomedicines. , 2021, , 291-301.		1
1661	Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. Journal of Experimental and Clinical Cancer Research, 2021, 40, 28.	3.5	72
1662	Boosting cancer therapy efficiency via photoinduced radical production. Chemical Science, 2021, 12, 9500-9505.	3.7	8

#	Article	IF	Citations
1663	PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX. International Journal of Molecular Sciences, 2021, 22, 1120.	1.8	8
1664	The design of cyclometalated iridium(<scp>iii</scp>)â€“metformin complexes for hypoxic cancer treatment. Chemical Communications, 2021, 57, 1093-1096.	2.2	11
1665	Melatonin and hyperbaric oxygen therapies suppress colorectal carcinogenesis through pleiotropic effects and multifaceted mechanisms. International Journal of Biological Sciences, 2021, 17, 3728-3744.	2.6	13
1666	Revealing the Potential Application of EC-Synthetic Retinoid Analogues in Anticancer Therapy. Molecules, 2021, 26, 506.	1.7	11
1667	Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity. OncoImmunology, 2021, 10, 1950953.	2.1	39
1668	Effect of hypoxia on proliferation and glucocorticoid resistance of T-cell acute lymphoblastic leukaemia. Hematology, 2021, 26, 775-784.	0.7	0
1669	Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner. Clinical Epigenetics, 2021, 13, 18.	1.8	38
1670	Synthesis and evaluation of gallium-68-labeled nitroimidazole-based imaging probes for PET diagnosis of tumor hypoxia. Annals of Nuclear Medicine, 2021, 35, 360-369.	1.2	3
1671	Regulatory perspectives of nanomedicines for cancer treatment. , 2021, , 29-49.		0
1672	Time-resolved analysis of photoluminescence at a single wavelength for ratiometric and multiplex biosensing and bioimaging. Chemical Science, 2021, 12, 11020-11027.	3.7	15
1673	Recent advances in peptide-based nanomaterials for targeting hypoxia. Nanoscale Advances, 2021, 3, 6027-6039.	2.2	6
1674	Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors. EJNMMI Research, 2021, 11, 9.	1.1	4
1675	Therapeutic strategies. , 2021, , 139-154.		0
1676	Stimuli-responsive transmembrane anion transport by AIE-active fluorescent probes. Organic and Biomolecular Chemistry, 2021, 19, 7446-7459.	1.5	8
1677	Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth. Cancer Research, 2021, 81, 1252-1264.	0.4	44
1678	Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy. Theranostics, 2021, 11, 3580-3594.	4.6	33
1679	The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell International, 2021, 21, 62.	1.8	296
1680	Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma. Theranostics, 2021, 11, 5313-5329.	4.6	11

#	Article	IF	Citations
1681	A light-controlled multi-step drug release nanosystem targeting tumor hypoxia for synergistic cancer therapy. Chemical Science, 2021, 12, 11810-11820.	3.7	12
1682	Organometallic Chemistry of Drugs Based on Iron. , 2021, , .		0
1683	Progress of exosomes in the diagnosis and treatment of lung cancer. Biomedicine and Pharmacotherapy, 2021, 134, 111111.	2.5	89
1684	p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 831.	1.7	16
1685	Bacteriaâ€Based Cancer Immunotherapy. Advanced Science, 2021, 8, 2003572.	5.6	115
1686	Recent Development on Controlled Synthesis of Mnâ€Based Nanostructures for Bioimaging and Cancer Therapy. Advanced Therapeutics, 2021, 4, 2100018.	1.6	15
1687	Azo-Based Hypoxia-Responsive Self-Assembly Near-Infrared Fluorescent Nanoprobe for In Vivo Real-Time Bioimaging of Tumors. ACS Applied Bio Materials, 2021, 4, 2752-2758.	2.3	4
1688	Non-canonical roles of canonical telomere binding proteins in cancers. Cellular and Molecular Life Sciences, 2021, 78, 4235-4257.	2.4	21
1689	Tumor Microenvironment Triggered Cascadeâ€Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Advanced Healthcare Materials, 2021, 10, e2002036.	3.9	14
1690	Therapeutic Strategies Against Cancer Stem Cells in Esophageal Carcinomas. Frontiers in Oncology, 2020, 10, 598957.	1.3	9
1691	Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Frontiers in Oncology, 2020, 10, 612802.	1.3	31
1692	Cancerâ€associatedâ€plateletâ€inspired nanomedicines for cancer therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1702.	3.3	20
1693	Preparation and Bioevaluation of Novel 99mTc-Labeled Complexes with a 2-Nitroimidazole HYNIC Derivative for Imaging Tumor Hypoxia. Pharmaceuticals, 2021, 14, 158.	1.7	5
1694	BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells. Immunology Letters, 2021, 230, 27-35.	1.1	7
1695	mTOR Pathway Activation Assessed by Immunohistochemistry in Cervical Biopsies of HPV-associated Endocervical Adenocarcinomas (HPVA): Correlation With Silva Invasion Patterns. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 527-533.	0.6	2
1696	High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer, 2021, 21, 302.	1.1	11
1697	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 2021, 39, 1072-1080.	1.2	4
1698	Enamine N-Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents. ACS Central Science, 2021, 7, 631-640.	5.3	24

#	Article	IF	Citations
1699	Biomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy. Advanced Science, 2021, 8, 2003679.	5.6	87
1700	Synthesis of Mitochondria-Anchored Nitroimidazoles with a Versatile NIR Fluorophore for Hypoxic Tumor-Targeting Imaging and Chemoradiotherapy. Journal of Medicinal Chemistry, 2021, 64, 3381-3391.	2.9	15
1701	Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cellular and Molecular Immunology, 2021, 18, 1085-1095.	4.8	74
1702	HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-9.	1.9	6
1703	Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer, 2021, 24, 823-834.	2.7	24
1704	Resistance of Hypoxic Cells to Ionizing Radiation Is Mediated in Part via Hypoxia-Induced Quiescence. Cells, 2021, 10, 610.	1.8	19
1705	Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. Biomedicines, 2021, 9, 290.	1.4	24
1706	An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs. ACS Sensors, 2021, 6, 823-832.	4.0	28
1707	Applications of Biomaterials in 3D Cell Culture and Contributions of 3D Cell Culture to Drug Development and Basic Biomedical Research. International Journal of Molecular Sciences, 2021, 22, 2491.	1.8	58
1708	Immune Checkpoint Inhibitorâ€Based Strategies for Synergistic Cancer Therapy. Advanced Healthcare Materials, 2021, 10, e2002104.	3.9	47
1709	Two-Photon Fluorescent Probes for Detecting Enzyme Activities in Live Tissues. ACS Applied Bio Materials, 2021, 4, 2957-2973.	2.3	17
1710	Cardiotoxicity of antiangiogenic drugs: causes and mechanisms. OnCOReview, 2021, 11, 12-18.	0.1	1
1711	Hypoxia in Breast Cancerâ€"Scientific Translation to Therapeutic and Diagnostic Clinical Applications. Frontiers in Oncology, 2021, 11, 652266.	1.3	35
1712	NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer. Journal of Nanobiotechnology, 2021, 19, 64.	4.2	46
1713	Targeted Regulation of Bloodâ€"Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma. ACS Applied Materials & Interfaces, 2021, 13, 11657-11671.	4.0	34
1714	Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. Cells, 2021, 10, 678.	1.8	53
1716	Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. Translational Oncology, 2021, 14, 101017.	1.7	35
1717	Hypoxia Transcriptomic Modifications Induced by Proton Irradiation in U87 Glioblastoma Multiforme Cell Line. Journal of Personalized Medicine, 2021, 11, 308.	1.1	10

#	Article	IF	Citations
1718	The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Medical Oncology, 2021, 38, 60.	1.2	26
1719	Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations. Cancers, 2021, 13, 1804.	1.7	5
1720	Hypoxia/Temperature/pH Triple Stimuliâ€“Responsive Block Copolymers: Synthesis, Selfâ€Assembly, and Controlled Drug Release. Macromolecular Materials and Engineering, 2021, 306, 2100073.	1.7	5
1721	Metal-organic frameworks for therapeutic gas delivery. Advanced Drug Delivery Reviews, 2021, 171, 199-214.	6.6	55
1722	Nanozyme-Powered Giant Unilamellar Vesicles for Mimicry and Modulation of Intracellular Oxidative Stress. ACS Applied Materials & Interfaces, 2021, 13, 21087-21096.	4.0	15
1723	ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-Î² receptor II in breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 149.	3.5	34
1724	Skeletal Muscleâ€“Adipose Tissueâ€“Tumor Axis: Molecular Mechanisms Linking Exercise Training in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 4469.	1.8	5
1725	Tumor Microenvironment-Responsive Theranostic Nanoplatform for Guided Molecular Dynamic/Photodynamic Synergistic Therapy. ACS Applied Materials & Interfaces, 2021, 13, 17392-17403.	4.0	13
1726	Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging. Journal of Medicinal Chemistry, 2021, 64, 5593-5602.	2.9	9
1727	Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1Î± pathways in breast cancer. Phytomedicine, 2021, 84, 153503.	2.3	23
1728	Zeolitic Imidazolate Framework Platform for Combinational Starvation Therapy and Oxygen Self-Sufficient Photodynamic Therapy against a Hypoxia Tumor. ACS Applied Bio Materials, 2021, 4, 4413-4421.	2.3	17
1729	The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. Current Medicinal Chemistry, 2021, 28, 893-909.	1.2	23
1730	Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence. Cancers, 2021, 13, 1797.	1.7	2
1731	Multifunctional <scp>MnO₂</scp> nanoparticles for tumor microenvironment modulation and cancer therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1720.	3.3	97
1732	Prion Protein of Extracellular Vesicle Regulates the Progression of Colorectal Cancer. Cancers, 2021, 13, 2144.	1.7	11
1733	Evaluation of the effect of <scp>3D</scp> porous <scp>Chitosanâ€alginate</scp> scaffold stiffness on breast cancer proliferation and migration. Journal of Biomedical Materials Research - Part A, 2021, 109, 1990-2000.	2.1	17
1734	Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells, 2021, 10, 1006.	1.8	45
1735	Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. International Journal of Molecular Sciences, 2021, 22, 5703.	1.8	118

#	Article	IF	Citations
1736	Multifunctional Graphdiyneâ€“Cerium Oxide Nanozymes Facilitate MicroRNA Delivery and Attenuate Tumor Hypoxia for Highly Efficient Radiotherapy of Esophageal Cancer. Advanced Materials, 2021, 33, e2100556.	11.1	119
1737	Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 2309.	1.7	9
1738	Strategies of Alleviating Tumor Hypoxia and Enhancing Tumor Therapeutic Effect by Macromolecular Nanomaterials. Macromolecular Bioscience, 2021, 21, e2100092.	2.1	14
1739	Ferrocene-containing polymersome nanoreactors for synergistically amplified tumor-specific chemodynamic therapy. Journal of Controlled Release, 2021, 333, 500-510.	4.8	54
1740	NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Science Advances, 2021, 7, .	4.7	15
1741	Copper(II) Pyridyl Aminophenolates: Hypoxiaâ€Selective, Nucleusâ€Targeting Cytotoxins, and Magnetic Resonance Probes. Chemistry - A European Journal, 2021, 27, 9839-9849.	1.7	10
1742	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	2.2	20
1743	Advances in Application of Azobenzene as a Trigger in Biomedicine: Molecular Design and Spontaneous Assembly. Advanced Materials, 2021, 33, e2007290.	11.1	118
1744	Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Frontiers in Immunology, 2021, 12, 656364.	2.2	175
1745	Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 659253.	1.3	55
1746	Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer. Cancer Cell International, 2021, 21, 251.	1.8	16
1748	From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Advanced Materials, 2021, 33, e2008094.	11.1	60
1749	Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers. World Journal of Gastrointestinal Oncology, 2021, 13, 312-331.	0.8	7
1750	Tumor necrosis: A synergistic consequence of metabolic stress and inflammation. BioEssays, 2021, 43, e2100029.	1.2	24
1751	Rational construction of a reversible arylazo-based NIR probe for cycling hypoxia imaging in vivo. Nature Communications, 2021, 12, 2772.	5.8	37
1752	Antiangiogenesis Combined with Inhibition of the Hypoxia Pathway Facilitates Low-Dose, X-ray-Induced Photodynamic Therapy. ACS Nano, 2021, 15, 11112-11125.	7.3	16
1753	Role of Calixarene in Chemotherapy Delivery Strategies. Molecules, 2021, 26, 3963.	1.7	37
1754	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 186.	3.5	77

#	Article	IF	Citations
1755	Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. Nature Communications, 2021, 12, 3807.	5.8	12
1756	Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma. Cancers, 2021, 13, 2809.	1.7	10
1757	Plasmon-pyroelectric nanostructures used to produce a temperature-mediated reactive oxygen species for hypoxic tumor therapy. Nano Today, 2021, 38, 101110.	6.2	20
1758	Eradication of large established tumors by drug-loaded bacterial particles via a neutrophil-mediated mechanism. Journal of Controlled Release, 2021, 334, 52-63.	4.8	1
1759	Association of genetic polymorphism rs2071676 in carbonic anhydrase gene (CA9) with the risk of squamous cell carcinoma of lungs and esophagus. Biologia (Poland), 2021, 76, 2777-2784.	0.8	0
1760	Microbots Gene Delivery System Based on Bifidobacteria in a Tumor Model. Applied Sciences (Switzerland), 2021, 11, 5544.	1.3	1
1761	Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy. Oncotarget, 2021, 12, 1165-1177.	0.8	6
1762	Perspectives on Hypoxia Signaling in Tumor Stroma. Cancers, 2021, 13, 3070.	1.7	18
1763	Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents. Molecules, 2021, 26, 3327.	1.7	2
1764	Reviewâ€"Advances in the Application of Microenvironment-Responsive NIR-II Fluorescent Probes in Organisms. ECS Journal of Solid State Science and Technology, 2021, 10, 076002.	0.9	10
1765	Interfering with Tumor Hypoxia for Radiotherapy Optimization. Journal of Experimental and Clinical Cancer Research, 2021, 40, 197.	3.5	70
1766	Peritumoral edema in breast cancer at preoperative MRI: an interpretative study with histopathological review toward understanding tumor microenvironment. Scientific Reports, 2021, 11, 12992.	1.6	20
1767	Responsive optical probes for deep-tissue imaging: Photoacoustics and second near-infrared fluorescence. Advanced Drug Delivery Reviews, 2021, 173, 141-163.	6.6	49
1768	Intermittent hypoxia-induced downregulation of microRNA-320b promotes lung cancer tumorigenesis by increasing CDT1 via USP37. Molecular Therapy - Nucleic Acids, 2021, 24, 528-541.	2.3	13
1769	Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis. Journal of Medicinal Chemistry, 2021, 64, 8621-8643.	2.9	9
1770	Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects. Journal of Controlled Release, 2021, 334, 237-247.	4.8	16
1771	Sunitinib and Evofosfamide (<scp>TH</scp>-302) in Systemic Treatment-NaÃ¯ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <scp>GETNE</scp>-1408 Trial. Oncologist, 2021, 26, 941-949.	1.9	12
1772	Extracellular Vesicle Transmission of Chemoresistance to Ovarian Cancer Cells Is Associated with Hypoxia-Induced Expression of Glycolytic Pathway Proteins, and Prediction of Epithelial Ovarian Cancer Disease Recurrence. Cancers, 2021, 13, 3388.	1.7	32

#	Article	IF	Citations
1773	Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer. International Journal of Molecular Sciences, 2021, 22, 8153.	1.8	12
1774	A General Approach to Design Dual Ratiometric Fluorescent and Photoacoustic Probes for Quantitatively Visualizing Tumor Hypoxia Levels Inâ€...Vivo. Angewandte Chemie - International Edition, 2022, 61, .	7.2	70
1775	A General Approach to Design Dual Ratiometric Fluorescent and Photoacoustic Probes for Quantitatively Visualizing Tumor Hypoxia Levels Inâ€...Vivo. Angewandte Chemie, 2022, 134, .	1.6	12
1776	Therapeutic targeting of the hypoxic tumour microenvironment. Nature Reviews Clinical Oncology, 2021, 18, 751-772.	12.5	185
1777	The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. Nature Communications, 2021, 12, 4308.	5.8	45
1778	Evaluation of a Refined Implantable Resonator for Deep-Tissue EPR Oximetry in the Clinic. Applied Magnetic Resonance, 2021, 52, 1321-1342.	0.6	3
1779	Non-CpG methylationâ€"a key epigenetic modification in cancer. Briefings in Functional Genomics, 2021, 20, 304-311.	1.3	10
1780	Oxygen-Based Nanocarriers to Modulate Tumor Hypoxia for Ameliorated Anti-Tumor Therapy: Fabrications, Properties, and Future Directions. Frontiers in Molecular Biosciences, 2021, 8, 683519.	1.6	18
1781	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	1.8	29
1782	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?â€"An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. Cancers, 2021, 13, 3429.	1.7	8
1783	Nitric Oxide and Immune Responses in Cancer: Searching for New Therapeutic Strategies. Current Medicinal Chemistry, 2022, 29, 1561-1595.	1.2	14
1784	Development of an Amino Sugar-Based Supramolecular Hydrogelator with Reduction Responsiveness. Jacs Au, 2021, 1, 1639-1646.	3.6	13
1785	Regulation and Functions of Protumoral Unconventional T Cells in Solid Tumors. Cancers, 2021, 13, 3578.	1.7	4
1786	Nanopoxia: Targeting Cancer Hypoxia by Antimoneneâ€Based Nanoplatform for Precision Cancer Therapy. Advanced Functional Materials, 2021, 31, 2104607.	7.8	18
1787	Overcoming Tumor Hypoxia through Multiple Pathways Using an All-in-One Polymeric Therapeutic Agent to Enhance Synergistic Cancer Photo/Chemotherapy Effects. Bioconjugate Chemistry, 2021, 32, 1864-1874.	1.8	8
1788	The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. Cancers, 2021, 13, 3433.	1.7	67
1789	The Effects of Physical Exercise on Tumor Vasculature: Systematic Review and Meta-analysis. International Journal of Sports Medicine, 2021, 42, 1237-1249.	0.8	5
1790	Smallâ€Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery. Small, 2021, 17, e2101460.	5.2	87

#	Article	IF	Citations
1791	Key radioresistance regulation models and marker genes identified by integrated transcriptome analysis in nasopharyngeal carcinoma. Cancer Medicine, 2021, 10, 7404-7417.	1.3	10
1792	Anion-Responsive Manganese Porphyrin Facilitates Chloride Transport and Induces Immunogenic Cell Death. CCS Chemistry, 2022, 4, 2409-2419.	4.6	8
1793	Nanoprobe-Based Magnetic Resonance Imaging of Hypoxia Predicts Responses to Radiotherapy, Immunotherapy, and Sensitizing Treatments in Pancreatic Tumors. ACS Nano, 2021, 15, 13526-13538.	7.3	30
1794	Synthesis and evaluation of multivalent nitroimidazole-based near-infrared fluorescent agents for neuroblastoma and colon cancer imaging. Bioorganic Chemistry, 2021, 113, 104990.	2.0	3
1795	Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes. Acta Pharmaceutica Sinica B, 2022, 12, 1487-1499.	5.7	11
1796	The Transcriptional Coactivator, ALL1â€Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer. Hepatology, 2021, 74, 1952-1970.	3.6	10
1797	An Engineered Patientâ€Derived Tumor Organoid Model That Can Be Disassembled to Study Cellular Responses in a Graded 3D Microenvironment. Advanced Functional Materials, 2021, 31, 2105349.	7.8	15
1798	Flavylium-Based Hypoxia-Responsive Probe for Cancer Cell Imaging. Molecules, 2021, 26, 4938.	1.7	5
1799	Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy. Cancers, 2021, 13, 4046.	1.7	11
1800	A Mitochondrial Oxidative Stress Amplifier to Overcome Hypoxia Resistance for Enhanced Photodynamic Therapy. Small Methods, 2021, 5, e2100581.	4.6	32
1801	Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Science Advances, 2021, 7, .	4.7	65
1802	Switching Reactive Oxygen Species into Reactive Nitrogen Species by Photocleaved O₂â€Released Nanoplatforms Favors Hypoxic Tumor Repression. Advanced Science, 2021, 8, e2101065.	5.6	64
1803	Hypoxia in Cancer and Fibrosis: Part of the Problem and Part of the Solution. International Journal of Molecular Sciences, 2021, 22, 8335.	1.8	13
1804	TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy. International Journal of Nanomedicine, 2021, Volume 16, 5909-5921.	3.3	17
1805	Selective Thrombosis of Tumor for Enhanced Hypoxiaâ€Activated Prodrug Therapy. Advanced Materials, 2021, 33, e2104504.	11.1	45
1806	Multifunctional Hybrid Hydrogel Enhanced Antitumor Therapy through Multiple Destroying DNA Functions by a Tripleâ€Combination Synergistic Therapy. Advanced Healthcare Materials, 2021, 10, e2101190.	3.9	14
1807	Tirapazamine encapsulated hyaluronic acid nanomicelles realized targeted and efficient photo-bioreductive cascading cancer therapy. Chinese Chemical Letters, 2021, 32, 2400-2404.	4.8	12
1808	Semiconducting Polymer Nanoparticles as Activatable Nanomedicines for Combinational Phototherapy. ACS Applied Polymer Materials, 2021, 3, 4375-4389.	2.0	28

#	Article	IF	Citations
1809	Inâ€cell generation of anticancer phenanthridine through bioorthogonal cyclization: a paradigm in antitumor prodrug development. Angewandte Chemie, 2021, 133, 24245.	1.6	4
1810	Tumor-Associated Macrophages and Their Functional Transformation in the Hypoxic Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 741305.	2.2	76
1811	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
1812	Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. Scientific Reports, 2021, 11, 19350.	1.6	37
1813	PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer. Molecular Medicine Reports, 2021, 24, .	1.1	7
1814	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology, 2022, 237, 346-372.	2.0	13
1815	Recent advances in ruthenium(II) and iridium(III) complexes containing nanosystems for cancer treatment and bioimaging. Coordination Chemistry Reviews, 2021, 443, 214016.	9.5	68
1816	miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1Î± in NSCLC. Molecular Therapy - Oncolytics, 2021, 22, 368-379.	2.0	6
1817	Impact of hypoxia on cervical cancer outcomes. International Journal of Gynecological Cancer, 2021, 31, 1459-1470.	1.2	17
1818	The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers, 2021, 13, 4932.	1.7	19
1819	Azocalix[4]arene-Rhodamine Supramolecular Hypoxia-Sensitive Systems: A Search for the Best Calixarene Hosts and Rhodamine Guests. Molecules, 2021, 26, 5451.	1.7	10
1821	Zwitterionic Block Copolymer Prodrug Micelles for pH Responsive Drug Delivery and Hypoxia-Specific Chemotherapy. Molecular Pharmaceutics, 2022, 19, 1766-1777.	2.3	11
1822	Lack of MOF Decreases Susceptibility to Hypoxia and Promotes Multidrug Resistance in Hepatocellular Carcinoma via HIF-1Î±. Frontiers in Cell and Developmental Biology, 2021, 9, 718707.	1.8	7
1823	Eribulin improves tumor oxygenation demonstrated by 18F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 821-833.	3.3	1
1824	Therapeutic Modification of Hypoxia. Clinical Oncology, 2021, 33, e492-e509.	0.6	12
1825	Computational Analysis of Photophysical Properties and Reactivity of a New Phototherapeutic Cyclometalated Au(III)â€Hydride Complex. Chemistry - A European Journal, 2021, 27, 15528-15535.	1.7	5
1826	Inâ€Cell Generation of Anticancer Phenanthridine Through Bioorthogonal Cyclization in Antitumor Prodrug Development. Angewandte Chemie - International Edition, 2021, 60, 24043-24047.	7.2	14
1827	Small-molecule probes for fluorescent detection of cellular hypoxia-related nitroreductase. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114199.	1.4	20

#	Article	IF	Citations
1828	Advanced Delivery Systems Based on Lysine or Lysine Polymers. Molecular Pharmaceutics, 2021, 18, 3652-3670.	2.3	26
1829	Hypoxia-targeted cupric-tirapazamine liposomes potentiate radiotherapy in prostate cancer spheroids. International Journal of Pharmaceutics, 2021, 607, 121018.	2.6	11
1830	The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment. Cancers, 2021, 13, 4577.	1.7	6
1831	Engineered in vitro tumor models for cell-based immunotherapy. Acta Biomaterialia, 2021, 132, 345-359.	4.1	13
1832	A pair of long intergenic non-coding RNA LINC00887 variants act antagonistically to control Carbonic Anhydrase IX transcription upon hypoxia in tongue squamous carcinoma progression. BMC Biology, 2021, 19, 192.	1.7	10
1833	Enhanced radiotherapy efficacy and induced anti-tumor immunity in HCC by improving hypoxia microenvironment using oxygen microcapsules. Chemical Engineering Journal, 2021, 422, 130109.	6.6	24
1834	Nitro-Pyrazinotriazapentalene scaffoldsâ€“ nitroreductase quantification and in vitro fluorescence imaging of hypoxia. Sensors and Actuators B: Chemical, 2021, 346, 130504.	4.0	12
1835	Elevated LncRNA TRERNA1 correlated with activation of HIF-1Î± predicts poor prognosis in hepatocellular carcinoma. Pathology Research and Practice, 2021, 227, 153612.	1.0	6
1836	Photothermal photodynamic therapy and enhanced radiotherapy of targeting copolymer-coated liquid metal nanoparticles on liver cancer. Colloids and Surfaces B: Biointerfaces, 2021, 207, 112023.	2.5	21
1837	Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188585.	3.3	48
1838	Delivery of therapeutic oligonucleotides in nanoscale. Bioactive Materials, 2022, 7, 292-323.	8.6	29
1839	Challenges and opportunities of nanotechnology in cancer immunotherapy. , 2022, , 197-239.		1
1840	Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer. Frontiers in Immunology, 2020, 11, 609337.	2.2	13
1841	Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression. Scientific Reports, 2021, 11, 419.	1.6	7
1842	High expression of hypoxia inducible factor 1Î± related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC. Scientific Reports, 2021, 11, 1199.	1.6	9
1843	Receptor-interacting protein in malignant digestive neoplasms. Journal of Cancer, 2021, 12, 4362-4371.	1.2	3
1844	Growth of tumor emboli within a vessel model reveals dependence on the magnitude of mechanical constraint. Integrative Biology (United Kingdom), 2021, 13, 1-16.	0.6	8
1845	A PdMo bimetallene with precise wavelength adjustment and catalysis for synergistic photothermal ablation and hydrogen therapy of cancer at different depths. Journal of Materials Chemistry B, 2021, 9, 6441-6459.	2.9	11

#	Article	IF	Citations
1846	Discovery of a highly efficient nitroaryl group for detection of nitroreductase and imaging of hypoxic tumor cells. Organic and Biomolecular Chemistry, 2021, 19, 3469-3478.	1.5	10
1847	Role of mitochondrial reactive oxygen species in glioblastoma drug resistance and strategies for therapeutic intervention. , 2021, , 263-292.		0
1848	Hypoxia-sensitive long noncoding RNA CASC15 promotes lung tumorigenesis by regulating the SOX4/Î²-catenin axis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 12.	3.5	16
1849	Small molecule based fluorescent chemosensors for imaging the microenvironment within specific cellular regions. Chemical Society Reviews, 2021, 50, 12098-12150.	18.7	236
1850	Hypoxia-Triggered Self-Assembly of Ultrasmall Iron Oxide Nanoparticles to Amplify the Imaging Signal of a Tumor. Journal of the American Chemical Society, 2021, 143, 1846-1853.	6.6	91
1851	Hypoxia-Directed Drug Strategies to Target the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2014, 772, 111-145.	0.8	19
1852	Intratumoral Hypoxia as the Genesis of Genetic Instability and Clinical Prognosis in Prostate Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 189-204.	0.8	28
1853	Application of MOBILE (Mapping of Oxygen By Imaging Lipids relaxation Enhancement) to Study Variations in Tumor Oxygenation. Advances in Experimental Medicine and Biology, 2013, 789, 281-288.	0.8	7
1854	Exploiting â€œHif Addictionâ€•For Cancer Therapy. Cancer Drug Discovery and Development, 2014, , 329-341.	0.2	2
1855	Hypoxia and Gene Expression. Cancer Drug Discovery and Development, 2014, , 91-119.	0.2	2
1856	Hypoxia, Metastasis, and Antiangiogenic Therapies. Cancer Drug Discovery and Development, 2014, , 205-227.	0.2	2
1857	Molecular Genetics of Dysregulated pH Homeostasis. , 2014, , .		1
1858	Necrosis in the Tumor Microenvironment and Its Role in Cancer Recurrence. Advances in Experimental Medicine and Biology, 2020, 1225, 89-98.	0.8	14
1859	Multiple Dynamics in Tumor Microenvironment Under Radiotherapy. Advances in Experimental Medicine and Biology, 2020, 1263, 175-202.	0.8	5
1860	Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms. Advances in Experimental Medicine and Biology, 2020, 1277, 143-158.	0.8	12
1861	The Role of Hypoxia in Radiation Response. , 2016, , 29-42.		1
1862	Introducing Drug Transport Early in the Design of Hypoxia Selective Anticancer Agents Using a Mathematical Modelling Approach. SIMAI Springer Series, 2012, , 337-353.	0.4	4
1863	Aerobic reactions of antitumor active dirhodium(II) tetraacetate Rh2(CH3COO)4 with glutathione. Journal of Biological Inorganic Chemistry, 2018, 23, 231-239.	1.1	16

#	Article	IF	Citations
1864	Role of MSCs in Antitumor Drug Resistance. , 2017, , 295-333.		1
1865	Activatable fluorescent probe based on aggregation-induced emission for detecting hypoxia-related pathological conditions. Analytica Chimica Acta, 2020, 1125, 152-161.	2.6	26
1866	Hypoxia and cancer related pathology. Cancer Letters, 2020, 486, 1-7.	3.2	42
1867	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine and Growth Factor Reviews, 2017, 36, 67-77.	3.2	71
1868	Tuning the redox potentials of ternary cobalt(III) complexes containing various hydroxamates. Inorganica Chimica Acta, 2018, 472, 234-242.	1.2	10
1869	Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia. Journal of Controlled Release, 2020, 324, 413-429.	4.8	76
1870	Multifunctional nanoparticles as photosensitizer delivery carriers for enhanced photodynamic cancer therapy. Materials Science and Engineering C, 2020, 115, 111099.	3.8	53
1871	Real-Time Ratiometric Imaging of Micelles Assembly State in a Microfluidic Cancer-on-a-Chip. ACS Applied Bio Materials, 2021, 4, 669-681.	2.3	22
1872	Endothelial Cords Promote Tumor Initial Growth prior to Vascular Function through a Paracrine Mechanism. Scientific Reports, 2016, 6, 19404.	1.6	10
1873	Chemical Biology of O-GlcNAc Glycosylation. Chemical Biology, 2017, , 94-149.	0.1	2
1874	Molecular and nanoengineering approaches towards activatable cancer immunotherapy. Chemical Society Reviews, 2020, 49, 4234-4253.	18.7	228
1875	Smart strategies to overcome tumor hypoxia toward the enhancement of cancer therapy. Nanoscale, 2020, 12, 21519-21533.	2.8	26
1876	Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends. Nanotechnology, 2021, 32, 062001.	1.3	10
1877	Hypoxia-responsive nanogel as IL-12 carrier for anti-cancer therapy. Nanotechnology, 2021, 32, 095107.	1.3	13
1878	Increased local tumor control through nanoparticle-mediated, radiation-triggered release of nitrite, an important precursor for reactive nitrogen species. Physics in Medicine and Biology, 2020, 65, 195003.	1.6	4
1886	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight, 2018, 3, .	2.3	44
1887	Exogenous sickle erythrocytes combined with vascular disruption trigger disseminated tumor vaso-occlusion and lung tumor regression. JCI Insight, 2019, 4, .	2.3	3
1888	Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. Journal of Clinical Investigation, 2018, 128, 3840-3852.	3.9	79

#	Article	IF	Citations
1889	Let there be oxygen and T cells. Journal of Clinical Investigation, 2018, 128, 4761-4763.	3.9	3
1890	Investigating long noncoding RNAs using animal models. Journal of Clinical Investigation, 2016, 126, 2783-2791.	3.9	23
1891	The impact of hypoxia on tumor-associated macrophages. Journal of Clinical Investigation, 2016, 126, 3672-3679.	3.9	401
1892	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. Journal of Clinical Investigation, 2016, 126, 3526-3540.	3.9	82
1893	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. Journal of Clinical Investigation, 2018, 128, 5137-5149.	3.9	269
1894	Symphony of epigenetic and metabolic regulationâ€"interaction between the histone methyltransferase EZH2 and metabolism of tumor. Clinical Epigenetics, 2020, 12, 72.	1.8	33
1895	The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma. EJNMMI Research, 2020, 10, 57.	1.1	2
1896	The feasibility of [18F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study. EJNMMI Research, 2020, 10, 103.	1.1	4
1897	Analysis of Differentially Expressed lncRNAs and mRNAs for the Identification of Hypoxia-Regulated Angiogenic Genes in Colorectal Cancer by RNA-Seq. Medical Science Monitor, 2019, 25, 2009-2015.	0.5	8
1898	Simultaneous photoacoustic imaging of intravascular and tissue oxygenation. Optics Letters, 2019, 44, 3773.	1.7	44
1899	Phosphorylation of seryl-tRNA synthetase by ATM/ATR is essential for hypoxia-induced angiogenesis. PLoS Biology, 2020, 18, e3000991.	2.6	15
1900	The Role of Hypoxia-Inducible Factor 1Î± in Determining the Properties of Castrate-Resistant Prostate Cancers. PLoS ONE, 2013, 8, e54251.	1.1	70
1901	A Functional Yeast Survival Screen of Tumor-Derived cDNA Libraries Designed to Identify Anti-Apoptotic Mammalian Oncogenes. PLoS ONE, 2013, 8, e64873.	1.1	17
1902	The Antioxidant N-Acetylcysteine Prevents HIF-1 Stabilization under Hypoxia In Vitro but Does Not Affect Tumorigenesis in Multiple Breast Cancer Models In Vivo. PLoS ONE, 2013, 8, e66388.	1.1	28
1903	The Effect of Antitumor Glycosides on Glioma Cells and Tissues as Studied by Proton HR-MAS NMR Spectroscopy. PLoS ONE, 2013, 8, e78391.	1.1	9
1904	Monocarboxylate Transporters 1â€"4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival. PLoS ONE, 2014, 9, e105038.	1.1	59
1905	Intermittent Hypoxia Effect on Osteoclastogenesis Stimulated by Neuroblastoma Cells. PLoS ONE, 2014, 9, e105555.	1.1	9
1906	A Combined Gene Signature of Hypoxia and Notch Pathway in Human Glioblastoma and Its Prognostic Relevance. PLoS ONE, 2015, 10, e0118201.	1.1	45

#	Article	IF	Citations
1907	Phosphorescence Monitoring of Hypoxic Microenvironment in Solid-Tumors to Evaluate Chemotherapeutic Effects Using the Hypoxia-Sensitive Iridium (III) Coordination Compound. PLoS ONE, 2015, 10, e0121293.	1.1	18
1908	Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging. PLoS ONE, 2015, 10, e0131037.	1.1	36
1909	A Lab Assembled Microcontroller-Based Sensor Module for Continuous Oxygen Measurement in Portable Hypoxia Chambers. PLoS ONE, 2016, 11, e0148923.	1.1	16
1910	2-Deoxyglucose Reverses the Promoting Effect of Insulin on Colorectal Cancer Cells In Vitro. PLoS ONE, 2016, 11, e0151115.	1.1	27
1911	MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS ONE, 2016, 11, e0155289.	1.1	21
1912	TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers. PLoS ONE, 2016, 11, e0157453.	1.1	39
1913	Assessment of intratumor hypoxia by integrated 18F-FDG PET / perfusion CT in a liver tumor model. PLoS ONE, 2017, 12, e0173016.	1.1	7
1914	Leptin decreases BC cell susceptibility to NK lysis via PGC1A pathway. Endocrine Connections, 2020, 9, 578-586.	0.8	2
1915	Hypoxia-Inducible Factor 1 Alpha (HIF-1Î±) and Its Prognostic Value in Acute Myeloid Leukemia. Hematology & Transfusion International Journal, 2017, 4, .	0.1	5
1916	Luminescent Probe Based Techniques for Hypoxia Imaging. Journal of Nanomedicine Research, 2017, 6, .	1.8	13
1917	Enhancer-bound Nrf2 licenses HIF-1Î± transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells. Aging, 2021, 13, 364-375.	1.4	14
1918	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes and Cancer, 2017, 7, 340-354.	0.6	20
1919	Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience, 2014, 1, 216-228.	0.9	33
1920	Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget, 2016, 7, 72322-72342.	0.8	67
1921	Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts. Oncotarget, 2017, 8, 1392-1404.	0.8	9
1922	Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor Î³ promotes chemoresistance of non-small cell lung cancer. Oncotarget, 2017, 8, 8083-8094.	0.8	29
1923	Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget, 2017, 8, 9899-9910.	0.8	115
1924	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. Oncotarget, 2017, 8, 21315-21326.	0.8	39

#	Article	IF	Citations
1925	Flattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer. Oncotarget, 2017, 8, 30092-30099.	0.8	9
1926	Expression of HIF-1Î± in medullary thyroid cancer identifies a subgroup with poor prognosis. Oncotarget, 2017, 8, 28650-28659.	0.8	19
1927	The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy. Oncotarget, 2017, 8, 23702-23712.	0.8	28
1928	Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget, 2017, 8, 42857-42875.	0.8	62
1929	HIF-2Î± dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression. Oncotarget, 2017, 8, 42887-42900.	0.8	12
1930	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget, 2017, 8, 87638-87646.	0.8	10
1931	Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. Oncotarget, 2014, 5, 6353-6364.	0.8	31
1932	The ERÎ²4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERÎ² variants ERÎ²2 and ERÎ²5 increase aggressiveness of TNBC by regulation of hypoxic signaling. Oncotarget, 2018, 9, 12201-12211.	0.8	15
1933	Hypoxic-induced truncation of voltage-dependent anion channel 1 is mediated by both asparagine endopeptidase and calpain 1 activities. Oncotarget, 2018, 9, 12825-12841.	0.8	12
1934	Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. Oncotarget, 2018, 9, 27039-27058.	0.8	9
1935	Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma. Oncotarget, 2018, 9, 33634-33647.	0.8	22
1936	Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer. Oncotarget, 2015, 6, 13803-13821.	0.8	35
1937	Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget, 2015, 6, 5536-5546.	0.8	65
1938	Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics. Oncotarget, 2012, 3, 84-97.	0.8	365
1939	The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. Oncotarget, 2015, 6, 31985-31996.	0.8	7
1940	Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment. Oncotarget, 2015, 6, 34732-34744.	0.8	7
1941	MiR224-3p inhibits hypoxia-induced autophagy by targeting autophagy-related genes in human glioblastoma cells. Oncotarget, 2015, 6, 41620-41637.	0.8	49
1942	Targeting Notch to overcome radiation resistance. Oncotarget, 2016, 7, 7610-7628.	0.8	50

#	Article	IF	Citations
1943	SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway. Oncotarget, 2016, 7, 18356-18370.	0.8	21
1944	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget, 2016, 7, 46678-46691.	0.8	35
1945	Zinc finger protein 91 (ZFP91) activates HIF-1Î± via NF-ÎºB/p65 to promote proliferation and tumorigenesis of colon cancer. Oncotarget, 2016, 7, 36551-36562.	0.8	42
1946	Phage display library selection of a hypoxia-binding scFv antibody for liver cancer metabolic marker discovery. Oncotarget, 2016, 7, 38105-38121.	0.8	11
1947	Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents. Current Medicinal Chemistry, 2015, 22, 2819-2857.	1.2	116
1948	Imaging Agents in Targeting Tumor Hypoxia. Current Medicinal Chemistry, 2016, 23, 1775-1800.	1.2	8
1949	Hypoxia Responsive Drug Delivery Systems in Tumor Therapy. Current Pharmaceutical Design, 2016, 22, 2808-2820.	0.9	34
1950	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Current Pharmaceutical Design, 2016, 22, 4360-4373.	0.9	53
1951	Recent Advances in Strategies for Extracellular Matrix Degradation and Synthesis Inhibition for Improved Therapy of Solid Tumors. Current Pharmaceutical Design, 2020, 26, 5456-5467.	0.9	11
1952	Tumor-targeted Drug Delivery by Nanocomposites. Current Drug Metabolism, 2020, 21, 599-613.	0.7	7
1953	The Role of the PERK/eIF2Î±/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress. Current Molecular Medicine, 2016, 16, 533-544.	0.6	527
1954	Physicochemical Considerations of Tumor Selective Drug Delivery and Activity Confinement with Particular Reference to 1,2-Bis(Sulfonyl)-1- Alkylhydrazines Delivery. Current Drug Delivery, 2020, 17, 362-374.	0.8	5
1955	Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action. Current Cancer Drug Targets, 2013, 13, 814-828.	0.8	16
1956	Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends. Current Topics in Medicinal Chemistry, 2019, 19, 691-712.	1.0	25
1957	RON - The Con in Colorectal Carcinoma. Open Colorectal Cancer Journal, 2012, 5, 15-21.	0.5	3
1958	The Utility of Serum CA9 for Prognostication in Prostate Cancer. Anticancer Research, 2016, 36, 4489-4492.	0.5	13
1959	The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions. Anticancer Research, 2017, 37, 547-554.	0.5	6
1960	Inhibition of Ubiquitin-conjugating Enzyme E2 May Activate the Degradation of Hypoxia-inducible Factors and, thus, Overcome Cellular Resistance to Radiation in Colorectal Cancer. Anticancer Research, 2017, 37, 2425-2436.	0.5	17

#	Article	IF	Citations
1961	Involvement of the ERK/HIF-1Î±/EMT Pathway in XCL1-Induced Migration of MDA-MB-231 and SK-BR-3 Breast Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 89.	1.8	17
1962	Computed tomography perfusion imaging as a potential imaging biomarker of colorectal cancer. World Journal of Gastroenterology, 2014, 20, 17345.	1.4	11
1963	Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy. Radiation Oncology Journal, 2016, 34, 239-249.	0.7	45
1964	Population and singleâ€'cell transcriptome analyses reveal diverse transcriptional changes associated with radioresistance in esophageal squamous cell carcinoma. International Journal of Oncology, 2019, 55, 1237-1248.	1.4	11
1965	Analysis of Sensitivity and Cell Death Pathways Mediated by Anti-cancer Drugs Using Three-dimensional Culture System. International Journal of Cancer Research, 2017, 14, 1-12.	0.2	5
1966	Role of hypoxia-activated prodrugs in combination with radiation therapy: An <i>in silico</i> approach. Mathematical Biosciences and Engineering, 2019, 16, 6257-6273.	1.0	11
1967	Understanding and targeting resistance to anti-angiogenic therapies. Journal of Gastrointestinal Oncology, 2013, 4, 253-63.	0.6	66
1968	Improving chemoradiotherapy with nanoparticle therapeutics. Translational Cancer Research, 2013, 2, 320-329.	0.4	25
1969	Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy. Annals of Translational Medicine, 2015, 3, 187.	0.7	2
1970	Defining lung cancer stem cells exosomal payload of miRNAs in clinical perspective. World Journal of Stem Cells, 2020, 12, 406-421.	1.3	16
1971	Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia. Molecular Imaging and Radionuclide Therapy, 2016, 25, 19-25.	0.3	1
1972	Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World Journal of Biological Chemistry, 2011, 2, 193.	1.7	26
1973	Cyclic Voltammetric Investigation of Interactions between Bisnitroaromatic Compounds and ds.DNA. Journal of the Korean Chemical Society, 2014, 58, 153-159.	0.2	11
1974	Positron emission tomography to assess hypoxia and perfusion in lung cancer. World Journal of Clinical Oncology, 2014, 5, 824.	0.9	10
1975	Leptin signaling and cancer chemoresistance: Perspectives. World Journal of Clinical Oncology, 2017, 8, 106.	0.9	59
1976	The Involvement of the ERK-Hypoxia-Angiogenesis Signaling Axis and HIF-1 in Hepatocellular Carcinoma. , 0, , .		1
1977	Co-culture Microdevice with Oxygen Gradient for Tumor Microenvironment Model and Metastasis Imaging. American Journal of Biomedical Engineering, 2012, 2, 175-180.	0.9	7
1978	TGF-Î² inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics, 2020, 10, 1910-1922.	4.6	110

#	Article	IF	Citations
1979	The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. ELife, 2020, 9, .	2.8	168
1980	Graphdiyne: from Preparation to Biomedical Applications. Chemical Research in Chinese Universities, 2021, 37, 1-19.	1.3	10
1981	Multiparameter persistent homology landscapes identify immune cell spatial patterns in tumors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	33
1982	Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Advanced Drug Delivery Reviews, 2021, 179, 114004.	6.6	55
1983	DNA Damage Radiosensitizers Geared Towards Hydrated Electrons. , 2022, , 125-169.		3
1984	Unboxing the molecular modalities of mutagens in cancer. Environmental Science and Pollution Research, 2022, 29, 62111-62159.	2.7	19
1985	Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy. International Journal of Molecular Sciences, 2021, 22, 10689.	1.8	18
1986	Anti-cancer efficacy includingÂRb-deficient tumorsÂandÂVHL-independent HIF1Î±Âproteasomal destabilizationÂby dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports, 2021, 11, 20871.	1.6	9
1987	Involvement of hydrogen peroxide in sonodynamical effect with sinoporphyrin sodium in hypoxic situation. Free Radical Research, 2021, 55, 958-969.	1.5	0
1988	Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved. International Journal of Molecular Sciences, 2021, 22, 10874.	1.8	14
1989	Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. Molecular Cancer Therapeutics, 2021, 20, 2372-2383.	1.9	17
1990	Precise Subcellular Organelle Targeting for Boosting Endogenousâ€Stimuliâ€Mediated Tumor Therapy. Advanced Materials, 2021, 33, e2101572.	11.1	47
1991	Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. Annual Review of Medicine, 2022, 73, 251-265.	5.0	30
1992	Sulforaphane Causes Cell Cycle Arrest and Apoptosis in Human Glioblastoma U87MG and U373MG Cell Lines under Hypoxic Conditions. International Journal of Molecular Sciences, 2021, 22, 11201.	1.8	4
1993	Emerging Roles of Energy Metabolism in Ferroptosis Regulation of Tumor Cells. Advanced Science, 2021, 8, e2100997.	5.6	105
1994	LW1497, an Inhibitor of Malate Dehydrogenase, Suppresses TGF-Î²1-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells by Downregulating Slug. Antioxidants, 2021, 10, 1674.	2.2	4
1995	Hypoxia-Responsive Polyprodrug Nanocarriers for Near-Infrared Light-Boosted Photodynamic Chemotherapy. Biomacromolecules, 2021, 22, 4857-4870.	2.6	18
1996	Hypoxia signaling: Challenges and opportunities for cancer therapy. Seminars in Cancer Biology, 2022, 85, 185-195.	4.3	17

#	Article	IF	Citations
1997	Research progress of azido-containing Pt(IV) antitumor compounds. European Journal of Medicinal Chemistry, 2022, 227, 113927.	2.6	17
1998	Altitude acclimatization via hypoxia-mediated oxidative eustress involves interplay of protein nitrosylation and carbonylation: A redoxomics perspective. Life Sciences, 2022, 296, 120021.	2.0	2
1999	Overall Neutrophil-to-Lymphocyte Ratio and SUVmax of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation. Frontiers in Oncology, 2021, 11, 679287.	1.3	7
2000	Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes. ACS Omega, 2021, 6, 27654-27667.	1.6	6
2001	Development and biological evaluation of AzoBGNU: A novel hypoxia-activated DNA crosslinking prodrug with AGT-inhibitory activity. Biomedicine and Pharmacotherapy, 2021, 144, 112338.	2.5	5
2002	Counteracting Hypoxia in Radio-Resistant Metastatic Lesions. , 2013, , 255-269.		0
2003	Therapy Resistance in Prostate Cancer: A Stem Cell Perspective. Pancreatic Islet Biology, 2013, , 279-300.	0.1	0
2004	Abstract 2941: The role of lysine acetylation in the tumor cell response to stress.. , 2013, , .		0
2006	Elucidation of Cancer Drivers Through Comparative Omic Data Analyses. , 2014, , 113-147.		0
2007	Sphingosine-1-Phosphate in Hypoxic Signaling. , 2014, , 199-217.		0
2008	Intravital Microscopy for Molecular Imaging in Cancer Research. , 2014, , 233-262.		0
2009	A Genomic Analysis of Cellular Responses and Adaptions to Extracellular Acidosis. , 2014, , 135-157.		0
2011	Endothelial Cells: A Key Player in Angiogenesis and Lymphangiogenesis. MOJ Cell Science & Report, 2014, 1, .	0.1	0
2013	Targeting Cancer Stem Cells and the Tumor Microenvironment. , 2015, , 445-476.		0
2014	The Impact of Cancer Treatments on Aging. , 2016, , 85-119.		0
2016	Application of Functional Molecular Imaging in Radiation Oncology. Cancer Drug Discovery and Development, 2017, , 103-134.	0.2	0
2017	HIF1Î±: A Key Emerging Player in Pancreatic Cancer. , 2017, , 363-369.		0
2018	Neuropilin-1-Expressing Monocytes: Implications for Therapeutic Angiogenesis and Cancer Therapy. , 2017, , 213-224.		0

#	Article	IF	Citations
2019	Progression of Lung Cancer: Role of Hypoxia and the Metabolic Tumor Microenvironment. , 2017, , 287-299.		0
2020	Role of Hypoxia-Inducible Factor (HIF) in Liver Cancer. , 2017, , 465-478.		0
2022	Pulmonary function impairment predicted poor prognosis of patients with hepatocellular carcinoma after hepatectomy. Oncotarget, 2017, 8, 75326-75335.	0.8	2
2024	Effect of oxygenated water as a new treatment modality on experimentally induced hamster buccal pouch carcinogenesis. Al-Azhar Journal of Dental Science, 2018, 21, 261-273.	0.0	2
2027	Blockade of Hypoxia: The Impact on Tumor Growth in an Experimental Tumor Model. Immunoregulation, 0, , 153-158.	0.1	0
2029	The Unfolded Protein Response in Triple-Negative Breast Cancer. Cancer Drug Discovery and Development, 2019, , 133-161.	0.2	0
2030	Mathematical Modelling of DNA Damages in Irradiated Cells at Different Oxygenation Degrees. Cybernetics and Computer Engineering, 2019, 2019, 51-64.	0.5	0
2031	Do Patient-derived Spheroid Culture Models Have Relevance in Chondrosarcoma Research?. Clinical Orthopaedics and Related Research, 2021, 479, 477-490.	0.7	6
2033	Engineered Red Blood Cell Biomimetic Nanovesicle with Oxygen Self-Supply for Near-Infrared-II Fluorescence-Guided Synergetic Chemo-Photodynamic Therapy against Hypoxic Tumors. ACS Applied Materials & Interfaces, 2021, 13, 52435-52449.	4.0	34
2034	BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma. Cell Death and Disease, 2021, 12, 1020.	2.7	8
2035	Oxygen-Abundant and pH/NIR Dual-Responsive Nanocarriers for Tumor Hypoxia Reduction Therapy. ACS Applied Nano Materials, 2021, 4, 11480-11492.	2.4	5
2036	Targeting Hypoxia: Revival of Old Remedies. Biomolecules, 2021, 11, 1604.	1.8	8
2037	Current understandings and clinical translation of nanomedicines for breast cancer therapy. Advanced Drug Delivery Reviews, 2022, 180, 114034.	6.6	32
2038	Lipoprotein-biomimetic nanostructure enables tumor-targeted penetration delivery for enhanced photo-gene therapy towards glioma. Bioactive Materials, 2022, 13, 286-299.	8.6	19
2039	Multifunctional Nanotheranostic Agent for NIRâ€II Imagingâ€Guided Synergetic Photothermal/Photodynamic Therapy. Advanced Therapeutics, 2021, 4, 2000240.	1.6	9
2040	Identification of potent human carbonic anhydrase IX inhibitors: a combination of pharmacophore modeling, 3D-QSAR, virtual screening and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2022, 40, 4516-4531.	2.0	8
2041	Recent advances in functionalized upconversion nanoparticles for light-activated tumor therapy. RSC Advances, 2021, 11, 35472-35488.	1.7	12
2042	Bone as a New Milieu for Disseminated Tumor Cells: An Overview of Bone Metastasis. , 2020, , 78-95.		0

#	Article	IF	Citations
2043	Imaging of the Tumour Microenvironment. RSC Detection Science, 2020, , 211-231.	0.0	0
2044	Sulphonate functionalized AIEgens: Strategic approach beyond waterâ€solubility for sensing and imaging applications. ChemPhotoChem, 0, , .	1.5	8
2045	The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. International Journal of Radiation Biology, 2022, 98, 439-451.	1.0	24
2046	Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking. Analytical Chemistry, 2021, 93, 15080-15087.	3.2	10
2049	Luminescent Conjugated Polymer Dots for Biomedical Applications. , 2021, , 197-230.		0
2051	Design and Synthesis of Protecting Groups for Pro-oligo Type Nucleic Acid-based Drugs. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2020, 78, 886-893.	0.0	0
2052	Verification of the role of exosomal microRNA in colorectal tumorigenesis using human colorectal cancer cell lines. PLoS ONE, 2020, 15, e0242057.	1.1	9
2053	The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance. American Journal of Cancer Research, 2012, 2, 372-82.	1.4	6
2054	Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1Î±. International Journal of Clinical and Experimental Pathology, 2013, 6, 2323-32.	0.5	5
2055	Imaging radiation response in tumor and normal tissue. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 317-32.	1.0	10
2056	The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy. Annals of Translational Medicine, 2015, 3, 261.	0.7	8
2060	Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like properties. Anticancer Research, 2014, 34, 3891-904.	0.5	5
2061	The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions. American Journal of Cancer Research, 2017, 7, 1084-1095.	1.4	3
2062	High HIF-1Î± expression predicts poor prognosis of patients with colon adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2018, 11, 5635-5646.	0.5	6
2063	A novel red-emitting two-photon fluorescent probe for imaging nitroreductases in cancer cells and tumor tissues with hypoxia conditions. Journal of Photochemistry and Photobiology A: Chemistry, 2022, 424, 113657.	2.0	5
2064	Hypoxia modulates human mast cell adhesion to hyaluronic acid. Immunologic Research, 2022, 70, 152-160.	1.3	4
2065	SUVmax for predicting regional control in oropharyngeal cancer. European Archives of Oto-Rhino-Laryngology, 2022, 279, 3167-3177.	0.8	3
2066	Membrane-Activated Fluorescent Probe for High-Fidelity Imaging of Mitochondrial Membrane Potential. ACS Sensors, 2021, 6, 4009-4018.	4.0	23

#	Article	IF	Citations
2067	Small Two-Photon Organic Fluorogenic Probes: Sensing and Bioimaging of Cancer Relevant Biomarkers. Analytical Chemistry, 2022, 94, 177-192.	3.2	35
2068	Intrabody Targeting HIF-1Î± Mediates Transcriptional Downregulation of Target Genes Related to Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 12335.	1.8	2
2069	Tumorâ€Microenvironmentâ€Responsive Nanomedicine for Enhanced Cancer Immunotherapy. Advanced Science, 2022, 9, e2103836.	5.6	142
2070	A Hypoxia-Associated Prognostic Gene Signature Risk Model and Prognosis Predictors in Gliomas. Frontiers in Oncology, 2021, 11, 726794.	1.3	6
2071	Tipping cancer cells over the edge: the context-dependent cost of high ploidy. Cancer Research, 2021, , canres.2794.2021.	0.4	4
2072	Characterization of a novel glucocorticoid-resistant human B-cell acute lymphoblastic leukemia cell line, with AMPK, mTOR and fatty acid synthesis pathway inhibition. Cancer Cell International, 2021, 21, 623.	1.8	1
2073	Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 751568.	1.6	10
2074	Review of Functionalized Nanomaterials for Photothermal Therapy of Cancers. ACS Applied Nano Materials, 2021, 4, 11353-11385.	2.4	75
2075	What do cellular responses to acidity tell us about cancer?. Cancer and Metastasis Reviews, 2021, 40, 1159-1176.	2.7	15
2076	Periodic mesoporous organosilica coupled with chlorin e6 and catalase for enhanced photodynamic therapy to treat triple-negative breast cancer. Journal of Colloid and Interface Science, 2022, 610, 634-642.	5.0	8
2077	HAX1 maintains the glioma progression in hypoxia through promoting mitochondrial fission. Journal of Cellular and Molecular Medicine, 2021, 25, 11170-11184.	1.6	6
2078	Hypoxia-sensitive drug delivery to tumors. Journal of Controlled Release, 2022, 341, 431-442.	4.8	11
2079	Protein Modification at Tyrosine with Iminoxyl Radicals. Journal of the American Chemical Society, 2021, 143, 19844-19855.	6.6	16
2080	Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nature Biotechnology, 2022, 40, 527-538.	9.4	128
2081	Ultra-sensitive responsive near-infrared fluorescent nitroreductase probe with strong specificity for imaging tumor and detecting the invasiveness of tumor cells. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 268, 120634.	2.0	7
2082	Hypoxia and Its Influence on Radiotherapy Response of HPV-Positive and HPV-Negative Head and Neck Cancer. Cancers, 2021, 13, 5959.	1.7	13
2083	Dinitro Derivative of Naphthalimide as a Fluorescent Probe for Tumor Hypoxia Imaging. Polycyclic Aromatic Compounds, 2023, 43, 54-63.	1.4	1
2084	Synthesis of 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: a way forward for targeting hypoxia and drug resistance of cancer cells. RSC Advances, 2021, 11, 38782-38795.	1.7	3

#	Article	IF	Citations
2086	Anti-hypoxia nanosized drug delivery systems improving cancer therapy. Nano Today, 2022, 42, 101376.	6.2	12
2087	Rhodol-derived turn-on fluorescent chemosensor for ultrasensitive detection of nitroreductase activity in bacteria and bioimaging in oral cancer cells. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 270, 120836.	2.0	0
2088	Constructing firefly luciferin bioluminescence probes for in vivo imaging. Organic and Biomolecular Chemistry, 2022, 20, 1360-1372.	1.5	14
2089	Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer Cell International, 2022, 22, 13.	1.8	16
2090	Dihydropyrimidinase like 3 as a novel target of wild type p53 suppresses MAPK pathway in response to hypoxia. Biocell, 2022, 46, 1181-1188.	0.4	0
2091	In Vivo Identification of Adducts from the New Hypoxia-Activated Prodrug CP-506 Using DNA Adductomics. Chemical Research in Toxicology, 2022, 35, 275-282.	1.7	8
2092	Novel Use of Hypoxia-Inducible Polymerizable Protein to Augment Chemotherapy for Pancreatic Cancer. Pharmaceutics, 2022, 14, 128.	2.0	1
2093	Five hypoxia and immunity related genes as potential biomarkers for the prognosis of osteosarcoma. Scientific Reports, 2022, 12, 1617.	1.6	6
2094	DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds. Frontiers in Oncology, 2021, 11, 749178.	1.3	2
2096	Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. Molecular Cancer, 2022, 21, 19.	7.9	63
2097	The Expression Pattern of Hypoxia-Related Genes Predicts the Prognosis and Mediates Drug Resistance in Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 814621.	1.8	4
2098	Influence of Hypoxia on Radiosensitization of Cancer Cells by 5-Bromo-2â€²-deoxyuridine. International Journal of Molecular Sciences, 2022, 23, 1429.	1.8	6
2099	Tumor-Acidity and Bioorthogonal Chemistry-Mediated On-Site Size Transformation Clustered Nanosystem to Overcome Hypoxic Resistance and Enhance Chemoimmunotherapy. ACS Nano, 2022, 16, 721-735.	7.3	41
2100	Enhanced Chemodynamic Therapy by Cuâ€“Fe Peroxide Nanoparticles: Tumor Microenvironment-Mediated Synergistic Fenton Reaction. ACS Nano, 2022, 16, 2535-2545.	7.3	120
2101	Low-Dose-Rate Irradiation Suppresses the Expression of Cell Cycle-Related Genes, Resulting in Modification of Sensitivity to Anti-Cancer Drugs. Cells, 2022, 11, 501.	1.8	2
2102	Palladium cubes with Pt shell deposition for localized surface plasmon resonance enhanced photodynamic and photothermal therapy of hypoxic tumors. Biomaterials Science, 2021, 10, 216-226.	2.6	12
2103	Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies â€” exemplified by polyunsaturated fatty acids and other ROS-modulating agents. Drug Delivery and Translational Research, 2022, 12, 2303-2334.	3.0	7
2104	HIF-1Î± inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer. Cancer Letters, 2022, 531, 39-56.	3.2	37

#	Article	IF	Citations
2105	Oxygen-carrying microfluidic microcapsules for enhancing chemo-sonodynamic therapy on patient-derived tumor organoid models. Chemical Engineering Journal, 2022, 435, 134871.	6.6	29
2106	Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect. Advanced Drug Delivery Reviews, 2022, 183, 114138.	6.6	33
2107	The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?. Frontiers in Immunology, 2022, 13, 828875.	2.2	31
2108	Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy. Pharmaceuticals, 2022, 15, 187.	1.7	17
2109	New Pyridinium Salt Derivatives of 2-(Hydrazinocarbonyl)-3-phenyl-1H-indole-5- sulfonamide as Selective Inhibitors of Tumour-Related Human Carbonic Anhydrase Isoforms IX and XII. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 2637-2646.	0.9	6
2110	Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model. Cells, 2022, 11, 560.	1.8	2
2111	Optimized spectral filter design enables more accurate estimation of oxygen saturation in spectral imaging. Biomedical Optics Express, 2022, 13, 2156.	1.5	6
2112	Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling. Frontiers in Pharmacology, 2022, 13, 803602.	1.6	3
2113	Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma. Advanced Materials, 2022, 34, e2110364.	11.1	131
2114	Streptococcus lutetiensis Induces Autophagy via Oxidative Stress in Bovine Mammary Epithelial Cells. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-16.	1.9	4
2115	Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis. Nature Cell Biology, 2022, 24, 242-252.	4.6	14
2116	Nitroaromatics as hypoxic cell radiosensitizers: A 2D-QSAR approach to explore structural features contributing to radiosensitization effectiveness. European Journal of Medicinal Chemistry Reports, 2022, , 100035.	0.6	3
2117	Core-shell structured nanoparticles for photodynamic therapy-based cancer treatment and related imaging. Coordination Chemistry Reviews, 2022, 458, 214427.	9.5	30
2120	Visualizing nitroreductase activity in living cells and tissues under hypoxia and hepatic inflammation. Analyst, The, 2022, 147, 1449-1456.	1.7	5
2121	Biosurfactant as a vehicle for targeted antitumor and anticancer drug delivery. , 2022, , 299-317.		1
2122	Dual-lifetime luminescent probe for time-resolved ratiometric oxygen sensing and imaging. Dalton Transactions, 2022, 51, 6095-6102.	1.6	3
2124	Biosurfactants for pharmacological interventions in cancer therapy. , 2022, , 421-437.		0
2125	Stimulus-responsive self-assembled prodrugs in cancer therapy. Chemical Science, 2022, 13, 4239-4269.	3.7	48

#	Article	IF	Citations
2126	MicroRNA-29 Ameliorates Fibro-Inflammation and Insulin Resistance in HIF1Î±-Deficient Obese Adipose Tissue by Inhibiting Endotrophin Generation. Diabetes, 2022, 71, 1746-1762.	0.3	12
2127	Bioinspired NiO Nanospheres: Exploring In Vitro Toxicity Using Bm-17 and L. rohita Liver Cells, DNA Degradation, Docking, and Proposed Vacuolization Mechanism. ACS Omega, 2022, 7, 6869-6884.	1.6	33
2128	Tumor Dormancy: Biologic and Therapeutic Implications. World Journal of Oncology, 2022, 13, 8-19.	0.6	9
2129	Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy. Disease-a-Month, 2023, 69, 101353.	0.4	4
2130	Nanotechnology Tools Enabling Biological Discovery. ACS Nano, 2022, 16, 5062-5084.	7.3	18
2131	Drug delivery strategy in hepatocellular carcinoma therapy. Cell Communication and Signaling, 2022, 20, 26.	2.7	21
2132	Strategies for enhancing cancer chemodynamic therapy performance. Exploration, 2022, 2, .	5.4	103
2133	Accurate Three-Dimensional Thermal Dosimetry and Assessment of Physiologic Response Are Essential for Optimizing Thermoradiotherapy. Cancers, 2022, 14, 1701.	1.7	13
2134	Harnessing the Immunogenic Potential of Gold Nanoparticle-Based Platforms as a Therapeutic Strategy in Breast Cancer Immunotherapy: A Mini Review. Frontiers in Immunology, 2022, 13, 865554.	2.2	3
2135	Sequential Ultrasound-Triggered and Hypoxia-Sensitive Nanoprodrug for Cascade Amplification of Sonochemotherapy. ACS Nano, 2022, 16, 5439-5453.	7.3	44
2136	Ginsengenin derivatives synthesized from 20(R)-panaxotriol: Synthesis, characterization, and antitumor activity targeting HIF-1 pathway. Journal of Ginseng Research, 2022, 46, 738-749.	3.0	8
2137	Cellular mechanism of action of 2-nitroimidazoles as hypoxia-selective therapeutic agents. Redox Biology, 2022, 52, 102300.	3.9	9
2138	Drugâ€grafted DNA as a novel chemogene for targeted combinatorial cancer therapy. Exploration, 2022, 2, .	5.4	12
2139	Naphthalimide-Based Azo-Functionalized Supramolecular Vesicle in Hypoxia-Responsive Drug Delivery. Langmuir, 2022, 38, 3480-3492.	1.6	7
2140	A novel HIF1Î±-STIL-FOXM1 axis regulates tumor metastasis. Journal of Biomedical Science, 2022, 29, 24.	2.6	5
2141	A Prognostic Model for Patients with Hepatocellular Carcinoma Based on Hypoxia-Related Long Noncoding RNAs. Journal of Nanomaterials, 2022, 2022, 1-10.	1.5	0
2142	Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer. Journal of Nanobiotechnology, 2022, 20, 178.	4.2	26
2143	Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. Biomarkers in Medicine, 2022, 16, 435-448.	0.6	0

#	Article	IF	Citations
2144	18F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 13.	0.9	1
2145	Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion. Journal of Experimental and Clinical Cancer Research, 2022, 41, 122.	3.5	20
2146	Radiation and chemotherapy variable response induced by tumor cell hypoxia: impact of radiation dose, anticancer drug, and type of cancer. Radiation and Environmental Biophysics, 2022, 61, 263-277.	0.6	3
2147	Efficiency assessment of irrigation as an alternative method for improving the regenerative potential of nonhealing wounds. Wound Repair and Regeneration, 2022, , .	1.5	3
2148	Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework. Biomaterials, 2022, 283, 121449.	5.7	89
2149	Bioorthogonal chemistry and illumination controlled programmed size-changeable nanomedicine for synergistic photodynamic and hypoxia-activated therapy. Biomaterials, 2022, 284, 121480.	5.7	13
2150	A Nanoparticle-Conjugated Anti-TBK1 siRNA Induces Autophagy-Related Apoptosis and Enhances cGAS-STING Pathway in GBM Cells. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-13.	0.5	4
2151	RNA Hydrogel Combined with MnO2 Nanoparticles as a Nano-Vaccine to Treat Triple Negative Breast Cancer. Frontiers in Chemistry, 2021, 9, 797094.	1.8	15
2152	Long Noncoding RNA HCG18 Promotes Malignant Phenotypes of Breast Cancer Cells via the HCG18/miR-103a-3p/UBE2O/mTORC1/HIF-1Î±â€“Positive Feedback Loop. Frontiers in Cell and Developmental Biology, 2021, 9, 675082.	1.8	10
2153	Aberrant role of pyruvate kinase M2 in the regulation of gamma-secretase and memory deficits in Alzheimerâ€™s disease. Cell Reports, 2021, 37, 110102.	2.9	19
2154	The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer. International Journal of Molecular Sciences, 2022, 23, 370.	1.8	29
2155	Assembly Transformation Jointly Driven by the LAP Enzyme and GSH Boosting Theranostic Capability for Effective Tumor Therapy. ACS Applied Materials & Interfaces, 2021, 13, 59787-59802.	4.0	12
2156	Impact of cancer metabolism on therapy resistance â€“ Clinical implications. Drug Resistance Updates, 2021, 59, 100797.	6.5	43
2157	Is Hypoxic/Altitude Training an Important Topic in the Field of Hypoxia?. Journal of Science in Sport and Exercise, 0, , .	0.4	4
2158	miR-140-5p Attenuates Hypoxia-Induced Breast Cancer Progression by Targeting Nrf2/HO-1 Axis in a Keap1-Independent Mechanism. Cells, 2022, 11, 12.	1.8	15
2159	Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients. EJNMMI Research, 2021, 11, 130.	1.1	9
2160	Conditionally Activatable Photoredox Catalysis in Living Systems. Journal of the American Chemical Society, 2022, 144, 163-173.	6.6	69
2161	Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1Î± (HIF-1Î±). Bioengineered, 2022, 13, 950-962.	1.4	16

#	Article	IF	Citations
2162	Tumor acidity/redox hierarchical-activable nanoparticles for precise combination of X-ray-induced photodynamic therapy and hypoxia-activated chemotherapy. Journal of Materials Chemistry B, 2022, 10, 3849-3860.	2.9	8
2164	Effects of Oxygen Tension for Membrane Lipidome Remodeling of Cockayne Syndrome Cell Models. Cells, 2022, 11, 1286.	1.8	6
2165	Noncovalent Dual-Locked Near-Infrared Fluorescent Probe for Precise Imaging of Tumor via Hypoxia/Glutathione Activation. Analytical Chemistry, 2022, 94, 6574-6581.	3.2	17
2166	Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Frontiers in Chemistry, 2022, 10, 830133.	1.8	4
2167	Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers. Pharmaceutics, 2022, 14, 847.	2.0	6
2168	Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203, 110328.	2.0	4
2190	The combined signatures of hypoxia and cellular landscape provides a prognostic and therapeutic biomarker in hepatitis B virusâ€related hepatocellular carcinoma. International Journal of Cancer, 2022, 151, 809-824.	2.3	11
2191	Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy. Molecular Diagnosis and Therapy, 2022, 26, 283-291.	1.6	3
2192	Improving the synergistic combination of programmed deathâ€1/programmed death ligandâ€1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 560-574.	0.9	3
2193	Turn-on silicon-based fluorescent probe for visualizing endogenous CO during hypoxia. New Journal of Chemistry, 2022, 46, 10213-10218.	1.4	3
2194	Delivery of CXCL9/10/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer. Cancer Nanotechnology, 2022, 13, .	1.9	7
2195	HIF-1Î± stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/Î²-catenin signalling pathway. British Journal of Cancer, 2022, 127, 474-487.	2.9	15
2196	p53N236S Activates Autophagy in Response to Hypoxic Stress Induced by DFO. Genes, 2022, 13, 763.	1.0	2
2197	Hypoxia-Responsive Azobenzene-Linked Hyaluronate Dot Particles for Photodynamic Tumor Therapy. Pharmaceutics, 2022, 14, 928.	2.0	5
2198	Turn-on Fluorescent Biosensors for Imaging Hypoxia-like Conditions in Living Cells. Journal of the American Chemical Society, 2022, 144, 8185-8193.	6.6	26
2199	Prospective Application of Ferroptosis in Hypoxic Cells for Tumor Radiotherapy. Antioxidants, 2022, 11, 921.	2.2	18
2200	Installing Reduction Responsiveness into Biomolecules by Introducing Nitroaryl Groups. Chemistry - A European Journal, 2022, 28, .	1.7	3
2201	Fluorogenic and Mitochondria-Localizable Probe Enables Selective Labeling and Imaging of Nitroreductase. Analytical Chemistry, 2022, 94, 7272-7277.	3.2	19

#	Article	IF	Citations
2202	Targeting <scp>DNA</scp> topoisomerase <scp>IIÎ±</scp> (<scp>TOP2A</scp>) in the hypoxic tumour microenvironment using unidirectional hypoxiaâ€activated prodrugs (<scp>uHAPs</scp>). IUBMB Life, 2023, 75, 40-54.	1.5	4
2203	Assessment of Nanoparticle-Mediated Tumor Oxygen Modulation by Photoacoustic Imaging. Biosensors, 2022, 12, 336.	2.3	10
2204	A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer. Nano Letters, 2022, 22, 3983-3992.	4.5	14
2205	Twoâ€Photon Smallâ€Molecule Fluorogenic Probes for Visualizing Endogenous Nitroreductase Activities from Tumor Tissues of a Cancer Patient. Advanced Healthcare Materials, 2022, 11, e2200400.	3.9	18
2206	Dual-responsive nanosystem based on TGF-Î² blockade and immunogenic chemotherapy for effective chemoimmunotherapy. Drug Delivery, 2022, 29, 1358-1369.	2.5	9
2207	Advancements on Small Molecule PROTACs Containing an Indole/Spiro-fused Oxoindole Scaffolds: An Emerging Degrader Targeting Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, .	0.9	0
2208	A dual-channel fluorescent ratio probe with hypoxia targeting and hypoxia activation capacity for tumour imaging. Polymer Chemistry, 2022, 13, 3358-3366.	1.9	2
2209	Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model. Chemical Science, 2022, 13, 6899-6919.	3.7	13
2210	Self-delivery of metal-coordinated mitochondria protonophore uncoupler for O2-exhausting enhanced bioreductive therapy. Biomaterials, 2022, 286, 121576.	5.7	5
2211	The design basis and application in urology of the tumor-on-a-chip platform. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 331-342.	0.8	1
2212	State-of-the-art accounts of hyperpolarized ¹⁵N-labeled molecular imaging probes for magnetic resonance spectroscopy and imaging. Chemical Science, 2022, 13, 7378-7391.	3.7	15
2213	Stressing the Regulatory Role of Long Non-Coding RNA in the Cellular Stress Response during Cancer Progression and Therapy. Biomedicines, 2022, 10, 1212.	1.4	3
2214	Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives. Chemical Engineering Journal, 2022, 446, 137147.	6.6	35
2215	Nir-Ii Light-Assisted Radiotherapy Based on Ultrasmall Hfo2-Embedded Porous Carbon Nanooctahedra for Overcoming Tumor Radioresistance. SSRN Electronic Journal, 0, , .	0.4	0
2216	Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches. Journal of Personalized Medicine, 2022, 12, 854.	1.1	12
2217	Recent Progress of Metal-Organic Framework-Based Photodynamic Therapy for Cancer Treatment. International Journal of Nanomedicine, 0, Volume 17, 2367-2395.	3.3	23
2218	A three-dimensional biomimetic microfluidic chip to study the behavior of hepatic stellate cell under the tumor microenvironment. Chinese Chemical Letters, 2023, 34, 107573.	4.8	2
2219	Targeting the Ezrin Adaptor Protein Sensitizes Metastatic Breast Cancer Cells to Chemotherapy and Reduces Neoadjuvant Therapyâ€“induced Metastasis. Cancer Research Communications, 2022, 2, 456-470.	0.7	3

#	Article	IF	Citations
2220	Modelling the effect of vascular status on tumour evolution and outcome after thermal therapy. Applied Mathematical Modelling, 2022, 110, 207-240.	2.2	3
2221	Comprehensive assessments of immunoâ€oncology drugâ€based combination therapies as firstâ€line treatment for advanced renal cell carcinoma. International Journal of Urology, 2022, 29, 816-822.	0.5	1
2222	Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn offâ€“on Probes for Hypoxia Imaging. Cancers, 2022, 14, 2686.	1.7	11
2224	A Novel Defined Hypoxia-Related Gene Signature for Prognostic Prediction of Patients With Ewing Sarcoma. Frontiers in Genetics, 0, 13, .	1.1	3
2225	The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions. Clinical and Translational Oncology, 2022, 24, 1702-1714.	1.2	5
2226	Progress and perspective on hydrogen sulfide donors and their biomedical applications. Medicinal Research Reviews, 2022, 42, 1930-1977.	5.0	21
2227	Hypoxia-reinforced antitumor RNA interference mediated by micelleplexes with programmed disintegration. Acta Biomaterialia, 2022, 148, 194-205.	4.1	6
2228	Hypoxia-inducible CircPFKFB4 Promotes Breast Cancer Progression by Facilitating the CRL4^{DDB2} E3 Ubiquitin Ligase-mediated p27 Degradation. International Journal of Biological Sciences, 2022, 18, 3888-3907.	2.6	9
2229	Impact of tumor microenvironment on adoptive T cell transfer activity. International Review of Cell and Molecular Biology, 2022, , 1-31.	1.6	8
2230	3D Culture Modeling of Metastatic Breast Cancer Cells in Additive Manufactured Scaffolds. ACS Applied Materials & Interfaces, 2022, 14, 28389-28402.	4.0	8
2231	A photochemical-responsive nanoparticle boosts doxorubicin uptake to suppress breast cancer cell proliferation by apoptosis. Scientific Reports, 2022, 12, .	1.6	5
2232	The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?. Frontiers in Immunology, 0, 13, .	2.2	4
2233	Maternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size. Dermatology and Therapy, 2022, 12, 1659-1670.	1.4	8
2234	A Multimodal Therapeutic Nanoplatform Overcoming Tumor Hypoxia Heterogeneity for Improved Tumor Chemoradiotherapy. Advanced Functional Materials, 2022, 32, .	7.8	17
2235	Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment. Journal of Visualized Experiments, 2022, , .	0.2	6
2236	Effects of Ultrafine Single-Nanometer Oxygen Bubbles on Radiation Sensitivity in a Tumor-Bearing Mouse Model. International Journal of Molecular Sciences, 2022, 23, 6838.	1.8	3
2237	A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis. Journal of Controlled Release, 2022, 348, 590-600.	4.8	36
2238	Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Medicine in Drug Discovery, 2022, 15, 100134.	2.3	39

#	Article	IF	Citations
2239	A novel fluorescent probe for the detection of Golgi nitroreductase under hypoxic conditions.. New Journal of Chemistry, 0, , .	1.4	0
2240	Degradable polyprodrugs: design and therapeutic efficiency. Chemical Society Reviews, 2022, 51, 6652-6703.	18.7	28
2241	The close interaction between hypoxia-related proteins and metastasis in pancarcinomas. Scientific Reports, 2022, 12, .	1.6	4
2242	Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	81
2243	CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p. Molecular Cancer, 2022, 21, .	7.9	44
2244	A Porous Bimetallic Au@Pt Coreâ€“Shell Oxygen Generator to Enhance Hypoxia-Dampened Tumor Chemotherapy Synergized with NIR-II Photothermal Therapy. ACS Nano, 2022, 16, 10711-10728.	7.3	31
2245	The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer. Journal of Histochemistry and Cytochemistry, 2022, 70, 479-494.	1.3	4
2246	Gold nanoclusters: Photophysical properties and photocatalytic applications. Frontiers in Chemistry, 0, 10, .	1.8	9
2247	Stimuli-responsive polyprodrug for cancer therapy. Materials Today Advances, 2022, 15, 100266.	2.5	4
2248	Spatial specific delivery of combinational chemotherapeutics to combat intratumoral heterogeneity. Journal of Controlled Release, 2022, 348, 1004-1015.	4.8	6
2249	Synthesis strategies, luminescence mechanisms, and biomedical applications of near-infrared fluorescent carbon dots. Coordination Chemistry Reviews, 2022, 470, 214703.	9.5	64
2250	Recent progresses on radiotherapeutics-based treatment of cancer with two-dimensional nanomaterials. Applied Materials Today, 2022, 29, 101584.	2.3	1
2251	Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma. Bioactive Materials, 2023, 20, 259-270.	8.6	10
2252	3D Disease Modelling of Hard and Soft Cancer Using PHA-Based Scaffolds. Cancers, 2022, 14, 3549.	1.7	4
2253	Silver ion-regulated ratiometric fluorescence assay for alkaline phosphatase detection based on carbon dots and o-phenylenediamine. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 282, 121682.	2.0	7
2254	Carbon quantum dots: A promising nanocarrier for bioimaging and drug delivery in cancer. Materials Today Communications, 2022, 32, 104068.	0.9	28
2255	PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib. Scientific Reports, 2022, 12, .	1.6	3
2256	Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer Journal (Sudbury, Mass), 2022, 28, 263-269.	1.0	0

#	Article	IF	Citations
2257	Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer. Advanced Science, 2022, 9, .	5.6	6
2258	Recent advances in redox-responsive nanoparticles for combined cancer therapy. Nanoscale Advances, 2022, 4, 3504-3516.	2.2	22
2259	Cancer Immunotherapy: Diverse Approaches and Obstacles. Current Pharmaceutical Design, 2022, 28, 2387-2403.	0.9	4
2260	Tumor homing-penetrating and nanoenzyme-augmented 2D phototheranostics against hypoxic solid tumors. Acta Biomaterialia, 2022, 150, 391-401.	4.1	3
2261	Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 8844.	1.8	4
2262	Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma. Nanomaterials, 2022, 12, 2832.	1.9	2
2263	A Boolean approach for novel hypoxia-related gene discovery. PLoS ONE, 2022, 17, e0273524.	1.1	0
2264	Potentiation of Drug Toxicity through Virus Latency Reversal Promotes Preferential Elimination of HIV Infected Cells. Advanced Therapeutics, 2022, 5, .	1.6	0
2265	Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Frontiers in Immunology, 0, 13, .	2.2	12
2266	Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing. Journal of Nanobiotechnology, 2022, 20, .	4.2	13
2267	Small-Molecule Fluorescent Probes for Detecting Several Abnormally Expressed Substances in Tumors. Micromachines, 2022, 13, 1328.	1.4	3
2268	NIR-II light-assisted radiotherapy based on ultrasmall HfO2-embedded porous carbon nanooctahedra for overcoming tumor radioresistance. Materials Today Nano, 2022, 20, 100253.	2.3	4
2269	Dynamic ginsenoside-sheltered nanocatalysts for safe ferroptosis-apoptosis combined therapy. Acta Biomaterialia, 2022, 151, 549-560.	4.1	11
2270	Carbonic anhydrase IX stratifies patient prognosis and identifies nodal status in animal models of nasopharyngeal carcinoma using a targeted imaging strategy. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	2
2272	Hypoxia-driven miR-1307â€“3p promotes hepatocellular carcinoma cell proliferation and invasion by modulating DAB2 interacting protein. Pathology Research and Practice, 2022, 237, 154066.	1.0	4
2273	Hypoxia-responsive near infrared thioxanthene-hemicyanine nanoparticle for multimodal imaging-guided photothermal/photodynamic therapy. Dyes and Pigments, 2022, 206, 110583.	2.0	3
2274	Recent advances in combretastatin A-4 codrugs for cancer therapy. European Journal of Medicinal Chemistry, 2022, 241, 114660.	2.6	14
2275	Injectable hyaluronan/MnO2 nanocomposite hydrogel constructed by metal-hydrazide coordinated crosslink mineralization for relieving tumor hypoxia and combined phototherapy. Journal of Colloid and Interface Science, 2022, 628, 79-94.	5.0	10

#	Article	IF	Citations
2276	In situ forming oxygen/ROS-responsive niche-like hydrogel enabling gelation-triggered chemotherapy and inhibition of metastasis. Bioactive Materials, 2023, 21, 86-96.	8.6	10
2277	Natural flavylium-inspired far-red to NIR-II dyes and their applications as fluorescent probes for biomedical sensing. Chemical Society Reviews, 2022, 51, 7170-7205.	18.7	38
2278	Validation of photoacoustic/ultrasound dual imaging in evaluating blood oxygen saturation. Biomedical Optics Express, 2022, 13, 5551.	1.5	4
2279	Research progress on tumor hypoxia-associative nanomedicine. Journal of Controlled Release, 2022, 350, 829-840.	4.8	28
2280	Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers. Biomaterials, 2022, 289, 121770.	5.7	12
2281	Recent advances in graphdiyne materials for biomedical applications. Nano Today, 2022, 46, 101616.	6.2	6
2282	Tumor oxygenation nanoliposome synergistic hypoxia-inducible-factor-1 inhibitor enhanced Iodine-125 seed brachytherapy for esophageal cancer. Biomaterials, 2022, 289, 121801.	5.7	6
2283	Platinum(IV) Complex-Loaded nanoparticles with photosensitive activity for cancer therapy. Coordination Chemistry Reviews, 2022, 472, 214789.	9.5	12
2284	Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors. Bioorganic Chemistry, 2022, 129, 106138.	2.0	1
2285	Determination of Toxicity Through Cytotoxicity Assays. , 2022, , 137-147.		0
2286	A nitroreductase responsive and photoactivated fluorescent probe for dual-controlled tumor hypoxia imaging. RSC Advances, 2022, 12, 23796-23800.	1.7	3
2287	New relativistic quantum chemical methods for understanding light-induced therapeutics. Dalton Transactions, 2022, 51, 16055-16064.	1.6	2
2288	Platinum nanoplatforms: classic catalysts claiming a prominent role in cancer therapy. Chemical Society Reviews, 2022, 51, 7662-7681.	18.7	19
2289	The Dbecms-Gbm Culture Model Recapitulates the Interaction between Cells and the Extracellular Matrix Without a Nutrient-Oxygen Gradient Interference. SSRN Electronic Journal, 0, , .	0.4	0
2290	Photoelectronâ€“photoion(s) coincidence studies of molecules of biological interest. Physical Chemistry Chemical Physics, 2022, 24, 22356-22370.	1.3	4
2291	Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an <i>in silico</i> approach. Mathematical Biosciences and Engineering, 2022, 19, 10941-10962.	1.0	0
2292	Heterogeneous Tumour Modeling Using PhysiCell andÂIts Implications inÂPrecision Medicine. Emergence, Complexity and Computation, 2022, , 157-189.	0.2	0
2293	Magnetic resonance elastography of malignant tumors. Frontiers in Physics, 0, 10, .	1.0	3

#	Article	IF	Citations
2294	Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies. Cancers, 2022, 14, 4182.	1.7	2
2295	Graphdiyne-Related Materials in Biomedical Applications and Their Potential in Peripheral Nerve Tissue Engineering. Cyborg and Bionic Systems, 2022, 2022, .	3.7	10
2296	Unraveling Mitochondrial Determinants of Tumor Response to Radiation Therapy. International Journal of Molecular Sciences, 2022, 23, 11343.	1.8	4
2297	ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene, 2022, 41, 4709-4723.	2.6	20
2298	Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. Journal of Hematology and Oncology, 2022, 15, .	6.9	93
2299	Recent Progress on NIR Fluorescent Probes for Enzymes. Molecules, 2022, 27, 5922.	1.7	11
2300	Chemical Modulation of Glucose Metabolism with a Fluorinated CaCO₃ Nanoregulator Can Potentiate Radiotherapy by Programming Antitumor Immunity. ACS Nano, 2022, 16, 13884-13899.	7.3	33
2301	Targeted Singlet Oxygen Delivery: A Bioorthogonal Metabolic Shunt Linking Hypoxia to Fast Singlet Oxygen Release. Angewandte Chemie, 0, , .	1.6	0
2302	Targeted Singlet Oxygen Delivery: A Bioorthogonal Metabolic Shunt Linking Hypoxia to Fast Singlet Oxygen Release. Angewandte Chemie - International Edition, 2022, 61, .	7.2	9
2303	Construction of a 3-mRNA hypoxia prognostic model to evaluate immune microenvironment in hepatocellular carcinoma. Medicine (United States), 2022, 101, e30589.	0.4	0
2304	Hypoxia-Activated PEGylated Paclitaxel Prodrug Nanoparticles for Potentiated Chemotherapy. ACS Nano, 2022, 16, 14693-14702.	7.3	24
2305	Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment. British Journal of Cancer, 2022, 127, 1760-1772.	2.9	23
2306	Targeting tumor hypoxia inhibits aggressive phenotype of dedifferentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	1
2308	Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges. Journal of Nanobiotechnology, 2022, 20, .	4.2	9
2309	Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy. Biomaterials, 2022, 290, 121821.	5.7	18
2310	Progress in the past five years of small organic molecule dyes for tumor microenvironment imaging. Chemical Communications, 2022, 58, 12642-12652.	2.2	11
2311	Smart systems in bio-encapsulation for cancer therapy. , 2022, , 223-236.		0
2312	Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy. Chemical Society Reviews, 2022, 51, 8957-9008.	18.7	83

#	Article	IF	Citations
2313	Harnessing the Power of Nanomaterials to Alleviate Tumor Hypoxia in Favor of Cancer Therapy. Nanomedicine and Nanotoxicology, 2022, , 135-174.	0.1	0
2314	Banoxantrone Coordinated Metalâ˜'Organic Framework for Photoacoustic Imagingâ€Guided High Intensity Focused Ultrasound Therapy. Advanced Healthcare Materials, 2023, 12, .	3.9	3
2315	Resveratrol-loaded gold nanoparticles enhance caspase-mediated apoptosis in PANC-1 pancreatic cells via mitochondrial intrinsic apoptotic pathway. Cancer Nanotechnology, 2022, 13, .	1.9	5
2316	Computational Simulation of Tumor-Induced Angiogenesis. Methods in Molecular Biology, 2023, , 275-283.	0.4	1
2317	Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia. Metabolites, 2022, 12, 943.	1.3	7
2319	PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer. , 2023, 1, 56-66.		8
2320	In Vivo Nitroreductase Imaging via Fluorescence and Chemical Shift Dependent ¹⁹F NMR. Angewandte Chemie, 2022, 134, .	1.6	1
2321	Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort. European Radiology, 2023, 33, 4475-4485.	2.3	3
2322	Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. Journal of Zhejiang University: Science B, 2022, 23, 793-811.	1.3	9
2323	Biodegradable Metalâ€“Organic-Frameworks-Mediated Protein Delivery Enables Intracellular Cascade Biocatalysis and Pyroptosis In Vivo. ACS Applied Materials & Interfaces, 2022, 14, 47472-47481.	4.0	10
2324	In Vivo Nitroreductase Imaging via Fluorescence and Chemical Shift Dependent ¹⁹F NMR. Angewandte Chemie - International Edition, 2022, 61, .	7.2	18
2325	Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer. Nature Communications, 2022, 13, .	5.8	43
2327	Effects of Six Weeks of Hypoxia Exposure on Hepatic Fatty Acid Metabolism in ApoE Knockout Mice Fed a High-Fat Diet. Life, 2022, 12, 1535.	1.1	0
2328	Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. Cancers, 2022, 14, 4920.	1.7	19
2329	Tumor Microenvironment-Based Stimuli-Responsive Nanoparticles for Controlled Release of Drugs in Cancer Therapy. Pharmaceutics, 2022, 14, 2346.	2.0	19
2330	Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research, 2022, 186, 106535.	3.1	20
2331	Aqua-(2-formylbenzoato)triphenyltin(IV) induces cell cycle arrest and apoptosis in hypoxic triple negative breast cancer cells. Toxicology in Vitro, 2023, 86, 105484.	1.1	2
2332	Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection. Chemical Society Reviews, 2022, 51, 9759-9830.	18.7	17

#	Article	IF	Citations
2333	A dual-response drug delivery system with X-ray and ROS to boost the anti-tumor efficiency of TPZ via enhancement of tumor hypoxia levels. Nanoscale, 2022, 15, 237-247.	2.8	4
2334	Fabrication of a Polymeric Inhibitor of Proximal Metabolic Enzymes in Hypoxia for Synergistic Inhibition of Cancer Cell Proliferation, Survival, and Migration. ACS Applied Materials & Interfaces, 2022, 14, 51790-51797.	4.0	1
2335	Quantitative Phase Imaging Detecting the Hypoxia-Induced Patterns in Healthy and Neoplastic Human Colonic Epithelial Cells. Cells, 2022, 11, 3599.	1.8	3
2336	A systematic study of HIF1A cofactors in hypoxic cancer cells. Scientific Reports, 2022, 12, .	1.6	2
2337	EGFR-dependent aerotaxis is a common trait of breast tumour cells. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	4
2338	Carbon Dot@MXene Nanozymes with Triple Enzymeâ€Mimic Activities for Mild NIRâ€Ⅱ Photothermalâ€Amplified Nanocatalytic Therapy. Advanced Healthcare Materials, 2023, 12, .	3.9	18
2339	Photodynamic therapy (PDT) as adjuvant treatment to brachytherapy for amelanotic choroidal melanoma. European Journal of Ophthalmology, 0, , 112067212211383.	0.7	0
2340	Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes. Cancers, 2022, 14, 5600.	1.7	1
2342	Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics. RSC Advances, 2022, 12, 32956-32978.	1.7	7
2343	Preparation of C6 cell membrane-coated doxorubicin conjugated manganese dioxide nanoparticles and its targeted therapy application in glioma. European Journal of Pharmaceutical Sciences, 2023, 180, 106338.	1.9	8
2345	Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma. Journal of Photochemistry and Photobiology B: Biology, 2023, 238, 112627.	1.7	11
2346	Applications and challenges of ultra-small particle size nanoparticles in tumor therapy. Journal of Controlled Release, 2023, 353, 699-712.	4.8	34
2347	Overcoming oxygen heterogeneity of tumor microenvironments to boost cancer immunotherapy by oxygen-switchable ROS/RNS nanogenerators. Nano Today, 2023, 48, 101696.	6.2	4
2348	Recent progress in the development of singlet oxygen carriers for enhanced photodynamic therapy. Coordination Chemistry Reviews, 2023, 478, 214979.	9.5	11
2349	Anti-hypoxic Agents for Improving Head and Neck Cancer Therapy. , 2022, , .		0
2350	Receptor-Specific Radionuclide Therapy. , 2022, , 1-32.		0
2351	A novel hypoxia-related genes signature for prognosis and immunotherapeutic sensitivity in uterine carcinosarcoma patients. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2022, 181, .	0.0	0
2352	The magic bullet: Niclosamide. Frontiers in Oncology, 0, 12, .	1.3	14

#	Article	IF	Citations
2353	A self-amplified necrotic targeting theranostic nanoparticle with deep tumor penetration for imaging-guided personalized chemo-photodynamic therapy. Chemical Engineering Journal, 2023, 455, 140465.	6.6	0
2354	Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs. International Journal of Molecular Sciences, 2022, 23, 14511.	1.8	6
2355	Integrated Analysis of TME and Hypoxia Identifies a Classifier to Predict Prognosis and Therapeutic Biomarkers in Soft Tissue Sarcomas. Cancers, 2022, 14, 5675.	1.7	1
2356	A carbon monoxide releasing metal organic framework nanoplatform for synergistic treatment of triple-negative breast tumors. Journal of Nanobiotechnology, 2022, 20, .	4.2	3
2357	Polystyrene-Based Slippery Surfaces Enable the Generation and Easy Retrieval of Tumor Spheroids. ACS Applied Bio Materials, 2022, 5, 5582-5594.	2.3	4
2358	Cationic telluroviologen derivatives as typeâ€I photosensitizers for tumor photodynamic theranostics. Aggregate, 2023, 4, .	5.2	23
2359	Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras. Science Advances, 2022, 8, .	4.7	14
2360	Nrf2 and Parkin-Hsc70 regulate the expression and protein stability of p62/SQSTM1 under hypoxia. Scientific Reports, 2022, 12, .	1.6	2
2361	Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis. BMC Cancer, 2022, 22, .	1.1	7
2362	A New Sonoâ€Chemo Sensitizer Overcoming Tumor Hypoxia for Augmented Sono/Chemoâ€Dynamic Therapy and Robust Immuneâ€Activating Response. Small, 2023, 19, .	5.2	9
2363	Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer. Acta Biomaterialia, 2023, 158, 547-559.	4.1	7
2364	Combretastatin Derivatives as Tubulin Inhibitors: A Fascinating Journey from Nature to Drug Discovery Strategies. , 2022, , 112-144.		0
2365	Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients. Scientific Reports, 2022, 12, .	1.6	2
2366	Photothermal Nanoheaters-Modified Spores for Safe and Controllable Antitumor Therapy. International Journal of Nanomedicine, 0, Volume 17, 6399-6412.	3.3	0
2367	Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties. Pharmaceutics, 2022, 14, 2708.	2.0	1
2368	Microneedleâ€Assisted Transdermal Delivery of 2D Bimetallic Metalâ€“Organic Framework Nanosheetâ€Based Cascade Biocatalysts for Enhanced Catalytic Therapy of Melanoma. Advanced Healthcare Materials, 2023, 12, .	3.9	9
2369	The Ginsenoside Compound K Suppresses Stem-Cell-like Properties and Colorectal Cancer Metastasis by Targeting Hypoxia-Driven Nur77-Akt Feed-Forward Signaling. Cancers, 2023, 15, 24.	1.7	5
2370	Decellularized brain extracellular matrix slice glioblastoma culture model recapitulates the interaction between cells and the extracellular matrix without a nutrient-oxygen gradient interference. Acta Biomaterialia, 2023, 158, 132-150.	4.1	6

#	Article	IF	Citations
2372	Evaluating Fate of Emerging Resistance Hitting the Brakes on Conventional Treatment Approach. , 2023, , 99-122.		0
2373	Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery. Current Drug Metabolism, 2022, 23, 1027-1053.	0.7	0
2374	Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemoâ€•and radioresistances. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	8
2375	Engineering lactate-modulating nanomedicines for cancer therapy. Chemical Society Reviews, 2023, 52, 973-1000.	18.7	17
2376	Hypoxia-induced ROS aggravate tumor progression through HIF-1Î±-SERPINE1 signaling in glioblastoma. Journal of Zhejiang University: Science B, 2023, 24, 32-49.	1.3	11
2377	Hypoxia signaling pathway: A central mediator in endocrine tumors. Frontiers in Endocrinology, 0, 13, .	1.5	3
2378	Bioresponsive Immunotherapeutic Materials. Advanced Materials, 0, , .	11.1	11
2379	Cytotoxic Activity of Herbal Medicines as Assessed in Vitro: A Review. Chemistry and Biodiversity, 2023, 20, .	1.0	11
2380	A Glutathione-Sensitive Cationic Polymer Delivery of CRISPR-Cas9 RNA Plasmid for Targeting Nasopharyngeal Carcinoma Gene Therapy. Colloids and Surfaces B: Biointerfaces, 2023, , 113146.	2.5	0
2381	Recent methods of droplet microfluidics and their applications in spheroids and organoids. Lab on A Chip, 0, , .	3.1	11
2382	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. Frontiers in Oncology, 0, 12, .	1.3	2
2384	Trienzyme-like Co3O4@TiO2-x nanozymes for heterojunction-enhanced nanocatalytic-sonodynamic tumor therapy. Chemical Engineering Journal, 2023, 458, 141485.	6.6	9
2385	Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects. Small, 2023, 19, .	5.2	1
2386	Tumor hypoxia: From basic knowledge to therapeutic implications. Seminars in Cancer Biology, 2023, 88, 172-186.	4.3	21
2387	Hypoxia-Triggered Bioreduction of Poly(N-oxide)â€“Drug Conjugates Enhances Tumor Penetration and Antitumor Efficacy. Journal of the American Chemical Society, 2023, 145, 1707-1713.	6.6	11
2388	Biomaterial-based in vitro 3D modeling of glioblastoma multiforme. , 2023, 1, 177-194.		2
2389	Cleavable collagenase-assistant nanosonosensitizer for tumor penetration and sonodynamic therapy. Biomaterials, 2023, 293, 121992.	5.7	16
2390	Recent Advances in Tetrakis (4â€Carboxyphenyl) Porphyrinâ€Based Nanocomposites for Tumor Therapy. Advanced NanoBiomed Research, 2023, 3, .	1.7	2

#	Article	IF	Citations
2391	Characterization of Apelin/APJ axis expression in Normal Testicular Tissue, Germ Cell Neoplasia In Situ, and Testicular Seminoma. Medical Records, 0, , .	0.4	0
2392	Notch signaling, hypoxia, and cancer. Frontiers in Oncology, 0, 13, .	1.3	3
2393	Mechanisms of drug resistance in HCC. Hepatology, 2024, 79, 926-940.	3.6	23
2394	The role of hypoxia-inducible factors in breast cancer stem cell specification. Pathology Research and Practice, 2023, 243, 154349.	1.0	3
2395	Anti-Hypoxia Nanoplatforms for Enhanced Photosensitizer Uptake and Photodynamic Therapy Effects in Cancer Cells. International Journal of Molecular Sciences, 2023, 24, 2656.	1.8	6
2396	Prognostic histological markers in oral tongue squamous cell carcinoma patients treated with (chemo)radiotherapy. Apmis, 0, , .	0.9	0
2397	Fluorescent Probes for Biological Species and Microenvironments: from Rational Design to Bioimaging Applications. Accounts of Chemical Research, 2023, 56, 258-269.	7.6	49
2398	Aquaporins in Tumor. Advances in Experimental Medicine and Biology, 2023, , 303-315.	0.8	1
2399	Intraoperative oxygen tension and redox homeostasis in Pseudomyxoma peritonei: A short case series. Frontiers in Oncology, 0, 13, .	1.3	0
2400	Biomaterials tools to modulate the tumour microenvironment in immunotherapy. , 2023, 1, 125-138.		34
2401	Cellular Invasion Assay for the Real-Time Tracking of Individual Cells in Spheroid or Tumor-like Mimics. Analytical Chemistry, 2023, 95, 3054-3061.	3.2	3
2402	Unveiling the gemcitabine drug complexation with cucurbit[n]urils (nâ€‰=â€‰6â€“8): a computational analysis. Structural Chemistry, 2023, 34, 1869-1882.	1.0	0
2403	Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment. Cancer Drug Resistance (Alhambra, Calif), 2023, 6, 138-150.	0.9	4
2404	Platinum Drugâ€Incorporating Polymeric Nanosystems for Precise Cancer Therapy. Small, 2023, 19, .	5.2	3
2405	Stimuliâ€Responsive Silica Silanol Conjugates: Strategic Nanoarchitectonics in Targeted Drug Delivery. Small, 0, , .	5.2	10
2406	A Concerted Redoxâ€•and Lightâ€Activated Agent for Controlled Multimodal Therapy against Hypoxic Cancer Cells. Advanced Materials, 2023, 35, .	11.1	8
2407	H2O2 responsive CO gas release platform with CA IX-Targeting for inhibiting tumor growth and metastasis. Chemical Engineering Journal, 2023, 463, 142371.	6.6	3
2408	Hypoxia-induced degradation of PICK1 by RBCK1 promotes the proliferation of nasopharyngeal carcinoma cells. Life Sciences, 2023, 321, 121594.	2.0	0

#	Article	IF	Citations
2409	First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer. Radiotherapy and Oncology, 2023, 183, 109592.	0.3	16
2410	Bioinspired microrobots: Opportunities and challenges in targeted cancer therapy. Journal of Controlled Release, 2023, 354, 439-452.	4.8	4
2411	Nanomedicines with high drug availability and drug sensitivity overcome hypoxia-associated drug resistance. Biomaterials, 2023, 294, 122023.	5.7	10
2413	Influence of 2-Nitroimidazoles in the Response of FaDu Cells to Ionizing Radiation and Hypoxia/Reoxygenation Stress. Antioxidants, 2023, 12, 389.	2.2	1
2414	Synthetic, biological and optoelectronic properties of phenoxazine and its derivatives: a state of the art review. Molecular Diversity, 0, , .	2.1	3
2415	Hierarchical design of intelligent Î±-MnO2-based theranostics nanoplatform for TME-activated drug delivery and T1-weighted MRI. Journal of Drug Delivery Science and Technology, 2023, 81, 104262.	1.4	2
2416	HDAC8 Deacetylates HIF-1Î± and Enhances Its Protein Stability to Promote Tumor Growth and Migration in Melanoma. Cancers, 2023, 15, 1123.	1.7	7
2417	The Genesâ€“Stemnessâ€“Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints. International Journal of Molecular Sciences, 2023, 24, 3496.	1.8	0
2418	FBXO30 functions as a tumor suppressor and an E3 ubiquitin ligase for hZIP1â€'mediated HIFâ€'1Î± degradation in renal cell carcinoma. International Journal of Oncology, 2023, 62, .	1.4	1
2419	Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	81
2420	Revisiting the hallmarks of cancer: A new look at long noncoding RNAs in breast cancer. Pathology Research and Practice, 2023, 243, 154381.	1.0	1
2421	The sialyl-Tn antigen synthase genes regulates migrationâ€“proliferation dichotomy in prostate cancer cells under hypoxia. Glycoconjugate Journal, 2023, 40, 199-212.	1.4	2
2422	An Engineered Design of Self-Assembly Nanomedicine Guided by Molecular Dynamic Simulation for Photodynamic and Hypoxia-Directed Therapy. Molecular Pharmaceutics, 2023, 20, 2128-2137.	2.3	1
2423	Hypoxia-circular RNA crosstalk to promote breast cancer. Pathology Research and Practice, 2023, 244, 154402.	1.0	0
2424	Acidotic and hypoxic tumor microenvironment induces changes to histone acetylation and methylation in oral squamous cell carcinoma. Biomedical Chromatography, 0, , .	0.8	0
2425	Suprabasin enhances the invasion, migration, and angiogenic ability of oral squamous cell carcinoma cells under hypoxic conditions. Oncology Reports, 2023, 49, .	1.2	0
2426	Outersphere Approach to Increasing the Persistance of Oxygenâ€Sensitive Europium(II)â€Containing Contrast Agents for Magnetic Resonance Imaging with Perfluorocarbon Nanoemulsions toward Imaging of Hypoxia. Advanced Healthcare Materials, 0, , 2203209.	3.9	2
2427	Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine. Pharmaceuticals, 2023, 16, 433.	1.7	14

#	Article	IF	Citations
2428	The unfolding story of dying tumor cells during cancer treatment. Frontiers in Immunology, 0, 14, .	2.2	2
2429	Bacteria-Driven Tumor Microenvironment-Sensitive Nanoparticles Targeting Hypoxic Regions Enhances the Chemotherapy Outcome of Lung Cancer. International Journal of Nanomedicine, 0, Volume 18, 1299-1315.	3.3	5
2430	HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy. Journal of Controlled Release, 2023, 356, 649-662.	4.8	7
2431	Reactive oxygen species-powered cancer immunotherapy: Current status and challenges. Journal of Controlled Release, 2023, 356, 623-648.	4.8	28
2432	Ptâ€“N Coordination Rendering the Chemotherapeutic Agent with Photoactivated ROS Generation and Self-Reporting Cell Uptake. ACS Applied Bio Materials, 2023, 6, 1650-1657.	2.3	2
2433	Tailored Betaâ€Lapachone Nanomedicines for Cancerâ€Specific Therapy. Advanced Healthcare Materials, 2023, 12, .	3.9	1
2434	Extracellular vesicles released during hypoxia transport heparanase and enhance macrophage migration, endothelial tube formation and cancer cell stemness. , 2023, 1, .		3
2435	A self-charging salt water battery for antitumor therapy. Science Advances, 2023, 9, .	4.7	13
2436	Evolution-Informed Strategies for Combating Drug Resistance in Cancer. International Journal of Molecular Sciences, 2023, 24, 6738.	1.8	5
2437	Positron emission tomography imaging sheds new light on hypoxia and antitumor therapies. , 2023, 1, .		8
2439	The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer. Clinical and Translational Oncology, 0, , .	1.2	0
2440	Energy Metabolism Is Altered in Radioresistant Rectal Cancer. International Journal of Molecular Sciences, 2023, 24, 7082.	1.8	2
2441	piRNA-Based Cancer Therapy in Hypoxic Tumor. , 2023, , 161-180.		0
2442	Construction of Hypoxia-Related Prognostic Signature in Neuroblastoma Based on GEO Database. Advances in Clinical Medicine, 2023, 13, 5444-5455.	0.0	0
2443	Activatable Photodynamic Photosensitizers for Cancer Treatment. , 2023, , 345-377.		0
2444	Modulatory Effect of Vitamin C on Hypoxia Induced Breast Cancer Stem Cells. Advanced Pharmaceutical Bulletin, 0, , .	0.6	0
2445	Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication. Cell Reports Medicine, 2023, 4, 101014.	3.3	3
2446	Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma. British Journal of Cancer, 0, , .	2.9	1

#	Article	IF	Citations
2447	Glutathione and Esterase Dual-Responsive Smart Nano-drug Delivery System Capable of Breaking the Redox Balance for Enhanced Tumor Therapy. ACS Applied Materials & Interfaces, 2023, 15, 20697-20711.	4.0	3
2448	Azideâ€Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy. Advanced Materials, 2023, 35, .	11.1	10
2455	The Biocatalysis in Cancer Therapy. ACS Catalysis, 2023, 13, 7730-7755.	5.5	2
2456	Radiotracers for PET Imaging of the Brain. , 2023, , 93-109.		0
2457	Advances in PET imaging of cancer. Nature Reviews Cancer, 2023, 23, 474-490.	12.8	20
2467	Marine Natural Products Targeting Tumor Microenvironment. , 2023, , 35-58.		0
2469	Recent Progress in Hypoxia-Targeting: Peptide-Based Nanomaterials. , 2023, , 59-80.		0
2470	Novel Strategies in Radiotherapy to Reduce Hypoxia Using Nanomaterials. , 2023, , 115-129.		0
2480	Recent developments in the cleavage, functionalization, and conjugation of proteins and peptides at tyrosine residues. Chemical Science, 2023, 14, 7782-7817.	3.7	2
2490	A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy. Nanoscale, 2023, 15, 11813-11833.	2.8	6
2509	Activatable probes with potential for intraoperative tumor-specific fluorescence-imaging guided surgery. Journal of Materials Chemistry B, 2023, 11, 9777-9797.	2.9	1
2518	MicroRNA-495: a therapeutic and diagnostic tumor marker. Journal of Molecular Histology, 0, , .	1.0	0
2530	New Frontiers in Transarterial Chemoembolization: Combination with Systemic Therapies. , 2023, , 107-117.		0
2538	Bioorthogonal chemistry for prodrug activation in vivo. Chemical Society Reviews, 2023, 52, 7737-7772.	18.7	3
2542	Harnessing biomaterial architecture to drive anticancer innate immunity. Journal of Materials Chemistry B, 2023, 11, 10982-11005.	2.9	0
2571	A comprehensive review of biosurfactant production and its uses in the pharmaceutical industry. Archives of Microbiology, 2024, 206, .	1.0	0
2584	In Vitro Cytotoxicity Testing of Food Packaging. , 2024, , 137-148.		0